[
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"(5-HT)3 receptor antagonists, doses [N/V]"
},
{
	"jumpto":"ENAS5407_4.5.0.0",
	"name":"(C)RT regimen, selection [Rectal CA]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"(FOLFIRINOX), gemcitabine [Pancr]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"1st-line treat., good/intermed. Px [RCC]"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"3D conformal RT [TETs]"
},
{
	"jumpto":"ENAS5068_5.5.0.0",
	"name":"5-fluorouracil (5-FU)/folinic acid (FA) [Pancr]"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"5-fluorouracil (5-FU)[Anal cancer]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"5-fluorouracil (5-FU) [mCRC]"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"5-FU, in advanced penile CA [PenCa]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"5-FU [PenCa]"
},
{
	"jumpto":"ENAS5285_5.2.1.3",
	"name":"5-year disease-specific survival [RCC]"
},
{
	"jumpto":"ENAS5282_3.1.0.0",
	"name":"18F-FDG-PET (Oes CA)"
},
{
	"jumpto":"ENAS5271_4.2.1.0",
	"name":"AAIPI in patients ≤60 years, DLBCL"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Abdominal pain (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Abiraterone, palliative care [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Abiraterone, side effects [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Abiraterone, treatment of CRPC [PC]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Abiraterone [PC]"
},
{
	"jumpto":"ENAS5304_8.6.4.0",
	"name":"Ablative treatment with or without surgery, summary [mCRC]"
},
{
	"jumpto":"ENAS5268_2.2.3.0",
	"name":"AC-treated female patients, breast cancer [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.2.3",
	"name":"AC-treated female pts. with breast cancer, summary [N/V]"
},
{
	"jumpto":"ENAS5410_3.1.1.0",
	"name":"Acantholytic dysker­ato­sis [irAEs]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Acquired cystic disease-associated RCCs"
},
{
	"jumpto":"ENAS5268_4.0.0.0",
	"name":"Acute CINV in children, prevention [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.3.0",
	"name":"Acute emesis [N/V]"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Acute myeloid leukaemia [FN]"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Acute pelvic toxicity [Anal cancer]"
},
{
	"jumpto":"ENAS5265_5.1.1.0",
	"name":"Acute treatment, LMWH and UFH [VTE]"
},
{
	"jumpto":"ENAS5265_5.1.1.0",
	"name":"Acute treatment, solid tumours [VTE]"
},
{
	"jumpto":"ENAS5265_5.1.2.0",
	"name":"Acute treatment, thrombolytic therapy [VTE]"
},
{
	"jumpto":"ENAS5265_8.4.1.1",
	"name":"Acute treatment in solid tumours, summary [VTE]"
},
{
	"jumpto":"ENAS5265_8.4.1.1",
	"name":"Acute treatment with LMWH and UFH, summary [VTE]"
},
{
	"jumpto":"ENAS5265_8.4.1.2",
	"name":"Acute treatment with thrombolytic therapy, summary [VTE]"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Acyclovir [FN]"
},
{
	"jumpto":"ENAS5282_2.0.0.0",
	"name":"Adenocarcinomas (Oes CA)"
},
{
	"jumpto":"ENAS5282_4.1.6.0",
	"name":"Adenocarcinomas, management (Oes CA)"
},
{
	"jumpto":"ENAS5283_4.3.3.2",
	"name":"Adjuvant 5-FU/leucovorin therapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5092_4.2.2.0",
	"name":"Adjuvant ADT [PC]"
},
{
	"jumpto":"ENAS5094_4.3.0.0",
	"name":"Adjuvant chemotherapy [BC]"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"Adjuvant chemotherapy [mCRC]"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"Adjuvant chemotherapy [TS/T-NS]"
},
{
	"jumpto":"ENAS5283_4.3.3.1",
	"name":"Adjuvant treatment (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.3",
	"name":"Adjuvant treatment, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5284_7.3.1.6",
	"name":"Adjuvant treatment, summary [Bil]"
},
{
	"jumpto":"ENAS5068_8.3.4.0",
	"name":"Adjuvant treatment in pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5284_4.3.6.0",
	"name":"Adjuvant treatment [Bil]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Adjuvant treatment [TS/T-NS]"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"ADT [PC]"
},
{
	"jumpto":"ENAS5270_9.3.3.0",
	"name":"Advanced-stage cHL, summary"
},
{
	"jumpto":"ENAS5064_7.3.3.0",
	"name":"Advanced-stage HCC treatment, summary"
},
{
	"jumpto":"ENAS5268_5.1.0.0",
	"name":"Advanced cancer, antiemetics [N/V]"
},
{
	"jumpto":"ENAS5285_5.2.2.1",
	"name":"Advanced disease, overview [RCC]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Advanced disease, summary [RCC]"
},
{
	"jumpto":"ENAS5064_4.4.0.0",
	"name":"Advanced HCC"
},
{
	"jumpto":"ENAS5064_6.0.0.0",
	"name":"Advanced HCC, follow-up"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Advanced pancreatic cancer, palliative care"
},
{
	"jumpto":"ENAS5304_5.14.4.0",
	"name":"Aflibercept [mCRC]"
},
{
	"jumpto":"ENAS5284_3.2.1.1",
	"name":"AJCC/UICC staging, cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5284_3.2.2.0",
	"name":"AJCC/UICC staging, gallbladder cancer [Bil]"
},
{
	"jumpto":"ENAS5269_5.4.0.0",
	"name":"Algo., FN mgmt."
},
{
	"jumpto":"ENAS5269_4.2.0.0",
	"name":"Algo., primary G-CSF prophylaxis [FN]"
},
{
	"jumpto":"ENAS5269_5.10.2.0",
	"name":"Algo., response assessment [FN]"
},
{
	"jumpto":"ENAS5284_4.2.0.0",
	"name":"Algorithm, BTC management [Bil]"
},
{
	"jumpto":"ENAS5285_6.2.2.2",
	"name":"Algorithm, systemic treatment [RCC]"
},
{
	"jumpto":"ENAS5263_14.4.0.0",
	"name":"Alimentary tract mucositis, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Alimentary tract mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5281_4.9.1.0",
	"name":"ALK-rearranged NSCLC patients"
},
{
	"jumpto":"ENAS5281_7.3.8.0",
	"name":"ALK-rearranged NSCLC patients, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_2.2.0.0",
	"name":"ALK gene (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Alkylating agents [Extra]"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Allogeneic haematopoietic stem cell transplantation [FN]"
},
{
	"jumpto":"ENAS5410_4.2.6.7",
	"name":"Allograft rejection, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.7.0",
	"name":"Allograft rejection [irAEs]"
},
{
	"jumpto":"ENAS5280_4.6.0.0",
	"name":"AlloSCT"
},
{
	"jumpto":"ENAS5280_7.3.6.0",
	"name":"AlloSCT in HCL, summary"
},
{
	"jumpto":"ENAS5064_5.0.0.0",
	"name":"Alpha fetoprotein"
},
{
	"jumpto":"ENAS5262_6.3.3.3",
	"name":"ALT, summary [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.1.0",
	"name":"Alternative therapy, overview [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.1",
	"name":"Alternative therapy, summary [FN]"
},
{
	"jumpto":"ENAS5262_4.3.5.0",
	"name":"ALT [CVC]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Amifostine [Mucosa]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Amikacin [CVC]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Amphiregulin [mCRC]"
},
{
	"jumpto":"ENAS5262_6.3.3.9",
	"name":"Amphotericin, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.11.0",
	"name":"Amphotericin [CVC]"
},
{
	"jumpto":"ENAS5063_2.2.1.0",
	"name":"Amsterdam criteria"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Anal cancer, advanced disease"
},
{
	"jumpto":"ENAS5062_3.3.0.0",
	"name":"Anal cancer, anatomic stage"
},
{
	"jumpto":"ENAS5062_4.5.0.0",
	"name":"Anal cancer, brachytherapy"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Anal cancer, chemoradiotherapy"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Anal cancer, diagnosis"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Anal cancer, diagnostic work-up"
},
{
	"jumpto":"ENAS5062_7.0.0.0",
	"name":"Anal cancer, follow-up"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"Anal cancer, initial mgmt."
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Anal cancer, metastatic disease"
},
{
	"jumpto":"ENAS5062_4.12.0.0",
	"name":"Anal cancer, palliative care"
},
{
	"jumpto":"ENAS5062_4.7.0.0",
	"name":"Anal cancer, post-operative chemoradiotherapy"
},
{
	"jumpto":"ENAS5062_3.3.0.0",
	"name":"Anal cancer, prognostic groups"
},
{
	"jumpto":"ENAS5062_5.0.0.0",
	"name":"Anal cancer, quality of life"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Anal cancer, radiotherapy"
},
{
	"jumpto":"ENAS5062_6.0.0.0",
	"name":"Anal cancer, response evaluation"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Anal cancer, risk assessment"
},
{
	"jumpto":"ENAS5062_3.4.0.0",
	"name":"Anal cancer, risk assessment factors"
},
{
	"jumpto":"ENAS5062_4.9.0.0",
	"name":"Anal cancer, salvage surgical treatment"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Anal cancer, staging"
},
{
	"jumpto":"ENAS5062_4.3.0.0",
	"name":"Anal cancer, surgical treatment"
},
{
	"jumpto":"ENAS5062_7.0.0.0",
	"name":"Anal cancer, surveillance"
},
{
	"jumpto":"ENAS5062_3.2.0.0",
	"name":"Anal cancer, TNM staging"
},
{
	"jumpto":"ENAS5062_4.6.0.0",
	"name":"Anal cancer, treatment of the elderly"
},
{
	"jumpto":"ENAS5062_8.2.0.0",
	"name":"Anal cancer staging, summary"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Analgesics [Mucosa]"
},
{
	"jumpto":"ENAS5409_3.0.0.0",
	"name":"Anaphylaxis, clinical criteria for diagnosis [IRs]"
},
{
	"jumpto":"ENAS5409_3.0.0.0",
	"name":"Anaphylaxis, diagnosis criteria [IRs]"
},
{
	"jumpto":"ENAS5281_3.3.0.0",
	"name":"Anatomic stage (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5061_4.3.0.0",
	"name":"Anatomic stage, early colon cancer"
},
{
	"jumpto":"ENAS5283_3.3.0.0",
	"name":"Anatomic stage/ prognostic groups (Gastric cancer)"
},
{
	"jumpto":"ENAS5064_2.0.0.0",
	"name":"Angiography, HCC"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Angiography, pancreatic arterial"
},
{
	"jumpto":"ENAS5273_4.2.0.0",
	"name":"Ann Arbor classification, FL"
},
{
	"jumpto":"ENAS5271_3.2.0.0",
	"name":"Ann Arbor staging classification, DLBCL"
},
{
	"jumpto":"ENAS5278_3.4.0.0",
	"name":"Ann Arbor staging classification, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5266_3.2.1.0",
	"name":"Anthracyclines and cytotoxics, overview [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.2.2.0",
	"name":"Anthracyclines and cytotoxics, summary [CV Tox]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Anthracyclines [Extra]"
},
{
	"jumpto":"ENAS5409_11.1.2.0",
	"name":"Anthracyclines [IRs]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Anti-angiogenic therapy [BC]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"Anti-EGFR monoclonal antibody therapies [mCRC]"
},
{
	"jumpto":"ENAS5086_5.3.0.0",
	"name":"Anti-folate doublet, unresectable mesothelioma"
},
{
	"jumpto":"ENAS5268_5.2.0.0",
	"name":"Anti-secretory drugs [N/V]"
},
{
	"jumpto":"ENAS5304_5.14.4.0",
	"name":"Antiangiogenic [mCRC]"
},
{
	"jumpto":"ENAS5262_6.3.3.3",
	"name":"Antibiotic lock therapy, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.5.0",
	"name":"Antibiotic lock therapy [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Antibiotic treatment, CVC-related infections [CVC]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Anticancer agents, classification [Extra]"
},
{
	"jumpto":"ENAS5266_8.0.0.0",
	"name":"Anticancer treatment, Tx of LVD [CV Tox]"
},
{
	"jumpto":"ENAS5268_5.2.0.0",
	"name":"Anticholinergics [N/V]"
},
{
	"jumpto":"ENAS5268_2.8.0.0",
	"name":"Anticipatory nausea and vomiting, prev."
},
{
	"jumpto":"ENAS5265_6.0.0.0",
	"name":"Anticoagulation, contraindications [VTE]"
},
{
	"jumpto":"ENAS5265_7.0.0.0",
	"name":"Anticoagulation and prognosis [VTE]"
},
{
	"jumpto":"ENAS5265_8.5.0.0",
	"name":"Anticoagulation contraindications, summary [VTE]"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Antidotes, after extravasation"
},
{
	"jumpto":"ENAS5268_2.3.1.0",
	"name":"Antiemetics, dose [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.1.0",
	"name":"Antiemetics, route of administration [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.1.0",
	"name":"Antiemetics, safety [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.1.0",
	"name":"Antiemetics, schedule [N/V]"
},
{
	"jumpto":"ENAS5268_5.1.0.0",
	"name":"Antiemetics in advanced cancer, overview [N/V]"
},
{
	"jumpto":"ENAS5268_6.4.1.0",
	"name":"Antiemetics in advanced cancer, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.2.3.0",
	"name":"Antiemetic treatment options, summary [N/V]"
},
{
	"jumpto":"ENAS5268_3.4.0.0",
	"name":"Antiemetic treatment options [N/V]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Antimetabolites [Extra]"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"APC-associated FAP"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"APC-associated FAP, definition"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"APC-associated FAP, prevalence"
},
{
	"jumpto":"ENAS5063_6.3.1.0",
	"name":"APC-associated FAP, summary"
},
{
	"jumpto":"ENAS5063_4.2.2.0",
	"name":"APC germline analysis"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Aprepitant [N/V]"
},
{
	"jumpto":"ENAS5266_9.4.0.0",
	"name":"Arrhythmias [CV Tox]"
},
{
	"jumpto":"ENAS5410_3.6.3.2",
	"name":"Arthralgia management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"ASA [Mucosa]"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Asbestos exposure [MPM]"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"Ascites [Early colon cancer]"
},
{
	"jumpto":"ENAS5063_2.4.0.0",
	"name":"Aspirin, Lynch syndrome"
},
{
	"jumpto":"ENAS5269_6.4.7.0",
	"name":"Assess. of response, summary [FN]"
},
{
	"jumpto":"ENAS5407_4.7.2.4",
	"name":"Assessment of distant metastases [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.7.2.3",
	"name":"Assessment of patients planned for surgery [Rectal CA]"
},
{
	"jumpto":"ENAS5269_5.10.1.0",
	"name":"Assessment of response [FN]"
},
{
	"jumpto":"ENAS5407_4.7.2.1",
	"name":"Assessment of the primary tumour response [Rectal CA]"
},
{
	"jumpto":"ENAS5266_3.4.2.0",
	"name":"Asymptomatic LVD [CV Tox]"
},
{
	"jumpto":"ENAS5063_4.2.1.0",
	"name":"Attenuated FAP, diagnosis"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Atypical mesothelial proliferation, immunohistochemistry (IHC)"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Australasian planning guidelines"
},
{
	"jumpto":"ENAS5098_3.0.0.0",
	"name":"Autoimmune disorders associated with thymoma [TETs]"
},
{
	"jumpto":"ENAS5285_6.2.2.5",
	"name":"Axitinib [RCC]"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Barcelona Clinic Liver Cancer (BCLC) staging"
},
{
	"jumpto":"ENAS5063_4.3.0.0",
	"name":"Barium contrast series [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5263_10.2.2.0",
	"name":"Basic oral care protocol, example [Mucosa]"
},
{
	"jumpto":"ENAS5094_2.0.0.0",
	"name":"BC, diagnosis"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"BC, follow-up"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"BC, long term implications"
},
{
	"jumpto":"ENAS5094_4.1.0.0",
	"name":"BC, management of local/ locoregional disease"
},
{
	"jumpto":"ENAS5094_4.4.0.0",
	"name":"BC, Organ preservation therapy"
},
{
	"jumpto":"ENAS5094_5.2.0.0",
	"name":"BC, second-line therapy"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"BC, staging and risk assessment"
},
{
	"jumpto":"ENAS5094_3.2.0.0",
	"name":"BC, TNM staging"
},
{
	"jumpto":"ENAS5094_2.0.0.0",
	"name":"BC, WHO classification"
},
{
	"jumpto":"ENAS5094_9.1.0.0",
	"name":"BC diagnosis, summary"
},
{
	"jumpto":"ENAS5094_5.2.0.0",
	"name":"BC relapse, treatment"
},
{
	"jumpto":"ENAS5094_9.2.0.0",
	"name":"BC staging and risk assessment, summary"
},
{
	"jumpto":"ENAS5268_2.8.0.0",
	"name":"Benzodiazepines [N/V]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Benzydamine mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"BEP [TS/T-NS]"
},
{
	"jumpto":"ENAS5064_4.4.0.0",
	"name":"Best supportive care (BSC)[HCC]"
},
{
	"jumpto":"ENAS5304_5.14.10.3",
	"name":"Best supportive care (BSC) [mCRC]"
},
{
	"jumpto":"ENAS5282_4.2.0.0",
	"name":"Best supportive care (Oes CA)"
},
{
	"jumpto":"ENAS5086_5.2.0.0",
	"name":"Best supportive care, MPM"
},
{
	"jumpto":"ENAS5063_2.2.2.0",
	"name":"Bethesda guidelines, colorectal tumors"
},
{
	"jumpto":"ENAS5304_5.14.4.0",
	"name":"Bevacizumab [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Bevacizumab [mCRC]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Bevacizumab [RCC]"
},
{
	"jumpto":"ENAS5063_5.1.0.0",
	"name":"Biallelic mutations"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Biliary obstruction [Pancr]"
},
{
	"jumpto":"ENAS5064_4.3.0.0",
	"name":"Biliary stent"
},
{
	"jumpto":"ENAS5064_4.3.0.0",
	"name":"Bilio-evteric anastomosis"
},
{
	"jumpto":"ENAS5279_3.2.0.0",
	"name":"BINET system [CLL]"
},
{
	"jumpto":"ENAS5285_4.0.0.0",
	"name":"Biology [RCC]"
},
{
	"jumpto":"ENAS5282_7.1.0.0",
	"name":"Biopsies, summary (Oes CA)"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Biopsy [TETs]"
},
{
	"jumpto":"ENAS5284_3.1.0.0",
	"name":"Bismuth-Corlette classification, peri-hilar cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Bisphosphonates, role [RCC]"
},
{
	"jumpto":"ENAS5285_9.4.2.3",
	"name":"Bisphosphonates, summary [RCC]"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Bladder ultrasonography [BC]"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"Bleomycin, non-seminoma [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Bleomycin, seminoma [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_4.1.0.0",
	"name":"Bleomycin/etoposide/cisplatin (BEP) [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"Blood tests in TS/T-NS"
},
{
	"jumpto":"ENAS5410_3.1.3.2",
	"name":"Body surface area schematic [irAEs]"
},
{
	"jumpto":"ENAS5281_4.14.2.0",
	"name":"Bone metastases (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.13.2",
	"name":"Bone metastases, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"Bone scan [PC]"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"Bowenoid papulosis [PenCa]"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"Bowen’s disease [PenCa]"
},
{
	"jumpto":"ENAS5062_8.3.4.0",
	"name":"Brachytherapy in anal cancer, summary"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"Brachytherapy [PenCa]"
},
{
	"jumpto":"ENAS5304_8.5.2.0",
	"name":"BRAF, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"BRAF mutation status [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.2.0",
	"name":"BRAF mutations [mCRC]"
},
{
	"jumpto":"ENAS5281_4.14.1.0",
	"name":"Brain and bone metastases (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.13.1",
	"name":"Brain and bone metastases, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.14.1.0",
	"name":"Brain metastases (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.13.1",
	"name":"Brain metastases, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"BRCA1 [Pancr]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"BRCA2 [Pancr]"
},
{
	"jumpto":"ENAS5268_6.1.7.0",
	"name":"Breakthrough ChT-induced emesis, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.7.0",
	"name":"Breakthrough refractory emesis, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.2.3.0",
	"name":"Breast cancer, AC-treated female patients [N/V]"
},
{
	"jumpto":"ENAS5263_14.8.3.0",
	"name":"Bristol stool chart, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.3.0.0",
	"name":"Bristol stool chart [Mucosa]"
},
{
	"jumpto":"ENAS5284_4.2.0.0",
	"name":"BTC management algorithm [Bil]"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"CA 19-9 [Pancr]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Cabazitaxel, treatment of CRPC [PC]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Cabazitaxel [PC]"
},
{
	"jumpto":"ENAS5285_6.2.2.6",
	"name":"Cabozantinib [RCC]"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Calretinin"
},
{
	"jumpto":"ENAS5283_5.0.0.0",
	"name":"Cancer genome atlas (Gastric cancer)"
},
{
	"jumpto":"ENAS5262_6.3.3.9",
	"name":"Candida, summary [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.10.0",
	"name":"Candidaemia [FN]"
},
{
	"jumpto":"ENAS5262_4.3.11.0",
	"name":"Candida [CVC]"
},
{
	"jumpto":"ENAS5269_6.4.6.10",
	"name":"Candidiasis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.10.0",
	"name":"Candidiasis [FN]"
},
{
	"jumpto":"ENAS5267_5.0.0.0",
	"name":"Cannulation [Extra]"
},
{
	"jumpto":"ENAS5283_4.3.2.0",
	"name":"Capecitabine, perioperative chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Capecitabine [Mucosa]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Capecitabine [Pancr]"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"CAPOX [mCRC]"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Capsule endoscopy"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Carbo-Px [TETs]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"CarboGem [BC]"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"Carbohydrate antigen (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Carboplatin, MPM therapy"
},
{
	"jumpto":"ENAS5268_6.1.4.2",
	"name":"Carboplatin, summary [N/V]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Carboplatin/gemcitabine [BC]"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Carboplatin [Anal cancer]"
},
{
	"jumpto":"ENAS5268_2.4.2.0",
	"name":"Carboplatin [N/V]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Carboplatin [TETs]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Carboplatin [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Carboplatin [TS/T-NS]"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Carcinoembryonic antigen (CEA)"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"Carcinoembryonic antigen (CEA)[Early colon cancer]"
},
{
	"jumpto":"ENAS5266_9.4.0.0",
	"name":"Cardiac function after chest RT, monitoring [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.3.0.0",
	"name":"Cardiac ischaemia, summary [CV Tox]"
},
{
	"jumpto":"ENAS5266_4.0.0.0",
	"name":"Cardiac ischaemia [CV Tox]"
},
{
	"jumpto":"ENAS5410_4.2.6.2",
	"name":"Cardiac toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5266_9.1.0.0",
	"name":"Cardiac toxicity induced by RT, overview [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.8.1.0",
	"name":"Cardiac toxicity induced by RT, summary [ CV Tox]"
},
{
	"jumpto":"ENAS5410_3.6.2.0",
	"name":"Cardiac toxicity [irAEs]"
},
{
	"jumpto":"ENAS5266_9.4.0.0",
	"name":"Cardiomyopathy [CV Tox]"
},
{
	"jumpto":"ENAS5266_3.2.2.0",
	"name":"Cardiotoxicity, mgmt."
},
{
	"jumpto":"ENAS5262_5.3.0.0",
	"name":"Catheter-induced thrombosis, diagnosis [CVC]"
},
{
	"jumpto":"ENAS5262_5.1.0.0",
	"name":"Catheter-induced thrombosis, overview [CVC]"
},
{
	"jumpto":"ENAS5262_5.6.0.0",
	"name":"Catheter-induced thrombosis, prevention [CVC]"
},
{
	"jumpto":"ENAS5262_5.2.0.0",
	"name":"Catheter-induced thrombosis, risk factors [CVC]"
},
{
	"jumpto":"ENAS5262_5.4.0.0",
	"name":"Catheter-induced thrombosis, treatment [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.2.0",
	"name":"Catheter-related infection [FN]"
},
{
	"jumpto":"ENAS5262_5.5.2.0",
	"name":"Catheter-related thrombosis, prevention [CVC]"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Catheter-related thrombosis, treatment [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Ceftazidime [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.7",
	"name":"Cellulitis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.7.0",
	"name":"Cellulitis [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.2",
	"name":"Central IV catheters, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.2.0",
	"name":"Central IV catheters [FN]"
},
{
	"jumpto":"ENAS5410_3.6.1.4",
	"name":"Central neurological toxicity mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5267_9.1.0.0",
	"name":"Central venous access device extravasation, overview"
},
{
	"jumpto":"ENAS5267_12.8.0.0",
	"name":"Central venous access device extravasation, summary [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Central venous access device [Extra]"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Cervical intra-epithelial neoplasia (CIN)"
},
{
	"jumpto":"ENAS5063_4.3.0.0",
	"name":"Cervical ultrasonography [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5304_5.14.5.0",
	"name":"Cetuximab + irinotecan [mCRC]"
},
{
	"jumpto":"ENAS5409_11.2.2.0",
	"name":"Cetuximab [IRs]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"Cetuximab [mCRC]"
},
{
	"jumpto":"ENAS5283_4.2.0.0",
	"name":"CF, cisplatin/5-fluorouracil (Gastric cancer)"
},
{
	"jumpto":"ENAS5267_6.3.0.0",
	"name":"Chemical phlebitis [Extra]"
},
{
	"jumpto":"ENAS5267_6.2.0.0",
	"name":"Chemical phlebitis [Extra]"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Chemoembolisation [mCRC]"
},
{
	"jumpto":"ENAS5063_4.4.0.0",
	"name":"Chemoprevention, Fam. Colorectal cancer"
},
{
	"jumpto":"ENAS5269_6.2.0.0",
	"name":"Chemoprophylaxis, summary [FN]"
},
{
	"jumpto":"ENAS5269_3.0.0.0",
	"name":"Chemoprophylaxis [FN]"
},
{
	"jumpto":"ENAS5283_4.3.3.2",
	"name":"Chemoradiotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Chemoradiotherapy, anal cancer"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Chemoradiotherapy, capectabine [Pancr]"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Chemoradiotherapy, locally advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5407_4.8.1.0",
	"name":"Chemoradiotherapy, postoperative indications [Rectal CA]"
},
{
	"jumpto":"ENAS5283_8.3.1.3",
	"name":"Chemoradiotherapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5062_8.3.3.0",
	"name":"Chemoradiotherapy in anal cancer, summary"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Chemoradiotherapy [Pancr]"
},
{
	"jumpto":"ENAS5283_4.3.3.3",
	"name":"Chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Chemotherapy, definitive [TETs]"
},
{
	"jumpto":"ENAS5263_10.2.1.0",
	"name":"Chemotherapy, mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Chemotherapy, PenCa"
},
{
	"jumpto":"ENAS5098_5.6.0.0",
	"name":"Chemotherapy, post-op [TETs]"
},
{
	"jumpto":"ENAS5407_4.8.2.0",
	"name":"Chemotherapy, postoperative [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.7.1.0",
	"name":"Chemotherapy, preoperative [Rectal CA]"
},
{
	"jumpto":"ENAS5283_8.3.1.3",
	"name":"Chemotherapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5265_2.2.0.0",
	"name":"Chemotherapy-associated VTE"
},
{
	"jumpto":"ENAS5268_4.0.0.0",
	"name":"Chemotherapy-induced nausea and vomiting in children"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Chemotherapy-induced nausea and vomiting [N/V]"
},
{
	"jumpto":"ENAS5098_5.12.0.0",
	"name":"Chemotherapy for advanced TETs"
},
{
	"jumpto":"ENAS5096_7.3.3.0",
	"name":"Chemotherapy in PenCa, summary"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, BEP (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, EP (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, TI-CE (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, TIP (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, VeIP (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, VIP/PEI (TS)"
},
{
	"jumpto":"ENAS5304_8.5.4.0",
	"name":"Chemotherapy sensitivity, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Chemotherapy sensitivity [mCRC]"
},
{
	"jumpto":"ENAS5281_4.3.1.0",
	"name":"Chemotherapy with platinum-doublets (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5097_4.1.0.0",
	"name":"Chemotherapy [TS/T-NS]"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Child-Pugh (CP) scoring"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Chlorhexidine mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5269_6.4.5.2",
	"name":"Choice of IV antibacterial, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.7.2.0",
	"name":"Choice of IV antibacterial [FN]"
},
{
	"jumpto":"ENAS5284_3.2.1.1",
	"name":"Cholangiocarcinoma, AJCC/UICC staging [Bil]"
},
{
	"jumpto":"ENAS5284_3.2.1.3",
	"name":"Cholangiocarcinoma, distal [Bil]"
},
{
	"jumpto":"ENAS5284_3.2.1.1",
	"name":"Cholangiocarcinoma, intra-hepatic [Bil]"
},
{
	"jumpto":"ENAS5284_3.2.1.2",
	"name":"Cholangiocarcinoma, peri-hilar [Bil]"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Choroidal neovascularisation, treatment"
},
{
	"jumpto":"ENAS5406_5.1.3.0",
	"name":"Chronic obstructive pulmonary disease [Early NSCLC]"
},
{
	"jumpto":"ENAS5268_2.7.0.0",
	"name":"ChT-induced emesis [N/V]"
},
{
	"jumpto":"ENAS5267_6.3.0.0",
	"name":"ChT drugs, causing local reactions [Extra]"
},
{
	"jumpto":"ENAS5268_2.6.0.0",
	"name":"ChT with low & minimal emetogenic potential, prev. [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"CINV, prevention"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Ciprofloxacin [CVC]"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Circulating tumour cell (CTC) [mCRC]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Cisplatin, definitive chemotherapy [TETs]"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Cisplatin, localised SCLC"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Cisplatin, MPM therapy"
},
{
	"jumpto":"ENAS5281_4.3.1.0",
	"name":"Cisplatin-based chemotherapy (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5096_4.3.0.0",
	"name":"Cisplatin-based chemotherapy [PenCa]"
},
{
	"jumpto":"ENAS5094_4.3.0.0",
	"name":"Cisplatin-based neoadjuvant chemotherapy [BC]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Cisplatin-based [PenCa]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Cisplatin-containing combination chemotherapy [BC]"
},
{
	"jumpto":"ENAS5268_6.1.2.2",
	"name":"Cisplatin-treated patients, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Cisplatin-treated patients [N/V]"
},
{
	"jumpto":"ENAS5282_4.1.6.0",
	"name":"Cisplatin/5-FU combined with 41.4–50.4 Gy RT (Oes CA)"
},
{
	"jumpto":"ENAS5281_4.3.2.0",
	"name":"Cisplatin and gemcitabine, treatment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Cisplatin [Anal cancer]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Cisplatin [BC]"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Cisplatin [PenCa]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Cisplatin [TS/T-NS]"
},
{
	"jumpto":"ENAS5280_4.2.2.0",
	"name":"Cladribine"
},
{
	"jumpto":"ENAS5063_4.2.1.0",
	"name":"Classical FAP, diagnosis"
},
{
	"jumpto":"ENAS5280_4.2.5.0",
	"name":"Classical HCL: Tx of newly diagnosed"
},
{
	"jumpto":"ENAS5280_4.4.2.0",
	"name":"Classical HCL: Tx of relapsed & refractory, interactive tool"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Classification, anticancer agents [Extra]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Classification [TETs]"
},
{
	"jumpto":"ENAS5094_6.0.0.0",
	"name":"Clinical mgmt.overview, interactive tool [BC]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Clinical myasthenia gravis [TETs]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Clinical trials [Pancr]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Clinical trials [TETs]"
},
{
	"jumpto":"ENAS5269_5.9.9.0",
	"name":"Clostridium difficile [FN]"
},
{
	"jumpto":"ENAS5269_5.9.2.0",
	"name":"CNS bacteraemia [FN]"
},
{
	"jumpto":"ENAS5271_7.3.2.0",
	"name":"CNS prophylaxis in DLBCL, summary"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Coeliac axis (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Coeliac plexus block (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5061_5.2.0.0",
	"name":"Colonic resection [Early colon cancer]"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Colonoscopy [Anal cancer]"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Colonoscopy [Early colon cancer]"
},
{
	"jumpto":"ENAS5304_5.2.2.0",
	"name":"Colorectal liver metastases (CLM) [mCRC]"
},
{
	"jumpto":"ENAS5304_5.5.0.0",
	"name":"Colorectal liver metastases [mCRC]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Combination chemotherapy [TETs]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Combination therapy [FN]"
},
{
	"jumpto":"ENAS5273_5.4.0.0",
	"name":"Combined chemoimmunotherapy in FL"
},
{
	"jumpto":"ENAS5408_3.1.0.0",
	"name":"Combined MIPI [MCL]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Common hepatic artery (CHA)"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Common initial symptoms, extravasation"
},
{
	"jumpto":"ENAS5267_12.5.1.0",
	"name":"Common initial symptoms, summary [Extra]"
},
{
	"jumpto":"ENAS5061_5.1.0.0",
	"name":"Complete endoscopic polypectomy"
},
{
	"jumpto":"ENAS5281_4.5.0.0",
	"name":"Comprehensive geriatric assessment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Computed tomography (CT) [BC]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Computed tomography (CT) [Pancr]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Computed tomography [TETs]"
},
{
	"jumpto":"ENAS5268_6.2.4.0",
	"name":"Concurrent chemoradiotherapy, summary [N/V]"
},
{
	"jumpto":"ENAS5268_3.5.0.0",
	"name":"Concurrent chemoradiotherapy [N/V]"
},
{
	"jumpto":"ENAS5086_5.4.3.0",
	"name":"Conformal radiotherapy"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"Congenital hypertrophy of retinal pigmented epithelium"
},
{
	"jumpto":"ENAS5273_5.5.0.0",
	"name":"Consolidation/ maintenance, FL"
},
{
	"jumpto":"ENAS5273_8.3.2.0",
	"name":"Consolidation/maintenance of FL, summary"
},
{
	"jumpto":"ENAS5266_3.4.3.0",
	"name":"Continuation of trastuzumab, LVEF [CV Tox]"
},
{
	"jumpto":"ENAS5265_6.0.0.0",
	"name":"Contraindications, anticoagulation [VTE]"
},
{
	"jumpto":"ENAS5265_8.5.0.0",
	"name":"Contraindications to anticoagulation, summary [VTE]"
},
{
	"jumpto":"ENAS5281_3.1.0.0",
	"name":"Contrast-enhanced CT (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5064_2.0.0.0",
	"name":"Contrast-enhanced ultrasound (CEUS)"
},
{
	"jumpto":"ENAS5283_4.3.3.2",
	"name":"Conventionally fractionated radiotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_8.6.2.5",
	"name":"Conversion strategic treatment goal, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.3.0",
	"name":"Conversion treatment, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.9.0.0",
	"name":"Conversion treatment [mCRC]"
},
{
	"jumpto":"ENAS5268_2.3.3.0",
	"name":"Corticosteroids, doses [N/V]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Corticosteroids [PC]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Craniospinal irradiation [N/V]"
},
{
	"jumpto":"ENAS5262_4.1.0.0",
	"name":"CRBSI [CVC]"
},
{
	"jumpto":"ENAS5063_4.3.0.0",
	"name":"CRC screening [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5281_4.9.1.0",
	"name":"Crizotinib, treatment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5269_5.9.2.0",
	"name":"CRI [FN]"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Crohn's disease"
},
{
	"jumpto":"ENAS5407_9.3.3.0",
	"name":"CRT regimen, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Cryoablation [RCC]"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"CT, PC follow-up [PC]"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"CT abdomen [Anal cancer]"
},
{
	"jumpto":"ENAS5061_3.0.0.0",
	"name":"CT colonography"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"CT thorax [Anal cancer]"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"CT [PC]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"CT [TETs]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"CT [TETs]"
},
{
	"jumpto":"ENAS5266_3.2.1.0",
	"name":"Cumulative dose-related cardiotoxicity, overview [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.2.2.0",
	"name":"Cumulative dose-related cardiotoxicity, summary [CV Tox]"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Curative treatment (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5276_4.8.0.0",
	"name":"Cutaneous B-cell lymphoma (CBCL)"
},
{
	"jumpto":"ENAS5276_7.3.9.0",
	"name":"Cutaneous B-cell lymphoma (CBCL), summary"
},
{
	"jumpto":"ENAS5267_9.2.0.0",
	"name":"CVAD extravasation, steps"
},
{
	"jumpto":"ENAS5262_4.1.0.0",
	"name":"CVC-related infection, overview"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"CVC-related infections, antibiotic treatment [CVC]"
},
{
	"jumpto":"ENAS5262_4.4.0.0",
	"name":"CVC-related infections, prevention"
},
{
	"jumpto":"ENAS5262_4.2.0.0",
	"name":"CVC infections, diagnosis"
},
{
	"jumpto":"ENAS5262_4.3.2.0",
	"name":"CVC infections, management"
},
{
	"jumpto":"ENAS5262_4.3.1.0",
	"name":"CVC infections, treatment"
},
{
	"jumpto":"ENAS5262_4.3.4.0",
	"name":"CVC removal , indications"
},
{
	"jumpto":"ENAS5266_10.1.0.0",
	"name":"CV eval. before anticancer treatment, summary [CV Tox]"
},
{
	"jumpto":"ENAS5266_2.0.0.0",
	"name":"CV eval. before anticancer treatment [CV Tox]"
},
{
	"jumpto":"ENAS5266_7.0.0.0",
	"name":"CV monitoring, after anticancer Tx [CV Tox]"
},
{
	"jumpto":"ENAS5266_7.0.0.0",
	"name":"CV monitoring, during anticancer Tx [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.6.0.0",
	"name":"CV monitoring after anticancer Tx, summary [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.6.0.0",
	"name":"CV monitoring during anticancer Tx, summary [CV Tox]"
},
{
	"jumpto":"ENAS5283_4.2.0.0",
	"name":"CX, cisplatin/capecitabine (Gastric cancer)"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Cyclophosphamide, second-line treatment [SCLC]"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Cyfra 21.1 [MPM]"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"Cystoscopy, BC follow-up [BC]"
},
{
	"jumpto":"ENAS5094_7.0.0.0",
	"name":"Cystoscopy, management of BC [BC]"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Cystoscopy [BC]"
},
{
	"jumpto":"ENAS5409_4.0.0.0",
	"name":"Cytokine release syndrome [IRs]"
},
{
	"jumpto":"ENAS5304_5.14.7.0",
	"name":"Cytoreduction (Shrinkage) [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Cytoreduction [mCRC]"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Cytoreductive nephrectomy [RCC]"
},
{
	"jumpto":"ENAS5304_8.6.6.0",
	"name":"Cytoreductive surgery, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.13.0.0",
	"name":"Cytoreductive surgery [mCRC]"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"Cytotoxic agents [Anal cancer]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Cytotoxic doublet [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Cytotoxic triplet [mCRC]"
},
{
	"jumpto":"ENAS5269_6.4.7.0",
	"name":"Daily follow-up, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.10.1.0",
	"name":"Daily follow-up [FN]"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Dalteparin [CVC]"
},
{
	"jumpto":"ENAS5262_6.3.3.7",
	"name":"Daptomycin, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.9.0",
	"name":"Daptomycin [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.7.0",
	"name":"Daptomycin [FN]"
},
{
	"jumpto":"ENAS5284_7.3.1.4",
	"name":"dCCA, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.4.0",
	"name":"dCCA [Bil]"
},
{
	"jumpto":"ENAS5278_3.3.0.0",
	"name":"Deauville criteria"
},
{
	"jumpto":"ENAS5064_4.3.0.0",
	"name":"Decompensated cirrhosis"
},
{
	"jumpto":"ENAS5267_2.0.0.0",
	"name":"Definition, extravasation"
},
{
	"jumpto":"ENAS5267_12.1.0.0",
	"name":"Definition of extravasation, summary"
},
{
	"jumpto":"ENAS5098_8.3.8.0",
	"name":"Definitive chemotherapy, summary [TETs]"
},
{
	"jumpto":"ENAS5098_8.3.7.0",
	"name":"Definitive radiotherapy, summary [TETs]"
},
{
	"jumpto":"ENAS5098_5.9.0.0",
	"name":"Definitive RT [TETs]"
},
{
	"jumpto":"ENAS5268_2.3.3.0",
	"name":"Delayed emesis [N/V]"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Denosumab [PC]"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Denosumab [RCC]"
},
{
	"jumpto":"ENAS5304_5.9.0.0",
	"name":"Depth of response [mCRC]"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"Desmoid tumor"
},
{
	"jumpto":"ENAS5281_4.14.1.0",
	"name":"Dexamethasone, metastases (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Dexamethasone [N/V]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Dexamethasone [PC]"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Dexrazoxane [Extra]"
},
{
	"jumpto":"ENAS5410_3.2.3.0",
	"name":"Diabetes mellitus [irAEs]"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Diagnosis (Gastric cancer)"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"Diagnosis (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_2.0.0.0",
	"name":"Diagnosis (Oes CA)"
},
{
	"jumpto":"ENAS5262_5.3.0.0",
	"name":"Diagnosis, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5279_2.0.0.0",
	"name":"Diagnosis, CLL"
},
{
	"jumpto":"ENAS5262_4.2.0.0",
	"name":"Diagnosis, CVC infections"
},
{
	"jumpto":"ENAS5271_2.0.0.0",
	"name":"Diagnosis, DLBCL"
},
{
	"jumpto":"ENAS5278_2.1.0.0",
	"name":"Diagnosis, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5061_3.0.0.0",
	"name":"Diagnosis, early colon cancer"
},
{
	"jumpto":"ENAS5406_3.0.0.0",
	"name":"Diagnosis, early NSCLC"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Diagnosis, extravasation [Extra]"
},
{
	"jumpto":"ENAS5273_2.0.0.0",
	"name":"Diagnosis, FL"
},
{
	"jumpto":"ENAS5280_2.1.0.0",
	"name":"Diagnosis, HCL"
},
{
	"jumpto":"ENAS5064_2.0.0.0",
	"name":"Diagnosis, hepatocellular cancer"
},
{
	"jumpto":"ENAS5270_2.0.0.0",
	"name":"Diagnosis, Hodgkin’s lymphoma"
},
{
	"jumpto":"ENAS5275_2.0.0.0",
	"name":"Diagnosis, MALT"
},
{
	"jumpto":"ENAS5265_3.0.0.0",
	"name":"Diagnosis, occult cancer idiopathic VTE"
},
{
	"jumpto":"ENAS5278_2.5.0.0",
	"name":"Diagnosis, PBL"
},
{
	"jumpto":"ENAS5278_2.6.0.0",
	"name":"Diagnosis, PBoL"
},
{
	"jumpto":"ENAS5276_2.0.0.0",
	"name":"Diagnosis, PCLs"
},
{
	"jumpto":"ENAS5278_2.4.0.0",
	"name":"Diagnosis, PCNSL"
},
{
	"jumpto":"ENAS5278_2.2.0.0",
	"name":"Diagnosis, PMBCL"
},
{
	"jumpto":"ENAS5277_2.0.0.0",
	"name":"Diagnosis, PTCL"
},
{
	"jumpto":"ENAS5278_2.3.0.0",
	"name":"Diagnosis, PTL"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Diagnosis, rectal cancer"
},
{
	"jumpto":"ENAS5071_2.0.0.0",
	"name":"Diagnosis, SCLC"
},
{
	"jumpto":"ENAS5271_5.2.1.0",
	"name":"Diagnosis, staging and risk assessment (DLBCL)"
},
{
	"jumpto":"ENAS5271_7.4.2.1",
	"name":"Diagnosis, staging and risk assessment in DLBCL, summary"
},
{
	"jumpto":"ENAS5281_7.1.0.0",
	"name":"Diagnosis, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_7.1.0.0",
	"name":"Diagnosis, summary (Oes CA)"
},
{
	"jumpto":"ENAS5284_7.1.0.0",
	"name":"Diagnosis, summary [Bil]"
},
{
	"jumpto":"ENAS5267_12.5.1.0",
	"name":"Diagnosis, summary [Extra]"
},
{
	"jumpto":"ENAS5304_8.1.0.0",
	"name":"Diagnosis, summary [mCRC]"
},
{
	"jumpto":"ENAS5263_14.7.0.0",
	"name":"Diagnosis, summary [Mucosa]"
},
{
	"jumpto":"ENAS5285_9.1.0.0",
	"name":"Diagnosis, summary [RCC]"
},
{
	"jumpto":"ENAS5274_2.0.0.0",
	"name":"Diagnosis, WM"
},
{
	"jumpto":"ENAS5283_8.1.0.0",
	"name":"Diagnosis and pathology (Gastric cancer)"
},
{
	"jumpto":"ENAS5407_9.1.0.0",
	"name":"Diagnosis and pathology of rectal cancer, summary"
},
{
	"jumpto":"ENAS5262_6.4.3.0",
	"name":"Diagnosis of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS5063_4.2.1.0",
	"name":"Diagnosis of classical FAP"
},
{
	"jumpto":"ENAS5279_7.1.0.0",
	"name":"Diagnosis of CLL, summary"
},
{
	"jumpto":"ENAS5262_6.3.2.0",
	"name":"Diagnosis of CVC infections, summary"
},
{
	"jumpto":"ENAS5271_7.1.0.0",
	"name":"Diagnosis of DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.1.1.0",
	"name":"Diagnosis of DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5061_8.2.0.0",
	"name":"Diagnosis of early colon cancer, summary"
},
{
	"jumpto":"ENAS5273_8.1.0.0",
	"name":"Diagnosis of FL, summary"
},
{
	"jumpto":"ENAS5280_7.1.0.0",
	"name":"Diagnosis of HCL, summary"
},
{
	"jumpto":"ENAS5270_9.1.0.0",
	"name":"Diagnosis of HL, summary"
},
{
	"jumpto":"ENAS5275_7.1.0.0",
	"name":"Diagnosis of MALT, summary"
},
{
	"jumpto":"ENAS5408_7.1.0.0",
	"name":"Diagnosis of MCL, summary"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Diagnosis of MPM"
},
{
	"jumpto":"ENAS5265_8.2.0.0",
	"name":"Diagnosis of occult cancer idiopathic VTE, summary"
},
{
	"jumpto":"ENAS5278_7.1.5.0",
	"name":"Diagnosis of PBL, summary"
},
{
	"jumpto":"ENAS5278_7.1.6.0",
	"name":"Diagnosis of PBoL, summary"
},
{
	"jumpto":"ENAS5092_7.1.0.0",
	"name":"Diagnosis of PC, summary"
},
{
	"jumpto":"ENAS5276_7.1.0.0",
	"name":"Diagnosis of PCLs, summary"
},
{
	"jumpto":"ENAS5278_7.1.4.0",
	"name":"Diagnosis of PCNSL, summary"
},
{
	"jumpto":"ENAS5096_7.1.0.0",
	"name":"Diagnosis of PenCa, summary"
},
{
	"jumpto":"ENAS5278_7.1.2.0",
	"name":"Diagnosis of PMBCL, summary"
},
{
	"jumpto":"ENAS5277_7.1.0.0",
	"name":"Diagnosis of PTCL, summary"
},
{
	"jumpto":"ENAS5278_7.1.3.0",
	"name":"Diagnosis of PTL, summary"
},
{
	"jumpto":"ENAS5071_6.1.0.0",
	"name":"Diagnosis of SCLC, summary"
},
{
	"jumpto":"ENAS5098_8.1.0.0",
	"name":"Diagnosis of TETs, summary"
},
{
	"jumpto":"ENAS5274_7.1.0.0",
	"name":"Diagnosis of WM, summary"
},
{
	"jumpto":"ENAS5284_2.0.0.0",
	"name":"Diagnosis [Bil]"
},
{
	"jumpto":"ENAS5408_2.0.0.0",
	"name":"Diagnosis [MCL]"
},
{
	"jumpto":"ENAS5304_2.0.0.0",
	"name":"Diagnosis [mCRC]"
},
{
	"jumpto":"ENAS5263_8.0.0.0",
	"name":"Diagnosis [Mucosa]"
},
{
	"jumpto":"ENAS5285_2.0.0.0",
	"name":"Diagnosis [RCC]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Diagnosis [TETs]"
},
{
	"jumpto":"ENAS5279_3.1.0.0",
	"name":"Diagnostic and staging work-up, CLL"
},
{
	"jumpto":"ENAS5278_3.2.0.0",
	"name":"Diagnostic work-up, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5273_4.3.0.0",
	"name":"Diagnostic work-up, FL"
},
{
	"jumpto":"ENAS5280_2.2.0.0",
	"name":"Diagnostic work-up, HCL"
},
{
	"jumpto":"ENAS5407_3.3.0.0",
	"name":"Diagnostic work-up in primary rectal cancer"
},
{
	"jumpto":"ENAS5269_6.4.6.9",
	"name":"Diarrhoea, summary [FN]"
},
{
	"jumpto":"ENAS5263_14.8.4.0",
	"name":"Diarrhoea, summary [Mucosa]"
},
{
	"jumpto":"ENAS5410_3.4.1.3",
	"name":"Diarrhoea and colitis management, interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001767",
	"name":"Diarrhoea and colitis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5269_5.9.9.0",
	"name":"Diarrhoea [FN]"
},
{
	"jumpto":"ENAS5263_9.4.0.0",
	"name":"Diarrhoea [Mucosa]"
},
{
	"jumpto":"ENAS5283_7.0.0.0",
	"name":"Dietary support for vit. and mineral deficiencies (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.6.0.0",
	"name":"Dietary support for vit. and mineral deficiencies (Gastric cancer)"
},
{
	"jumpto":"ENAS5268_2.2.4.0",
	"name":"Differences, NK1 RAs [N/V]"
},
{
	"jumpto":"ENAS5267_6.2.0.0",
	"name":"Differential diagnosis, extravasation"
},
{
	"jumpto":"ENAS5267_12.5.2.0",
	"name":"Differential diagnosis, summary [Extra]"
},
{
	"jumpto":"ENAS5278_2.1.0.0",
	"name":"Diffuse large B-cell lymphoma (DLBCL)"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Digital rectal examination"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Digital rectal examination, risk assessment"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Digital rectal examination [PC]"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Digital rectal examination [Rectal CA]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Dihydropyrimidine dehydrogenase (DPD) testing [mCRC]"
},
{
	"jumpto":"ENAS5266_3.4.3.0",
	"name":"Discontinuation of trastuzumab [CV Tox]"
},
{
	"jumpto":"ENAS5304_8.6.9.0",
	"name":"Discontinuation of treatment, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.7.0",
	"name":"Disease control (control of progression) [mCRC]"
},
{
	"jumpto":"ENAS5285_4.0.0.0",
	"name":"Diseases of chromosome 3p [RCC]"
},
{
	"jumpto":"ENAS5284_3.2.1.3",
	"name":"distal, cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5284_7.3.1.4",
	"name":"Distal cholangiocarcinoma, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.4.0",
	"name":"Distal cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5281_3.2.0.0",
	"name":"Distant metastasis (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5271_7.3.1.0",
	"name":"DLBCL treatment stratified according to age, summary"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"DNA-binding compounds [Extra]"
},
{
	"jumpto":"ENAS5063_2.2.1.0",
	"name":"DNA sequencing"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Docetaxel, side effects, [PC]"
},
{
	"jumpto":"ENAS5281_4.7.3.0",
	"name":"Docetaxel and nintedanib, Second-line treatment in NSCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.6.3",
	"name":"Docetaxel and nintedanib second-line treatment in NSCC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.7.3.0",
	"name":"Docetaxel and ramucirumab, Second-line treatment in NSCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.6.3",
	"name":"Docetaxel and ramucirumab second-line treatment in NSCC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Docetaxel [PC]"
},
{
	"jumpto":"ENAS5267_12.9.0.0",
	"name":"Documentation, summary [Extra]"
},
{
	"jumpto":"ENAS5267_10.0.0.0",
	"name":"Documentation [Extra]"
},
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"Dolasetron [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.3.1",
	"name":"Dose of antiemetics, summary [N/V]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Dose of G-CSF, summary [FN]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Dose of pegfilgrastim, summary [FN]"
},
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"Doses, (5-HT)3 receptor antagonists [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.3.0",
	"name":"Doses, corticosteroids [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.4.0",
	"name":"Doses, NK1 receptor antagonists[N/V]"
},
{
	"jumpto":"ENAS5086_5.4.3.0",
	"name":"Dosimetric constraints, EPP"
},
{
	"jumpto":"ENAS5281_4.5.0.0",
	"name":"Doublet therapy (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Doxepin mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Doxorubicin, second-line treatment [SCLC]"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Doxorubicin [Anal cancer]"
},
{
	"jumpto":"ENAS5266_2.0.0.0",
	"name":"Doxorubicin [CV Tox]"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"DRE, PC follow-up [PC]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"DRE [PC]"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"Duodenal polyps"
},
{
	"jumpto":"ENAS5269_6.4.8.0",
	"name":"Duration of therapy, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.11.0.0",
	"name":"Duration of therapy [FN]"
},
{
	"jumpto":"ENAS5265_8.4.3.0",
	"name":"Duration of Tx to prevent VTE recurr., summary"
},
{
	"jumpto":"ENAS5265_5.3.0.0",
	"name":"Duration of Tx to prevent VTE recurrence"
},
{
	"jumpto":"ENAS5280_2.3.0.0",
	"name":"Dx criteria for HCL and HCL-V"
},
{
	"jumpto":"ENAS5064_2.0.0.0",
	"name":"Dynamic contrast-enhanced MRI"
},
{
	"jumpto":"ENAS5061_8.4.5.0",
	"name":"Early coln cancer implications, summary"
},
{
	"jumpto":"ENAS5061_8.4.5.0",
	"name":"Early colon cancer follow-up, summary"
},
{
	"jumpto":"ENAS5061_8.4.3.0",
	"name":"Early colon cancer treatment, summary"
},
{
	"jumpto":"ENAS5406_3.0.0.0",
	"name":"Early NSCLC, diagnosis"
},
{
	"jumpto":"ENAS5406_2.0.0.0",
	"name":"Early NSCLC, screening"
},
{
	"jumpto":"ENAS5064_7.3.1.0",
	"name":"Early stage HCC treatment, summary"
},
{
	"jumpto":"ENAS5304_5.9.0.0",
	"name":"Early tumour shrinkage [mCRC]"
},
{
	"jumpto":"ENAS5277_7.3.2.0",
	"name":"EATL in PTCL, summary"
},
{
	"jumpto":"ENAS5281_4.3.1.0",
	"name":"EGFR- and ALK-negative disease (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.7.1.0",
	"name":"EGFR- and ALK-negative disease (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.6.1",
	"name":"EGFR- and ALK-negative disease, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.2.1",
	"name":"EGFR- and ALK-negative disease, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.7.0",
	"name":"EGFR-mutated, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.8.1.0",
	"name":"EGFR-mutated NSCLC patients"
},
{
	"jumpto":"ENAS5304_4.2.2.0",
	"name":"EGFR antibody therapy [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"EGFR ligands [mCRC]"
},
{
	"jumpto":"ENAS5281_2.2.0.0",
	"name":"EGFR mutations (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"EGFR mutation testing (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.8.1.0",
	"name":"EGFR TKIs (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.5.0.0",
	"name":"Elderly patients, management (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5283_8.3.3.0",
	"name":"Elderly patients, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5281_7.3.4.0",
	"name":"Elderly patients, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5304_8.6.12.3",
	"name":"Elderly patients, summary [mCRC]"
},
{
	"jumpto":"ENAS5283_4.5.0.0",
	"name":"Elderly patients with gastric cancer"
},
{
	"jumpto":"ENAS5263_11.3.0.0",
	"name":"Emergent data, systematic enteral nutrition [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.10.3.0",
	"name":"Emergent data of systematic enteral nutrition, summary [Mucosa]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Emerging biomarkers [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Emerging technologies [mCRC]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Emetogenicity, levels [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Emetogenic potential [N/V]"
},
{
	"jumpto":"ENAS5269_6.4.6.6",
	"name":"Encephalitis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Encephalitis [FN]"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Endo-anal ultrasound (EAUS)"
},
{
	"jumpto":"ENAS5407_3.3.0.0",
	"name":"Endorectal ultrasound [Rectal CA]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Endoscopic mucosal resection, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Endoscopic mucosal resection, management (Oes CA)"
},
{
	"jumpto":"ENAS5063_4.4.0.0",
	"name":"Endoscopic polypectomy [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Endoscopic resection, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Endoscopic resection, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Endoscopic resection criteria, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5284_2.0.0.0",
	"name":"Endoscopic retrograde cholangiopancreatography [Bil]"
},
{
	"jumpto":"ENAS5282_4.1.1.0",
	"name":"Endoscopic stenting, treatment (Oes CA)"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Endoscopic sub-mucosal dissection, management (Oes CA)"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Endoscopic submucosal dissection, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Endoscopic ultrasound (EUS)"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Endoscopic ultrasound (Gastric cancer)"
},
{
	"jumpto":"ENAS5277_7.3.3.0",
	"name":"ENKTCL in PTCL, summary"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Enoxaparin [CVC]"
},
{
	"jumpto":"ENAS5262_6.3.3.7",
	"name":"Enterococcus, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.9.0",
	"name":"Enterococcus [CVC]"
},
{
	"jumpto":"ENAS5277_4.4.0.0",
	"name":"Enteropathy-associated T-cell lymphoma (EATL)"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Enzalutamide, palliative care [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Enzalutamide, side effects [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Enzalutamide, treatment of CRPC [PC]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Enzalutamide [PC]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Epidermal growth factor receptor (EGFR) [Pancr]"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"Epidermoid cyst"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Epiregulin [mCRC]"
},
{
	"jumpto":"ENAS5266_2.0.0.0",
	"name":"Epirubicin [CV Tox]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Epithelioid angiomyolipoma [RCC]"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"EP [TS/T-NS]"
},
{
	"jumpto":"ENAS5281_4.7.1.0",
	"name":"Erlotinib, second-line treatment for EGFR- and ALK-negative disease (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.6.0.0",
	"name":"Erlotinib switch maintenance (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Erlotinib [Pancr]"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"Erythroplasia of Queyrat [PenCa]"
},
{
	"jumpto":"ENAS5268_3.2.0.0",
	"name":"ESMO antiemetic guidelines [N/V]"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Etoposide, localised SCLC"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Etoposide/ifosfamide/cisplatin (VIP/PEI) [TS/T-NS]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"European Society of Gastrointestinal Endoscopy"
},
{
	"jumpto":"ENAS5285_6.2.2.5",
	"name":"Everolimus [RCC]"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Examination under anaesthesia (EUA)"
},
{
	"jumpto":"ENAS5263_10.2.2.0",
	"name":"Example, basic oral care protocol [Mucosa]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Excision repair cross-complementation group 1 (ERCC1) [mCRC]"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Exophytic tumors"
},
{
	"jumpto":"ENAS5304_5.1.0.0",
	"name":"Expert multidisciplinary team (MDT) [mCRC]"
},
{
	"jumpto":"ENAS5304_5.1.0.0",
	"name":"Expert multidisciplinary team (MDT) [mCRC]"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"Extended decortification, surgery in MPM"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"Extended pleurectomy, surgery in MPM"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"External beam radiotherapy (EBRT) [PenCa]"
},
{
	"jumpto":"ENAS5064_4.5.0.0",
	"name":"External beam radiotherapy, HCC"
},
{
	"jumpto":"ENAS5277_4.5.0.0",
	"name":"Extranodal natural killer/T-cell lymphoma (ENKTCL)"
},
{
	"jumpto":"ENAS5276_4.6.0.0",
	"name":"Extranodal NK/T-cell lymphoma, nasal type"
},
{
	"jumpto":"ENAS5276_7.3.7.0",
	"name":"Extranodal NK/T-cell lymphoma, summary"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Extrapleural pneumonectomy (EPP)"
},
{
	"jumpto":"ENAS5086_5.4.3.0",
	"name":"Extrapleural pneumonectomy, choice of radiation"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Extravasation, common initial symptoms"
},
{
	"jumpto":"ENAS5267_2.0.0.0",
	"name":"Extravasation, definition"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Extravasation, diagnosis [Extra]"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Extravasation, Later symptoms"
},
{
	"jumpto":"ENAS5267_5.0.0.0",
	"name":"Extravasation, prevention [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Extravasation, risk factors [Extra]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"FA/5-FU/irinotecan/oxaliplatin"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Faecal incontinence"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Familial adenoomatous polyposis (FAP)[Early colon cancer]"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Familial cancer syndrome (Gastric cancer)"
},
{
	"jumpto":"ENAS5063_3.1.0.0",
	"name":"Familial colorectal cancer X syndrome"
},
{
	"jumpto":"ENAS5063_3.1.0.0",
	"name":"Familial colorectal cancer X syndrome, definition"
},
{
	"jumpto":"ENAS5063_6.2.0.0",
	"name":"Familial colorectal cancer X syndrome, summary"
},
{
	"jumpto":"ENAS5063_3.2.0.0",
	"name":"Familial colorectal cancer X syndrome, surveillance"
},
{
	"jumpto":"ENAS5281_3.1.0.0",
	"name":"FDG-PET-CT scanning (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_2.2.0.0",
	"name":"FDG-PET-CT scanning (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"FDG-PET/CT [PenCa]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"FDG-PET scan in TS"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"FDG-PET [Early colon cancer]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"FDG-PET [TS/T-NS]"
},
{
	"jumpto":"ENAS5269_2.0.0.0",
	"name":"Febrile neutropaenia"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Fibrinous pleurisy"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Fibulin-3 [MPM]"
},
{
	"jumpto":"ENAS5273_8.3.1.0",
	"name":"First-line of Rx in FL, summary"
},
{
	"jumpto":"ENAS5280_7.3.2.0",
	"name":"First-line of Rx in HCL, summary"
},
{
	"jumpto":"ENAS5408_4.1.0.0",
	"name":"First-line of Rx stage I-II [MCL]"
},
{
	"jumpto":"ENAS5408_4.2.0.0",
	"name":"First-line of Rx stage III-IV [MCL]"
},
{
	"jumpto":"ENAS5273_5.1.2.0",
	"name":"First-line of Rx stage III–IV, FL"
},
{
	"jumpto":"ENAS5273_5.1.1.0",
	"name":"First-line of Rx stage I–II, FL"
},
{
	"jumpto":"ENAS5274_4.2.0.0",
	"name":"First-line of treatment, WM"
},
{
	"jumpto":"ENAS5274_7.3.2.0",
	"name":"First-line of treatment in WM, summary"
},
{
	"jumpto":"ENAS5408_7.3.1.0",
	"name":"First-line Rx of MCL stage I-II, summary"
},
{
	"jumpto":"ENAS5408_7.3.2.0",
	"name":"First-line Rx of MCL stage III-IV, summary"
},
{
	"jumpto":"ENAS5285_6.2.2.4",
	"name":"First-line treat., poor prognosis [RCC]"
},
{
	"jumpto":"ENAS5281_4.3.1.0",
	"name":"First-line treatment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.2.1",
	"name":"First-line treatment, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"First-line treatment, summary [RCC]"
},
{
	"jumpto":"ENAS5281_4.3.3.0",
	"name":"First-line treatment for NSCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.3.2.0",
	"name":"First-line treatment for SCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5278_4.1.0.0",
	"name":"First-line treatment strategies, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"FISH, diagnosis (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_2.2.0.0",
	"name":"FISH, fluorescence in situ hybridisation (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Fistulae"
},
{
	"jumpto":"ENAS5062_4.9.0.0",
	"name":"Flap reconstruction"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Flexible sigmoidoscopy [Early colon cancer]"
},
{
	"jumpto":"ENAS5063_4.3.0.0",
	"name":"Flexible sigmoidoscopy [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5273_4.4.0.0",
	"name":"FLIPI risk factors"
},
{
	"jumpto":"ENAS5269_5.9.10.0",
	"name":"Fluconazole [FN]"
},
{
	"jumpto":"ENAS5282_4.1.6.0",
	"name":"Fluoropyrimidine, treatment (Oes CA)"
},
{
	"jumpto":"ENAS5269_5.1.0.0",
	"name":"FN, management"
},
{
	"jumpto":"ENAS5269_6.1.0.0",
	"name":"FN, summary"
},
{
	"jumpto":"ENAS5096_6.3.0.0",
	"name":"FNAC biopsy [PenCa]"
},
{
	"jumpto":"ENAS5269_5.8.0.0",
	"name":"FN management, key recommendations"
},
{
	"jumpto":"ENAS5269_5.4.0.0",
	"name":"FN mgmt., algo."
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"FOBT screening"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"FOLFIRINOX (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"FOLFIRINOX, 5-FU/cisplatin"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"FOLFIRINOX, metastatic pancreatic cancer"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"FOLFOX [mCRC]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Follicle-stimulating hormone (FSH) [TS/T-NS]"
},
{
	"jumpto":"ENAS5283_7.0.0.0",
	"name":"Follow-up & long term implications (Gastric cancer)"
},
{
	"jumpto":"ENAS5281_6.0.0.0",
	"name":"Follow-up (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5271_5.1.0.0",
	"name":"Follow-up, DLBCL"
},
{
	"jumpto":"ENAS5278_6.0.0.0",
	"name":"Follow-up, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5061_7.0.0.0",
	"name":"Follow-up, early colon cancer"
},
{
	"jumpto":"ENAS5270_8.0.0.0",
	"name":"Follow-up, HL"
},
{
	"jumpto":"ENAS5283_8.6.0.0",
	"name":"Follow-up, long term implications, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_7.6.0.0",
	"name":"Follow-up, long term implications, summary (Oes CA)"
},
{
	"jumpto":"ENAS5275_6.0.0.0",
	"name":"Follow-up, MALT"
},
{
	"jumpto":"ENAS5276_6.0.0.0",
	"name":"Follow-up, PCLs"
},
{
	"jumpto":"ENAS5071_5.0.0.0",
	"name":"Follow-up, SCLC"
},
{
	"jumpto":"ENAS5281_7.5.0.0",
	"name":"Follow-up, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5284_7.5.0.0",
	"name":"Follow-up, summary [Bil]"
},
{
	"jumpto":"ENAS5267_12.10.0.0",
	"name":"Follow-up, summary [Extra]"
},
{
	"jumpto":"ENAS5285_9.6.0.0",
	"name":"Follow-up, summary [RCC]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Follow-up, TETs"
},
{
	"jumpto":"ENAS5274_6.0.0.0",
	"name":"Follow-up, WM"
},
{
	"jumpto":"ENAS5407_9.7.0.0",
	"name":"Follow-up. Long term implications and survivorship, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5273_7.2.0.0",
	"name":"Follow-up after end of therapy, FL"
},
{
	"jumpto":"ENAS5279_6.0.0.0",
	"name":"Follow-up and long-term implications, CLL"
},
{
	"jumpto":"ENAS5273_7.1.0.0",
	"name":"Follow-up and long-term implications, FL"
},
{
	"jumpto":"ENAS5280_6.0.0.0",
	"name":"Follow-up and long-term implications, HCL"
},
{
	"jumpto":"ENAS5279_7.5.0.0",
	"name":"Follow-up and long-term implications in CLL, summary"
},
{
	"jumpto":"ENAS5273_8.5.0.0",
	"name":"Follow-up and long-term implications in FL, summary"
},
{
	"jumpto":"ENAS5408_7.5.0.0",
	"name":"Follow-up and long-term implications in MCL, summary"
},
{
	"jumpto":"ENAS5094_9.6.0.0",
	"name":"Follow-up and long term implications in BC, summary"
},
{
	"jumpto":"ENAS5280_7.5.0.0",
	"name":"Follow-up and long term implications in HCL, summary"
},
{
	"jumpto":"ENAS5092_7.5.0.0",
	"name":"Follow-up and long term implications in PC, summary"
},
{
	"jumpto":"ENAS5062_8.6.0.0",
	"name":"Follow-up in anal cancer, summary"
},
{
	"jumpto":"ENAS5271_7.4.1.0",
	"name":"Follow-up in DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.5.0.0",
	"name":"Follow-up in DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5064_7.3.5.0",
	"name":"Follow-up in HCC, summary"
},
{
	"jumpto":"ENAS5270_9.7.0.0",
	"name":"Follow-up in HL, summary"
},
{
	"jumpto":"ENAS5275_7.5.0.0",
	"name":"Follow-up in MALT, summary"
},
{
	"jumpto":"ENAS5276_7.4.0.0",
	"name":"Follow-up in PCLs, summary"
},
{
	"jumpto":"ENAS5096_7.5.0.0",
	"name":"Follow-up in PenCa, summary"
},
{
	"jumpto":"ENAS5097_7.4.0.0",
	"name":"Follow-up in TS/T-NS, summary"
},
{
	"jumpto":"ENAS5274_7.5.0.0",
	"name":"Follow-up in WM, summary"
},
{
	"jumpto":"ENAS5282_6.0.0.0",
	"name":"Follow-up long term implications (Oes CA)"
},
{
	"jumpto":"ENAS5068_8.5.0.0",
	"name":"Follow-up of pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5284_6.0.0.0",
	"name":"Follow-up [Bil]"
},
{
	"jumpto":"ENAS5267_11.0.0.0",
	"name":"Follow-up [Extra]"
},
{
	"jumpto":"ENAS5408_6.0.0.0",
	"name":"Follow-up [MCL]"
},
{
	"jumpto":"ENAS5263_13.0.0.0",
	"name":"Follow-up [Mucosa]"
},
{
	"jumpto":"ENAS5285_8.0.0.0",
	"name":"Follow-up [RCC]"
},
{
	"jumpto":"ENAS5407_8.1.0.0",
	"name":"Follow-up [Rectal CA]"
},
{
	"jumpto":"ENAS5283_4.3.3.4",
	"name":"Following preoperative chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Fondaparinux [CVC]"
},
{
	"jumpto":"ENAS5304_5.2.2.0",
	"name":"FONG score [mCRC]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Foseprepitant [N/V]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"FP monotherapy [mCRC]"
},
{
	"jumpto":"ENAS5279_4.2.2.2",
	"name":"Front-line treatment algo., interactive tool"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Fuhrman’s grade, management of metastatic disease [RCC]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Fusion biopsy [PC]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"G-CSF, dose [FN]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"G-CSF, route of application [FN]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"G-CSF, schedule [FN]"
},
{
	"jumpto":"ENAS5284_3.2.2.0",
	"name":"Gallbladder cancer, AJCC/UICC staging [Bil]"
},
{
	"jumpto":"ENAS5284_7.3.1.5",
	"name":"Gallbladder cancer, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.5.0",
	"name":"Gallbladder cancer [Bil]"
},
{
	"jumpto":"ENAS5269_5.9.5.0",
	"name":"Ganciclovir [FN]"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"Gardner's syndrome"
},
{
	"jumpto":"ENAS5283_4.2.0.0",
	"name":"Gastric CA treatment algo., interactive tool"
},
{
	"jumpto":"ENAS5275_4.2.0.0",
	"name":"Gastric MALT lymphoma stage IE-IIE, interactive tool"
},
{
	"jumpto":"ENAS5275_4.3.0.0",
	"name":"Gastric MALT lymphoma stage III-IV, interactive tool"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"Gastric polyps"
},
{
	"jumpto":"ENAS5063_4.3.0.0",
	"name":"Gastroduodenal endoscopy [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5263_14.8.3.0",
	"name":"Gastrointestinal mucositis grading, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.3.0.0",
	"name":"Gastrointestinal mucositis grading [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Gastrointestinal mucositis guideline [Mucosa]"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Gastrointestinal stromal tumours (Gastric cancer)"
},
{
	"jumpto":"ENAS5410_4.2.4.1",
	"name":"Gastrointestinal toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5284_7.3.1.5",
	"name":"GBC, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.5.0",
	"name":"GBC [Bil]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"GC [BC]"
},
{
	"jumpto":"ENAS5275_4.6.0.0",
	"name":"Gela grading system"
},
{
	"jumpto":"ENAS5409_2.0.0.0",
	"name":"Gell and coombs classification [IRs]"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Gemcitabine(Pancreatic cancer)"
},
{
	"jumpto":"ENAS5068_5.5.0.0",
	"name":"Gemcitabine, gemicitabine [Pancr]"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Gemcitabine, locally advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Gemcitabine, metastatic pancreatic cancer"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Gemcitabine-refractory [Pancr]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Gemcitabine/cisplatin (GC) [BC]"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Gemcitabine [PenCa]"
},
{
	"jumpto":"ENAS5267_12.6.2.0",
	"name":"General measures, summary [Extra]"
},
{
	"jumpto":"ENAS5267_7.2.0.0",
	"name":"General measures [Extra]"
},
{
	"jumpto":"ENAS5304_4.2.3.0",
	"name":"Genetic counselling [mCRC]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Gentamicin [CVC]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"Germ cell tumour (GCT) [TS/T-NS]"
},
{
	"jumpto":"ENAS5268_2.5.0.0",
	"name":"Germ cell tumours [N/V]"
},
{
	"jumpto":"ENAS5063_2.2.1.0",
	"name":"Germline genetic testing"
},
{
	"jumpto":"ENAS5263_14.6.0.0",
	"name":"GI mucositis in targeted therapy, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_7.0.0.0",
	"name":"GI mucositis in targeted therapy [Mucosa]"
},
{
	"jumpto":"ENAS5410_3.4.1.4",
	"name":"GI toxicity, follow-up and long term implications [irAEs]"
},
{
	"jumpto":"ENAS5410_3.4.1.1",
	"name":"GI toxicity, immune related [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.4.1",
	"name":"GI toxicity of anti-CTLA4 antibodies, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.4.2",
	"name":"GI toxicity of anti-PD-1 antibodies, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.4.2.0",
	"name":"GI toxicity of anti-PD-1 antibodies [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.4.3",
	"name":"GI toxicity of combined anti-CTLA4 and anti-PD-1 antibodies, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.4.3.0",
	"name":"GI toxicity of combined anti-CTLA4 and anti-PD-1 antibodies [irAEs]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Gleason grades [PC]"
},
{
	"jumpto":"ENAS5273_9.0.0.0",
	"name":"Glossary"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Glutamine [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"GM-CSF [Mucosa]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Good/intermed. Px, 1st-line treat. [RCC]"
},
{
	"jumpto":"ENAS5273_3.0.0.0",
	"name":"Grading of follicular lymphoma"
},
{
	"jumpto":"ENAS5262_6.3.3.8",
	"name":"Gram-negative bacillus, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.10.0",
	"name":"Gram-negative bacillus [CVC]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Granisetron [N/V]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Granulocyte-colony stimulating factor [BC]"
},
{
	"jumpto":"ENAS5406_4.1.0.0",
	"name":"Ground glass opacity areas [Early NSCLC]"
},
{
	"jumpto":"ENAS5273_5.2.0.0",
	"name":"Groupe d'Etude des lymphomes folliculaires"
},
{
	"jumpto":"ENAS5410_3.1.1.0",
	"name":"Grover’s dis­ease [irAEs]"
},
{
	"jumpto":"ENAS5275_4.4.0.0",
	"name":"H. pylori eradication, MALT"
},
{
	"jumpto":"ENAS5410_4.2.6.6",
	"name":"Haematological toxicities, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.6.0",
	"name":"Haematological toxicities [irAEs]"
},
{
	"jumpto":"ENAS5263_4.0.0.0",
	"name":"Haematopoietic stem cell transplantation [Mucosa]"
},
{
	"jumpto":"ENAS5262_6.2.2.0",
	"name":"Haemothorax, summary [CVC]"
},
{
	"jumpto":"ENAS5262_3.2.0.0",
	"name":"Haemothorax [CVC]"
},
{
	"jumpto":"ENAS5407_3.6.3.0",
	"name":"Haggitt's sub-classification [Rectal CA]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Half body irradiation [N/V]"
},
{
	"jumpto":"ENAS5064_4.5.0.0",
	"name":"HCC, external beam radiotherapy"
},
{
	"jumpto":"ENAS5064_6.0.0.0",
	"name":"HCC, follow-up"
},
{
	"jumpto":"ENAS5064_3.2.0.0",
	"name":"HCC, impact of therapy on prognosis"
},
{
	"jumpto":"ENAS5064_4.1.0.0",
	"name":"HCC, mgmt. of local disease"
},
{
	"jumpto":"ENAS5064_2.0.0.0",
	"name":"HCC, pathological diagnosis"
},
{
	"jumpto":"ENAS5064_4.1.0.0",
	"name":"HCC, radical therapies"
},
{
	"jumpto":"ENAS5064_5.0.0.0",
	"name":"HCC, response evaluation"
},
{
	"jumpto":"ENAS5064_3.3.0.0",
	"name":"HCC, staging and treatment strategy"
},
{
	"jumpto":"ENAS5064_4.4.0.0",
	"name":"HCC, systemic therapy"
},
{
	"jumpto":"ENAS5064_7.2.0.0",
	"name":"HCC staging, summary"
},
{
	"jumpto":"ENAS5064_7.3.1.0",
	"name":"HCC treatment, summary"
},
{
	"jumpto":"ENAS5064_7.3.4.0",
	"name":"HCC treatment response evaluation, summary"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"HCG [TS/T-NS]"
},
{
	"jumpto":"ENAS5263_10.2.1.0",
	"name":"Head & neck radiation, mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5275_7.3.1.0",
	"name":"Helicobacter pylori eradication in MALT, summary"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Hemi-thoracic radiotherapy (MPM)"
},
{
	"jumpto":"ENAS5304_5.5.0.0",
	"name":"Hepatic resection [mCRC]"
},
{
	"jumpto":"interactive_0001762",
	"name":"Hepatitis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.3.2.2",
	"name":"Hepatitis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Hepatocellular cancdr, staging"
},
{
	"jumpto":"ENAS5064_2.0.0.0",
	"name":"Hepatocellular cancer, diagnosis"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Hepatojejunostomy [Pancr]"
},
{
	"jumpto":"ENAS5277_4.6.0.0",
	"name":"Hepatosplenic T-cell lymphoma (HSTCL)"
},
{
	"jumpto":"ENAS5283_4.2.0.0",
	"name":"HER2, human epidermal growth factor receptor 2 (Gastric cancer)"
},
{
	"jumpto":"ENAS5063_2.1.0.0",
	"name":"Hereditary colorectal cancer"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Hereditary diffuse gastric cancer (Gastric cancer)"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"High-dose chemotherapy, prevention [N/V]"
},
{
	"jumpto":"ENAS5269_5.7.1.0",
	"name":"High-risk patients, overview [FN]"
},
{
	"jumpto":"ENAS5269_6.4.5.1",
	"name":"High-risk patients, summary [FN]"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"High conformal radiation techniques [mCRC]"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Highly emetogenic agents, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Highly emetogenic agents [N/V]"
},
{
	"jumpto":"ENAS5273_5.2.0.0",
	"name":"High tumour burden criteria, FL"
},
{
	"jumpto":"ENAS5304_8.6.6.0",
	"name":"HIPEC, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.13.0.0",
	"name":"HIPEC [mCRC]"
},
{
	"jumpto":"ENAS5407_3.6.3.0",
	"name":"Histopathology, rectal cancer"
},
{
	"jumpto":"ENAS5407_9.2.2.0",
	"name":"Histopathology of rectal cancer, summary"
},
{
	"jumpto":"ENAS5092_7.3.1.2",
	"name":"Hormone treatment of PC, summary"
},
{
	"jumpto":"ENAS5263_4.0.0.0",
	"name":"HSCT [Mucosa]"
},
{
	"jumpto":"ENAS5277_7.3.4.0",
	"name":"HSTCL in PTCL, summary"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"Human chorionic gonadotropin [TS/T-NS]"
},
{
	"jumpto":"ENAS5282_5.0.0.0",
	"name":"Human epidermal growth factor receptor 2 (HER2)-positive AC (Oes CA)"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Hyaluronidase [Extra]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Hyperbaric oxygen [Mucosa]"
},
{
	"jumpto":"ENAS5409_2.0.0.0",
	"name":"Hypersensitivity reaction [IRs]"
},
{
	"jumpto":"ENAS5266_10.4.0.0",
	"name":"Hypertension, summary [CV Tox]"
},
{
	"jumpto":"ENAS5266_5.0.0.0",
	"name":"Hypertension [CV Tox]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Hyperthermic intraperitoneal chemotherapy (HIPEC) [mCRC]"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Hypogonadism [TS/T-NS]"
},
{
	"jumpto":"ENAS5410_4.2.2.2",
	"name":"Hypophysitis, summary [irAEs]"
},
{
	"jumpto":"interactive_0001761",
	"name":"Hypophysitis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.2.2",
	"name":"Hypophysitis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.2.1",
	"name":"Hypophysitis [irAEs]"
},
{
	"jumpto":"ENAS5406_4.1.0.0",
	"name":"IASLC [Early NSCLC]"
},
{
	"jumpto":"ENAS5284_7.3.1.2",
	"name":"iCCA, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.2.0",
	"name":"iCCA [Bil]"
},
{
	"jumpto":"interactive_0001758",
	"name":"ICPI-related toxicity: management of suspected central neurological toxicity [tool]"
},
{
	"jumpto":"ENAS5266_2.0.0.0",
	"name":"Idarubicin [CV Tox]"
},
{
	"jumpto":"ENAS5278_3.8.2.0",
	"name":"IELSG score, interactive tool"
},
{
	"jumpto":"ENAS5278_3.11.0.0",
	"name":"IELSG staging"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Ifosfamide [PenCa]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"IHC [TETs]"
},
{
	"jumpto":"ENAS5063_4.4.0.0",
	"name":"Ileal pouch-anal anastamosis (IPAA)"
},
{
	"jumpto":"ENAS5063_4.4.0.0",
	"name":"Ileorectal anastamosis (IRA)"
},
{
	"jumpto":"ENAS5304_8.6.2.3",
	"name":"Imaging identification of resectable/unresectable disease, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.6.0.0",
	"name":"Imaging identification [mCRC]"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"Imaging in TS"
},
{
	"jumpto":"ENAS5285_5.2.2.1",
	"name":"IMDC risk groups"
},
{
	"jumpto":"ENAS5285_5.2.2.2",
	"name":"IMDC score [RCC]"
},
{
	"jumpto":"ENAS5262_6.2.2.0",
	"name":"Immediate complications, summary [CVC]"
},
{
	"jumpto":"ENAS5262_3.2.0.0",
	"name":"Immediate complications [CVC]"
},
{
	"jumpto":"ENAS5410_4.2.2.1",
	"name":"Immune-related endocrinopathies, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.1.1",
	"name":"Immune-related endocrinopathies [irAEs]"
},
{
	"jumpto":"ENAS5410_3.4.1.1",
	"name":"Immune-related gastrointestinal toxicity [irAEs]"
},
{
	"jumpto":"ENAS5410_3.3.2.1",
	"name":"Immune-related hepatotoxicity, management [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.3.1",
	"name":"Immune-related hepatotoxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.3.1.0",
	"name":"Immune-related hepatotoxicity [irAEs]"
},
{
	"jumpto":"ENAS5410_3.5.2.1",
	"name":"Immune-related pneumonitis, management [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.5.1",
	"name":"Immune-related pneumonitis, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.5.2.2",
	"name":"Immune-related pneumonitis mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001768",
	"name":"Immune-related pneumonitis mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.5.1.0",
	"name":"Immune-related pneumonitis [irAEs]"
},
{
	"jumpto":"ENAS5281_5.0.0.0",
	"name":"Immune-related response criteria (irRC)"
},
{
	"jumpto":"ENAS5410_3.1.2.0",
	"name":"Immune-related skin toxicities, diagnosis & pathology [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.3.1",
	"name":"Immune-related skin toxicities, grades [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.3.1",
	"name":"Immune-related skin toxicities, management of rash [irAEs]"
},
{
	"jumpto":"interactive_0001760",
	"name":"Immune-related skin toxicities mgmt. of rash, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.3.3",
	"name":"Immune-related skin toxicities mgmt. of rash, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.1.0",
	"name":"Immune-related skin toxicities [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.1.1",
	"name":"Immune-related skin toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.1.0",
	"name":"Immune-related toxicities [irAEs]"
},
{
	"jumpto":"ENAS5064_2.0.0.0",
	"name":"Immunohistochemical staging"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"Immunohistochemistry (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Immunohistochemistry [TETs]"
},
{
	"jumpto":"ENAS5409_11.2.5.0",
	"name":"Immunotherapy [IRs]"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"Incisional or excisional biopsy [PenCa]"
},
{
	"jumpto":"ENAS5262_4.3.4.0",
	"name":"Indications, CVC removal"
},
{
	"jumpto":"ENAS5262_6.3.3.2",
	"name":"Indications for CVC removal, summary"
},
{
	"jumpto":"ENAS5407_4.8.1.0",
	"name":"Indications for postoperative chemoradiotherapy [Rectal CA]"
},
{
	"jumpto":"ENAS5269_4.1.0.0",
	"name":"Indications for primary prophylaxis with G-CSF, overview [FN]"
},
{
	"jumpto":"ENAS5269_6.3.1.0",
	"name":"Indications for primary prophylaxis with G-CSF, summary [FN]"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"Induction chemoradiation therapy [BC]"
},
{
	"jumpto":"ENAS5408_4.2.0.0",
	"name":"Induction therapy in stage III non-indolent MCL"
},
{
	"jumpto":"ENAS5304_5.4.0.0",
	"name":"Infusional 5-FU/leucovorin/oxaliplatin (FOLFOX) [mCRC]"
},
{
	"jumpto":"ENAS5409_11.1.1.0",
	"name":"Infusion reactions, causative drugs [IRs]"
},
{
	"jumpto":"ENAS5409_2.0.0.0",
	"name":"Infusion reactions, definitions"
},
{
	"jumpto":"ENAS5409_7.0.0.0",
	"name":"Infusion reactions, diagnosis [IRs]"
},
{
	"jumpto":"ENAS5409_9.0.0.0",
	"name":"Infusion reactions, documentation [IRs]"
},
{
	"jumpto":"ENAS5409_12.0.0.0",
	"name":"Infusion reactions, follow-up [IRs]"
},
{
	"jumpto":"ENAS5409_8.1.0.0",
	"name":"Infusion reactions, management [IRs]"
},
{
	"jumpto":"ENAS5409_5.0.0.0",
	"name":"Infusion reactions, risk assessment [IRs]"
},
{
	"jumpto":"ENAS5409_6.0.0.0",
	"name":"Infusion reactions, signs and symptoms [IRs]"
},
{
	"jumpto":"ENAS5409_13.1.0.0",
	"name":"Infusion reactions, summary [IRs]"
},
{
	"jumpto":"ENAS5409_4.0.0.0",
	"name":"Infusion reactions, terminology criteria for adverse events [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.1",
	"name":"Infusion reactions and anthracyclines, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.1",
	"name":"Infusion reactions and chemotherapy, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.2",
	"name":"Infusion reactions and cituximab, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.1",
	"name":"Infusion reactions and monoclonal antibodies, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.2",
	"name":"Infusion reactions and platinum derivatives, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.3",
	"name":"Infusion reactions and rituximab, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.3",
	"name":"Infusion reactions and taxanes, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.5",
	"name":"Infusion reactions and taxanes, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.4",
	"name":"Infusion reactions and trastuzumab, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.1",
	"name":"Infusion reactions causative drugs, summary [IRs]"
},
{
	"jumpto":"ENAS5409_11.1.1.0",
	"name":"Infusion reactions charact. & mgmt., asso. with chemo drugs [IRs]"
},
{
	"jumpto":"ENAS5409_13.1.0.0",
	"name":"Infusion reactions definitions, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.4.0.0",
	"name":"Infusion reactions diagnosis, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.6.0.0",
	"name":"Infusion reactions documentation, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.9.0.0",
	"name":"Infusion reactions follow-up, summary [IRs]"
},
{
	"jumpto":"ENAS5409_8.3.2.0",
	"name":"Infusion reactions management, interactive tool [IRs]"
},
{
	"jumpto":"ENAS5409_13.5.1.0",
	"name":"Infusion reactions management, summary [IRs]"
},
{
	"jumpto":"interactive_0001748",
	"name":"Infusion reactions mgmt., interactive tool [IRs]"
},
{
	"jumpto":"ENAS5409_13.2.0.0",
	"name":"Infusion reactions risk assessment, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.3.0.0",
	"name":"Infusion reactions sign & symptoms, summary [IRs]"
},
{
	"jumpto":"ENAS5269_6.4.2.0",
	"name":"Initial assessment and investigations, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.2.0.0",
	"name":"Initial assessment and investigations [FN]"
},
{
	"jumpto":"ENAS5269_6.4.4.1",
	"name":"Inpatient oral antibacterial therapy, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Inpatient oral antibacterial therapy [FN]"
},
{
	"jumpto":"ENAS5262_6.2.1.0",
	"name":"Insertion, summary [CVC]"
},
{
	"jumpto":"ENAS5262_3.1.0.0",
	"name":"Insertion [CVC]"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Intensity-modulated radiotherapy (IMRT) [Anal]"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Intensity-modulated radiotherapy (IMRT) [MPM]"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Intensity modulated RT [TETs]"
},
{
	"jumpto":"ENAS5280_4.2.4.0",
	"name":"Interferon-α"
},
{
	"jumpto":"ENAS5271_4.6.2.0",
	"name":"Interim evaluation, DLBCL"
},
{
	"jumpto":"ENAS5270_9.3.2.0",
	"name":"Intermediate-stage cHL, summary"
},
{
	"jumpto":"ENAS5064_7.3.2.0",
	"name":"Intermediate-stage HCC treatment, summary"
},
{
	"jumpto":"ENAS5281_4.15.0.0",
	"name":"International association for the study of lung cancer (IASLC)"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"International consortium-developed molecular classification system [mCRC]"
},
{
	"jumpto":"ENAS5278_3.5.1.0",
	"name":"International prognostic index, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5271_3.3.0.0",
	"name":"International prognostic index, interactive tool"
},
{
	"jumpto":"ENAS5274_3.2.0.0",
	"name":"International scoring system for WM, interactive tool"
},
{
	"jumpto":"ENAS5407_4.7.2.6",
	"name":"Interval to surgery [Rectal CA]"
},
{
	"jumpto":"ENAS5269_6.4.6.8",
	"name":"Intra-abdominal or pelvic sepsis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.8.0",
	"name":"Intra-abdominal or pelvic sepsis [FN]"
},
{
	"jumpto":"ENAS5284_3.2.1.1",
	"name":"Intra-hepatic, cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5407_3.6.4.0",
	"name":"Intra-mesorectal plane [Rectal CA]"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"Intra-operative ultrasound"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Intraductal papillary mucinous neoplasm"
},
{
	"jumpto":"ENAS5284_7.3.1.2",
	"name":"Intrahepatic cholangiocarcinoma, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.2.0",
	"name":"Intrahepatic cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Intralesional injection [Mucosa]"
},
{
	"jumpto":"ENAS5262_6.1.0.0",
	"name":"Introduction, summary [CVC]"
},
{
	"jumpto":"ENAS5269_6.1.0.0",
	"name":"Introduction, summary [FN]"
},
{
	"jumpto":"ENAS5284_4.1.0.0",
	"name":"Introduction, treatment [Bil]"
},
{
	"jumpto":"ENAS5262_2.0.0.0",
	"name":"Introduction [CVC]"
},
{
	"jumpto":"ENAS5269_2.0.0.0",
	"name":"Introduction [FN]"
},
{
	"jumpto":"ENAS5278_3.5.2.0",
	"name":"IPI & aaIPI, interactive tool"
},
{
	"jumpto":"ENAS5410_2.5.0.0",
	"name":"irAEs, baseline assessment"
},
{
	"jumpto":"ENAS5410_2.1.0.0",
	"name":"irAEs, epidemiology"
},
{
	"jumpto":"ENAS5410_2.4.0.0",
	"name":"irAEs, general aspects"
},
{
	"jumpto":"ENAS5410_2.1.0.0",
	"name":"irAEs, overview"
},
{
	"jumpto":"ENAS5410_2.5.0.0",
	"name":"irAEs, patient selection and baseline assessment"
},
{
	"jumpto":"ENAS5410_4.1.1.0",
	"name":"irAEs epidemiology, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_4.1.1.0",
	"name":"irAEs general aspects, summary [irAEs]"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Irinotecan [Anal cancer]"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Irinotecan [Mucosa]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Irritants [Extra]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Iseganan antimicrobial mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"IV chemotherapy [N/V]"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Ivor-Lewis procedure, management (Oes CA)"
},
{
	"jumpto":"ENAS5282_7.3.1.2",
	"name":"Ivor-Lewis procedure, summary (Oes CA)"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Jaundice in introduction(Pancreatic cancer)"
},
{
	"jumpto":"ENAS5281_4.14.1.0",
	"name":"Karnofsky performance status (KPS)"
},
{
	"jumpto":"ENAS5269_5.8.0.0",
	"name":"Key recommendations, FN management"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"KGF-1/palifermin [Mucosa]"
},
{
	"jumpto":"ENAS5098_6.0.0.0",
	"name":"KIT sequencing [TETs]"
},
{
	"jumpto":"ENAS5284_7.3.1.3",
	"name":"Klatskin tumour, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.3.0",
	"name":"Klatskin tumour [Bil]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"KRAS exons [mCRC]"
},
{
	"jumpto":"ENAS5407_3.6.3.0",
	"name":"Kudo/Kikuchi (sm)-system [Rectal CA]"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Laparoscopic gastric mobilisation (Oes CA)"
},
{
	"jumpto":"ENAS5285_6.1.2.0",
	"name":"Laparoscopic RN [RCC]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Laparoscopic surgery, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Laparoscopic surgery recommended option for early gastric cancer, summary"
},
{
	"jumpto":"ENAS5283_8.2.0.0",
	"name":"Laparoscopy ± peritoneal washings, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Laparoscopy ± peritoneal washings for malignant cells (Gastric cancer)"
},
{
	"jumpto":"ENAS5061_5.2.0.0",
	"name":"Laproscopic colectomy"
},
{
	"jumpto":"ENAS5063_2.2.1.0",
	"name":"Large rearrangement analysis"
},
{
	"jumpto":"ENAS5097_7.3.5.0",
	"name":"Late relapse and toxicity treatment, summary"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Later symptoms, extravasation"
},
{
	"jumpto":"ENAS5267_12.5.1.0",
	"name":"Later symptoms, summary [Extra]"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Lauren classification (Gastric cancer)"
},
{
	"jumpto":"ENAS5406_2.0.0.0",
	"name":"LDCT [Early NSCLC]"
},
{
	"jumpto":"ENAS5266_3.1.0.0",
	"name":"Left ventricular dysfunction, overview [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.2.1.0",
	"name":"Left ventricular dysfunction, summary [CV Tox]"
},
{
	"jumpto":"ENAS5285_6.2.2.5",
	"name":"Lenvatinib [RCC]"
},
{
	"jumpto":"ENAS5408_3.5.0.0",
	"name":"Leukaemic non-nodal subtype of MCL"
},
{
	"jumpto":"ENAS5408_7.2.2.0",
	"name":"Leukaemic non-nodal subtype of MCL, summary"
},
{
	"jumpto":"ENAS5061_5.1.0.0",
	"name":"Level 4 invasion, malignant polyps"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Levels, emetogenicity [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Levels of emetogenicity, summary [N/V]"
},
{
	"jumpto":"ENAS5268_5.1.0.0",
	"name":"Levomepromazine [N/V]"
},
{
	"jumpto":"ENAS5270_9.3.1.0",
	"name":"Limited-stage cHL, summary"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Limited disease, management (Oes CA)"
},
{
	"jumpto":"ENAS5282_7.3.1.2",
	"name":"Limited disease, summary (Oes CA)"
},
{
	"jumpto":"ENAS5262_6.3.3.7",
	"name":"Linezolid, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.9.0",
	"name":"Linezolid [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.7.0",
	"name":"Linezolid [FN]"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Links staging of HCC"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Liposomal amphotericin B [FN]"
},
{
	"jumpto":"ENAS5266_2.0.0.0",
	"name":"Liposomal doxorubicin [CV Tox]"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Liquid circulating tumour (ct)DNA biopsies [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.2.2",
	"name":"Liver metastases, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.2.4",
	"name":"Liver metastases, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"Liver metastases [mCRC]"
},
{
	"jumpto":"ENAS5304_5.2.2.0",
	"name":"Liver metastases [mCRC]"
},
{
	"jumpto":"ENAS5064_4.1.0.0",
	"name":"Liver transplantation, HCC radical therapy"
},
{
	"jumpto":"ENAS5265_5.1.1.0",
	"name":"LMWH and UFH, acute treatment [VTE]"
},
{
	"jumpto":"ENAS5265_4.1.0.0",
	"name":"LMWHs enoxaparin [VTE]"
},
{
	"jumpto":"ENAS5407_9.3.1.1",
	"name":"Local.locoregional disease mgmt., summary [Rectal CA]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Local ablative treatments (LAT) [mCRC]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Local damage [Extra]"
},
{
	"jumpto":"ENAS5062_4.3.0.0",
	"name":"Local excision, anal cancer"
},
{
	"jumpto":"ENAS5285_5.2.1.1",
	"name":"Localised disease, overview [RCC]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Localised disease, summary [RCC]"
},
{
	"jumpto":"ENAS5282_7.3.1.3",
	"name":"Locally advanced disease, summary (Oes CA)"
},
{
	"jumpto":"ENAS5285_6.1.3.0",
	"name":"Locally advanced RCC"
},
{
	"jumpto":"ENAS5285_9.4.1.3",
	"name":"Locally advanced RCC, summary [RCC]"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"Local or locoregional disease [Anal cancer]"
},
{
	"jumpto":"ENAS5269_6.4.1.0",
	"name":"Local policies, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.1.0.0",
	"name":"Local policies [FN]"
},
{
	"jumpto":"ENAS5267_6.3.0.0",
	"name":"Local skin reactions [Extra]"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Local thermal ablation [mCRC]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Local treatments [mCRC]"
},
{
	"jumpto":"interactive_0001743",
	"name":"Locoregional LN staging, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.2.0.0",
	"name":"Locoregional LN staging, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.3.0.0",
	"name":"Locoregional NSCLC treatment, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Locoregional treatments [mCRC]"
},
{
	"jumpto":"ENAS5284_7.5.0.0",
	"name":"Long-term implications, summary [Bil]"
},
{
	"jumpto":"ENAS5284_6.0.0.0",
	"name":"Long-term implications [Bil]"
},
{
	"jumpto":"ENAS5263_13.0.0.0",
	"name":"Long-term implications [Mucosa]"
},
{
	"jumpto":"ENAS5265_5.2.0.0",
	"name":"Long-term treatment, solid tumours [VTE]"
},
{
	"jumpto":"ENAS5265_8.4.2.0",
	"name":"Long-term treatment in solid tumours, summary [VTE]"
},
{
	"jumpto":"ENAS5061_7.0.0.0",
	"name":"Long term implications, early colon cancer"
},
{
	"jumpto":"ENAS5285_9.6.0.0",
	"name":"Long term implications, summary [RCC]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Long term implications, TETs"
},
{
	"jumpto":"ENAS5285_8.0.0.0",
	"name":"Long term implications [RCC]"
},
{
	"jumpto":"ENAS5406_2.0.0.0",
	"name":"Low-dose computed tomography [Early NSCLC]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Low-level laser therapy [Mucosa]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Low-risk patients, oral therapy [FN]"
},
{
	"jumpto":"ENAS5269_6.4.4.1",
	"name":"Low-risk patients, summary [FN]"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Low emetogenic potential, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Low emetogenic potential [N/V]"
},
{
	"jumpto":"ENAS5408_3.2.0.0",
	"name":"Lugano classification [MCL]"
},
{
	"jumpto":"ENAS5275_3.0.0.0",
	"name":"Lugano staging system"
},
{
	"jumpto":"ENAS5406_4.6.0.0",
	"name":"Lung function test [Early NSCLC]"
},
{
	"jumpto":"ENAS5269_6.4.6.4",
	"name":"Lung infiltrates, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Lung infiltrates [FN]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Luteinising hormone (LH) [TS/T-NS]"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Lymphadenectomy, extended [Pancr]"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Lymphadenectomy, standard [Pancr]"
},
{
	"jumpto":"ENAS5068_8.3.3.0",
	"name":"Lymphadenectomy in pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5284_4.3.3.0",
	"name":"Lymphadenectomy [Bil]"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Lymph nodes, infrapyloric [Pancr]"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Lymph nodes, suprpyloric [Pancr]"
},
{
	"jumpto":"ENAS5276_4.4.0.0",
	"name":"Lymphoproliferative disorders (LPDs)"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Lynch-associated syndromes"
},
{
	"jumpto":"ENAS5063_2.4.0.0",
	"name":"Lynch syndrome, chemoprevention"
},
{
	"jumpto":"ENAS5063_2.1.0.0",
	"name":"Lynch syndrome, definition"
},
{
	"jumpto":"ENAS5063_2.2.3.0",
	"name":"Lynch syndrome, molecular diagnosis"
},
{
	"jumpto":"ENAS5063_2.1.0.0",
	"name":"Lynch syndrome, prevalence"
},
{
	"jumpto":"ENAS5063_2.4.0.0",
	"name":"Lynch syndrome, prophylactic surgery"
},
{
	"jumpto":"ENAS5063_6.1.1.0",
	"name":"Lynch syndrome, summary"
},
{
	"jumpto":"ENAS5063_2.3.0.0",
	"name":"Lynch syndrome, surveillance"
},
{
	"jumpto":"ENAS5063_2.4.0.0",
	"name":"Lynch syndrome, treatment"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"M-CAVI [BC]"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"Macroscopic resection, MPM surgery"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Magnetic resonance cholangiopancreatography (MRCP)"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Magnetic resonance imaging (MRI) [BC]"
},
{
	"jumpto":"ENAS5086_4.1.0.0",
	"name":"Magnetic resonance imaging (MRI) [MP]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Magnetic resonance imaging (MRI) [PC]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Magnetic resonance imaging (MRI) [TS/T-NS]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Magnetic resonance imaging [TETs]"
},
{
	"jumpto":"ENAS5281_4.6.0.0",
	"name":"Maintenance (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.5.0",
	"name":"Maintenance, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5304_5.14.10.1",
	"name":"Maintenance and second-line treatment options [mCRC]"
},
{
	"jumpto":"ENAS5281_4.6.0.0",
	"name":"Maintenance therapy (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5304_8.6.9.0",
	"name":"Maintenance therapy, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.3.0",
	"name":"Maintenance therapy [mCRC]"
},
{
	"jumpto":"ENAS5268_6.4.2.0",
	"name":"Malignant bowel obstruction, summary [N/V]"
},
{
	"jumpto":"ENAS5268_5.2.0.0",
	"name":"Malignant bowel obstruction [N/V]"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Malignant lymph nodes (Gastric cancer)"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Malignant pleural meothelioma, definition (MPM)"
},
{
	"jumpto":"ENAS5086_6.0.0.0",
	"name":"Malignant pleural mesothelioma, follow-up"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Malignant pleural mesothelioma, pathology"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Malignant pleural mesothelioma, post-op radiotherapy"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Malignant pleural mesothelioma, pre-op radiotherapy"
},
{
	"jumpto":"ENAS5086_5.4.1.0",
	"name":"Malignant pleural mesothelioma, radiotherapy"
},
{
	"jumpto":"ENAS5086_4.1.0.0",
	"name":"Malignant pleural mesothelioma, staging"
},
{
	"jumpto":"ENAS5086_4.2.0.0",
	"name":"Malignant pleural mesothelioma, TNM staging"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Malignant pleural mesothelioma, treatment"
},
{
	"jumpto":"ENAS5061_5.1.0.0",
	"name":"Malignant polyps, treatment"
},
{
	"jumpto":"ENAS5262_4.3.2.0",
	"name":"Management, CVC infections"
},
{
	"jumpto":"ENAS5269_5.1.0.0",
	"name":"Management, FN"
},
{
	"jumpto":"ENAS5263_11.1.0.0",
	"name":"Management, overview [Mucosa]"
},
{
	"jumpto":"ENAS5282_7.4.0.0",
	"name":"Management of advanced/metastatic disease (M1), summary (Oes CA)"
},
{
	"jumpto":"ENAS5407_6.1.0.0",
	"name":"Management of advanced/metastatic disease [Rectal CA]"
},
{
	"jumpto":"ENAS5092_7.3.2.1",
	"name":"Management of advanced PC, summary"
},
{
	"jumpto":"ENAS5267_7.1.0.0",
	"name":"Management of extravasation, overview"
},
{
	"jumpto":"ENAS5267_12.6.1.0",
	"name":"Management of extravasation, summary [Extra]"
},
{
	"jumpto":"ENAS5269_6.4.1.0",
	"name":"Management of FN, summary [FN]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Management of local/locoregional disease (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_7.3.1.1",
	"name":"Management of local/locoregional disease (M0), summary (Oes CA)"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Management of local/locoregional disease, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5094_9.3.1.0",
	"name":"Management of local/locoregional disease, summary [BC]"
},
{
	"jumpto":"ENAS5285_9.4.1.1",
	"name":"Management of local / locoregional disease, summary [RCC]"
},
{
	"jumpto":"ENAS5407_4.1.0.0",
	"name":"Management of local/locoregional disease [Rectal CA]"
},
{
	"jumpto":"ENAS5407_9.3.1.1",
	"name":"Management of local/locoregional rectal cancer, summary"
},
{
	"jumpto":"ENAS5092_7.3.1.1",
	"name":"Management of local PC, summary"
},
{
	"jumpto":"ENAS5092_4.2.1.0",
	"name":"Management of local PC [PC]"
},
{
	"jumpto":"ENAS5407_9.4.0.0",
	"name":"Management of local recurrence of rectal cancer, summary"
},
{
	"jumpto":"ENAS5407_5.1.0.0",
	"name":"Management of local recurrence [Rectal CA]"
},
{
	"jumpto":"ENAS5285_9.4.2.1",
	"name":"Management of metastatic disease, summary [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Management of metastatic disease, treatment [RCC]"
},
{
	"jumpto":"ENAS5092_4.3.1.0",
	"name":"Management of metastatic PC, overview"
},
{
	"jumpto":"ENAS5410_4.2.1.3",
	"name":"Management of rash, summary [irAEs]"
},
{
	"jumpto":"interactive_0001759",
	"name":"Management of thyroid gland disorders [tool]"
},
{
	"jumpto":"ENAS5098_4.2.0.0",
	"name":"Masaoka-Koga staging, TETs"
},
{
	"jumpto":"ENAS5098_8.2.0.0",
	"name":"Masaoka-Koga staging system, summary [TETs]"
},
{
	"jumpto":"ENAS5098_4.3.0.0",
	"name":"Masaoka-‍Koga stage"
},
{
	"jumpto":"ENAS5263_11.2.1.0",
	"name":"MASCC/ISOO guidelines, overview [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.10.2.0",
	"name":"MASCC/ISOO guidelines, summary [Mucosa]"
},
{
	"jumpto":"ENAS5268_3.2.0.0",
	"name":"MASCC antiemetic guidelines [N/V]"
},
{
	"jumpto":"ENAS5269_6.4.3.0",
	"name":"MASCC index, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.5.0.0",
	"name":"MASCC index [FN]"
},
{
	"jumpto":"ENAS5408_2.0.0.0",
	"name":"MCL, diagnosis"
},
{
	"jumpto":"ENAS5408_3.3.0.0",
	"name":"MCL, diagnostic work-up"
},
{
	"jumpto":"interactive_0001757",
	"name":"MCL therapeutic recom., interactive tool"
},
{
	"jumpto":"ENAS5408_4.3.0.0",
	"name":"MCL therapeutic recom., tool"
},
{
	"jumpto":"ENAS5268_2.4.1.0",
	"name":"MEC-induced acute nausea and vomiting, prophylaxis"
},
{
	"jumpto":"ENAS5268_6.1.4.1",
	"name":"MEC-induced acute nausea and vomiting prophylaxis, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.4.1.0",
	"name":"MEC-induced delayed nausea and vomiting, prophylaxis"
},
{
	"jumpto":"ENAS5268_6.1.4.1",
	"name":"MEC-induced delayed nausea and vomiting prophylaxis, summary [N/V]"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Mechlorethamine [Extra]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Median sternotomy [TETs]"
},
{
	"jumpto":"ENAS5265_4.2.0.0",
	"name":"Medical patients, prevention of VTE"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Meropenem [FN]"
},
{
	"jumpto":"ENAS5407_3.6.4.0",
	"name":"Mesorectal plane [Rectal CA]"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Mesothelial marker, calretinin"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Mesothelial marker, cytokeratin 5/6"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Mesothelial marker, podplanin (D240)"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Mesothelin"
},
{
	"jumpto":"ENAS5285_4.0.0.0",
	"name":"Metabolic RCCs"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Metallic stent [Pancr]"
},
{
	"jumpto":"ENAS5283_8.5.0.0",
	"name":"Metastasectomy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Metastasectomy [RCC]"
},
{
	"jumpto":"ENAS5304_8.6.4.0",
	"name":"Metastases at unfavourable/uncommon sites, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"Metastatic disease, first-line [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.4.0",
	"name":"Metastatic disease, second-line [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.5.0",
	"name":"Metastatic disease, third-line [mCRC]"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"Metastatic disease of non-clear cell histology, summary [RCC]"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Metastatic PC, palliative care [PC]"
},
{
	"jumpto":"ENAS5071_4.3.1.0",
	"name":"Metastatic SCLC, first-line treatment"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Metastatic SCLC, second-line treatment"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Metastatic TETs, treatment algorithm [TETs]"
},
{
	"jumpto":"ENAS5097_7.3.3.0",
	"name":"Metastatic TS/T-NS treatment, summary"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Methotrexate/carboplatin/vinblastine [BC]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Methotrexate/vinblastine/adriamycin/cisplatin [BC]"
},
{
	"jumpto":"ENAS5268_2.7.0.0",
	"name":"Metopimazine [N/V]"
},
{
	"jumpto":"ENAS5269_5.9.8.0",
	"name":"Metronidazole [FN]"
},
{
	"jumpto":"ENAS5276_7.3.1.0",
	"name":"MF and variants stage I, summary"
},
{
	"jumpto":"ENAS5276_7.3.2.0",
	"name":"MF and variants stage IIB, summary"
},
{
	"jumpto":"ENAS5276_7.3.3.0",
	"name":"MF and variants stage IV, summary"
},
{
	"jumpto":"ENAS5266_3.2.2.0",
	"name":"Mgmt., cardiotoxicity"
},
{
	"jumpto":"ENAS5266_3.4.2.0",
	"name":"Mgmt., trastuzumab cardiotoxicity"
},
{
	"jumpto":"ENAS5281_4.1.0.0",
	"name":"Mgmt. of advanced/ metastatic disease (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_4.2.0.0",
	"name":"Mgmt. of advanced/ metastatic disease (Oes CA)"
},
{
	"jumpto":"ENAS5281_7.3.1.0",
	"name":"Mgmt. of advanced/ metastatic disease, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5407_9.5.0.0",
	"name":"Mgmt. of advanced/metastatic rectal cancer, summary"
},
{
	"jumpto":"ENAS5284_7.3.2.1",
	"name":"Mgmt. of advanced and/or mets. disease, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.4.1.0",
	"name":"Mgmt. of advanced and/or mets. disease [Bil]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Mgmt. of advanced and metastatic BC"
},
{
	"jumpto":"ENAS5282_4.1.1.0",
	"name":"Mgmt. of local/ locoregional disease (Oes CA)"
},
{
	"jumpto":"ENAS5284_4.3.1.0",
	"name":"Mgmt. of local/ locoregional disease, overview [Bil]"
},
{
	"jumpto":"ENAS5284_7.3.1.1",
	"name":"Mgmt. of local/ locoregional disease, summary [Bil]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Mgmt. of local/ locoregional disease, treatment [RCC]"
},
{
	"jumpto":"ENAS5062_8.3.1.0",
	"name":"Mgmt. of local and locoregional anal cancer, summary"
},
{
	"jumpto":"ENAS5094_6.0.0.0",
	"name":"Mgmt. of local disease, interactive tool [BC]"
},
{
	"jumpto":"ENAS5062_8.3.10.0",
	"name":"Mgmt. of metastatic anal cancer, summary"
},
{
	"jumpto":"ENAS5094_6.0.0.0",
	"name":"Mgmt. of metastatic disease, interactive tool [BC]"
},
{
	"jumpto":"ENAS5263_14.10.4.0",
	"name":"Mgmt. of mucosal injury caused by cancer Tx, summary [Mucosa]"
},
{
	"jumpto":"ENAS5266_10.2.4.0",
	"name":"Mgmt. of trastuzumab cardiotoxicity, summary [CV Tox]"
},
{
	"jumpto":"ENAS5263_14.9.2.2",
	"name":"mIAS, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_10.2.3.0",
	"name":"mIAS [Mucosa]"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"MIBC, extended lymphadenectomy"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"MIBC, external beam radiotherapy"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"MIBC, neoadjuvant chemotherapy"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"MIBC, radical cystectomy (RC)"
},
{
	"jumpto":"ENAS5063_2.1.0.0",
	"name":"Microsatellite instability"
},
{
	"jumpto":"ENAS5304_4.2.3.0",
	"name":"Microsatellite instability (MSI)"
},
{
	"jumpto":"ENAS5304_8.5.3.0",
	"name":"Microsatellite instability, summary [mCRC]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Microscopic pancreatic intraepithelial"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Milan criteria"
},
{
	"jumpto":"ENAS5283_4.5.0.0",
	"name":"miniDOX regimen (Gastric cancer)"
},
{
	"jumpto":"ENAS5281_4.12.0.0",
	"name":"Minimally-invasive procedures in stage IV NSCLC"
},
{
	"jumpto":"ENAS5281_7.3.11.0",
	"name":"Minimally-invasive procedures in stage IV NSCLC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Minimally emetogenic, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Minimally emetogenic [N/V]"
},
{
	"jumpto":"ENAS5408_3.4.0.0",
	"name":"MIPI, interactive tool [MCL]"
},
{
	"jumpto":"ENAS5408_3.1.0.0",
	"name":"MIPI [MCL]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Misoprostol mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Misoprostol suppositories [Mucosa]"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"Mitomycin C (MMC)"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Mitomycin C [Extra]"
},
{
	"jumpto":"ENAS5266_2.0.0.0",
	"name":"Mitoxantrone [CV Tox]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"MM-398 [Pancr]"
},
{
	"jumpto":"ENAS5063_2.2.1.0",
	"name":"MMR deficiency"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Moderately emetogenic agents, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Moderately emetogenic agents [N/V]"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Molecular biology, rectal cancer"
},
{
	"jumpto":"ENAS5263_13.0.0.0",
	"name":"Molecular modelling [Mucosa]"
},
{
	"jumpto":"ENAS5304_8.2.0.0",
	"name":"Molecular pathology and biomarkers, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.7.0",
	"name":"Molecular profile [mCRC]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Molecular prognostication, summary [RCC]"
},
{
	"jumpto":"ENAS5285_5.2.3.0",
	"name":"Molecular prognostication [RCC]"
},
{
	"jumpto":"ENAS5281_4.2.1.0",
	"name":"Molecular test, treatment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5266_9.4.0.0",
	"name":"Monitoring, cardiac function after chest RT [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.8.3.0",
	"name":"Monitoring of cardiac func. after chest RT, summary [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.2.3.0",
	"name":"Monoclonal antibodies and targeted agents, summary [CV Tox]"
},
{
	"jumpto":"ENAS5266_3.3.0.0",
	"name":"Monoclonal antibodies and targeted agents [CV Tox]"
},
{
	"jumpto":"ENAS5409_11.2.1.0",
	"name":"Monoclonal antibodies [IRs]"
},
{
	"jumpto":"ENAS5281_4.3.2.0",
	"name":"Monoclonal antibody against EGFR, treatment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Morphine [Mucosa]"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"MPM, first-line therapy"
},
{
	"jumpto":"ENAS5086_5.5.1.0",
	"name":"MPM, indications for surgery"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"MPM, maintenance therapy"
},
{
	"jumpto":"ENAS5086_5.5.2.0",
	"name":"MPM, palliative surgery"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"MPM, radical surgery"
},
{
	"jumpto":"ENAS5086_5.2.0.0",
	"name":"MPM, second-line therapy"
},
{
	"jumpto":"ENAS5086_5.5.2.0",
	"name":"MPM, surgery for staging"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"MPM, surgical procedures definition"
},
{
	"jumpto":"ENAS5086_7.1.0.0",
	"name":"MPM diagnosis, summary"
},
{
	"jumpto":"ENAS5086_7.5.0.0",
	"name":"MPM follow-up, summary"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"MPM subtype, biphasic"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"MPM subtype, epitheloid"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"MPM subtype, sarcomatoid"
},
{
	"jumpto":"ENAS5064_5.0.0.0",
	"name":"mRECIST criteria, HCC"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"MRI [Early colon cancer]"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"MRI [PC]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"MRI [TETs]"
},
{
	"jumpto":"ENAS5304_4.2.3.0",
	"name":"MSI testing [mCRC]"
},
{
	"jumpto":"ENAS5263_2.0.0.0",
	"name":"mTOR inhibitor-associated stomatitis [Mucosa]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Mucinous cystic neoplasm (Pancreatic Cancer)"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Mucinous lesions (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5263_10.2.1.0",
	"name":"Mucositis, chemotherapy [Mucosa]"
},
{
	"jumpto":"ENAS5263_10.2.1.0",
	"name":"Mucositis, head & neck radiation [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.1.0.0",
	"name":"Mucositis, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.9.2.1",
	"name":"Mucositis caused by chemotherapy, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.9.2.1",
	"name":"Mucositis caused by head & neck radiation, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_2.0.0.0",
	"name":"Mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5266_2.0.0.0",
	"name":"MUGA scan [CV Tox]"
},
{
	"jumpto":"ENAS5063_2.1.0.0",
	"name":"Muir-Torre syndrome"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Multi-cycle chemotherapy [Mucosa]"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Multidisciplinary treatment planning, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Multiparametric MRI [PC]"
},
{
	"jumpto":"ENAS5268_2.5.0.0",
	"name":"Multiple-day cisplatin ChT, prev. [N/V]"
},
{
	"jumpto":"ENAS5064_2.0.0.0",
	"name":"Multiple-phase multidetector CT scan"
},
{
	"jumpto":"ENAS5266_2.0.0.0",
	"name":"Multiple gated acquisition scan [CV Tox]"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"Multiplex polymerase chain reaction (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"Multiplex systems (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"Muscle-invasive BC, treatment"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Muscle-invasive bladder cancer (MIBC)"
},
{
	"jumpto":"ENAS5407_3.6.4.0",
	"name":"Muscularis propria plane [Rectal CA]"
},
{
	"jumpto":"ENAS5063_5.4.0.0",
	"name":"MUTYH-associated polyposis, chemoprevention"
},
{
	"jumpto":"ENAS5063_5.1.0.0",
	"name":"MUTYH-associated polyposis, definition"
},
{
	"jumpto":"ENAS5063_5.2.0.0",
	"name":"MUTYH-associated polyposis, diagnosis"
},
{
	"jumpto":"ENAS5063_5.6.0.0",
	"name":"MUTYH-associated polyposis, follow-up"
},
{
	"jumpto":"ENAS5063_5.1.0.0",
	"name":"MUTYH-associated polyposis, prevalence"
},
{
	"jumpto":"ENAS5063_6.4.1.0",
	"name":"MUTYH-associated polyposis, summary"
},
{
	"jumpto":"ENAS5063_5.3.0.0",
	"name":"MUTYH-associated polyposis, surveillance"
},
{
	"jumpto":"ENAS5063_4.2.2.0",
	"name":"MUTYH associated polyposis (MAP)"
},
{
	"jumpto":"ENAS5063_4.2.2.0",
	"name":"MUTYH germline analysis"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"MVAC [BC]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Myasthenic crisis [TETs]"
},
{
	"jumpto":"ENAS5276_4.2.0.0",
	"name":"Mycosis fungoides (MF)"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Nanoliposomal irinotecan [Pancr]"
},
{
	"jumpto":"ENAS5268_5.3.0.0",
	"name":"Nausea and vomiting, opioid-induced"
},
{
	"jumpto":"ENAS5268_6.4.2.0",
	"name":"Nausea and vomiting in malignant bowel obstruction, summary [N/V]"
},
{
	"jumpto":"ENAS5263_14.8.2.0",
	"name":"NCI-CTCAE, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.2.0.0",
	"name":"NCI-CTCAE scale [Mucosa]"
},
{
	"jumpto":"ENAS5281_4.3.2.0",
	"name":"Necitumumab an immunoglobulin G1, treatment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Needle aspiration biopsy"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Neo-adjuvant chemotherapy, anal cancer"
},
{
	"jumpto":"ENAS5092_4.2.2.0",
	"name":"Neoadjuvant ADT [PC]"
},
{
	"jumpto":"ENAS5094_9.3.3.0",
	"name":"Neoadjuvant and adjuvant therapy in BC, summary"
},
{
	"jumpto":"ENAS5094_4.3.0.0",
	"name":"Neoadjuvant chemotherapy [BC]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Neoadjuvant chemotherapy [PenCa]"
},
{
	"jumpto":"ENAS5282_5.0.0.0",
	"name":"Neoadjuvant treatment (Oes CA)"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Neoadjuvant treatment [Pancr]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Neoadjuvant [TS/T-NS]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Neoplasia [Pancr]"
},
{
	"jumpto":"ENAS5061_5.1.0.0",
	"name":"Neoplastic polyp"
},
{
	"jumpto":"interactive_0001764",
	"name":"Nephritis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.4.2",
	"name":"Nephritis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Netupitant [N/V]"
},
{
	"jumpto":"ENAS5410_4.2.6.1",
	"name":"Neurological toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.1.1",
	"name":"Neurological toxicity [irAEs]"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Neurotoxicity [TS/T-NS]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"New onset diabetes (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"Next-generation sequencing, NGS (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.7.1.0",
	"name":"Nivolumab, second-line treatment for EGFR- and ALK-negative disease (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.7.3.0",
	"name":"Nivolumab, Second-line treatment in NSCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.7.2.0",
	"name":"Nivolumab, Second-line treatment in SCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.6.3",
	"name":"Nivolumab second-line treatment in NSCC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5285_6.2.2.6",
	"name":"Nivolumab [RCC]"
},
{
	"jumpto":"ENAS5268_2.2.4.0",
	"name":"NK1 RAs, differences [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.4.0",
	"name":"NK1 receptor antagonists, doses [N/V]"
},
{
	"jumpto":"ENAS5277_2.0.0.0",
	"name":"Nodal and extranodal PTCL subtypes"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Nodal dissection"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Nodal dissection [mCRC]"
},
{
	"jumpto":"ENAS5277_4.3.0.0",
	"name":"Nodal PTCL"
},
{
	"jumpto":"ENAS5277_7.3.1.0",
	"name":"Nodal PTCLs in PTCL, summary"
},
{
	"jumpto":"ENAS5285_6.2.2.7",
	"name":"Non-clear cell histology, treatment [RCC]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Non-DNA-binding compounds [Extra]"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Non-healing ulcer"
},
{
	"jumpto":"ENAS5064_2.0.0.0",
	"name":"Non-invasive criteria, hepatocellular cancer"
},
{
	"jumpto":"ENAS5094_4.1.0.0",
	"name":"Non-muscle-invasive BC, treatment"
},
{
	"jumpto":"ENAS5094_4.1.0.0",
	"name":"Non-muscle-invasive bladder cancer (NIBC)"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Non-vesicant [Extra]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"NRAS exons [mCRC]"
},
{
	"jumpto":"ENAS5281_7.3.2.3",
	"name":"NSCC first-line treatment, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.6.3",
	"name":"NSCC second-line treatment, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5406_7.0.0.0",
	"name":"NSCLC, follow-up and long term implications [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_6.0.0.0",
	"name":"NSCLC, personalised medicine [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.3.4.0",
	"name":"NSCLC, pretreatment risk assessment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.1.0.0",
	"name":"NSCLC, staging and risk assessment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.1.0.0",
	"name":"NSCLC, summary of recommendations [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.2.0.0",
	"name":"NSCLC diagnosis and pathology, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_3.0.0.0",
	"name":"NSCLC early, diagnosis"
},
{
	"jumpto":"ENAS5406_8.7.0.0",
	"name":"NSCLC follow-up, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.5.0.0",
	"name":"NSCLC locally advanced (stage III), staging [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.2.1.0",
	"name":"NSCLC locally advanced (stage III), treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.3.3.0",
	"name":"NSCLC locally advanced (stage III) staging, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.5.1.0",
	"name":"NSCLC locally advanced (stage III) systemic therapy, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.5.1.0",
	"name":"NSCLC locally advanced (stage III) treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.3.2.0",
	"name":"NSCLC locoregional staging, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.6.0.0",
	"name":"NSCLC personalised medicine, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.5.2.0",
	"name":"NSCLC resectable locally advanced (stage III) treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.2.2.0",
	"name":"NSCLC resectable locally advanced, treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.5.0",
	"name":"NSCLC stages I and II, postoperative radiotherapy [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.4.0",
	"name":"NSCLC stages I and II, radiofrequency ablation [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.3.0",
	"name":"NSCLC stages I and II, radiotherapy treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"NSCLC stages I and II, surgical treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.2.0",
	"name":"NSCLC stages I and II, systemic therapy [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.5.0",
	"name":"NSCLC stages I and II postop radiotherapy, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.3.0",
	"name":"NSCLC stages I and II primary radiotherapy treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.4.0",
	"name":"NSCLC stages I and II radiofrequency ablation, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.1.0",
	"name":"NSCLC stages I and II surgical treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.2.0",
	"name":"NSCLC stages I and II systemic therapy, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.3.1.0",
	"name":"NSCLC staging and risk assessment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.5.3.0",
	"name":"NSCLC unresectable locally advanced (stage III) treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.2.3.0",
	"name":"NSCLC unresectable locally advanced, treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5282_3.1.0.0",
	"name":"Nutritional status (Oes CA)"
},
{
	"jumpto":"ENAS5061_5.2.0.0",
	"name":"Obstructive colorectal cancer, treatment"
},
{
	"jumpto":"ENAS5265_3.0.0.0",
	"name":"Occult cancer idiopathic VTE, diagnosis"
},
{
	"jumpto":"ENAS5265_8.2.0.0",
	"name":"Occult cancer idiopathic VTE diagnosis, summary"
},
{
	"jumpto":"ENAS5281_3.3.0.0",
	"name":"Occult carcinoma (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Octreotide [Mucosa]"
},
{
	"jumpto":"ENAS5410_4.2.6.5",
	"name":"Ocular toxicities, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Ocular toxicities [irAEs]"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Oesophageal varices, HCC staging"
},
{
	"jumpto":"ENAS5275_3.0.0.0",
	"name":"Oesophagogastroduodenoscopy"
},
{
	"jumpto":"ENAS5268_6.1.3.2",
	"name":"Olanzapine, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.5.0",
	"name":"Olanzapine [N/V]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Oligometastatic disease (OMD) [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.2.1",
	"name":"Oligometastatic disease, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.4.0.0",
	"name":"Oncological criteria [mCRC]"
},
{
	"jumpto":"ENAS5275_4.5.0.0",
	"name":"Oncological therapy, MALT"
},
{
	"jumpto":"ENAS5275_7.3.2.0",
	"name":"Oncological therapy in MALT, summary"
},
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"Ondansetron [N/V]"
},
{
	"jumpto":"ENAS5268_5.3.0.0",
	"name":"Opioid-induced, nausea and vomiting"
},
{
	"jumpto":"ENAS5268_6.4.3.0",
	"name":"Opioid-induced nausea and vomiting, summary [N/V]"
},
{
	"jumpto":"ENAS5268_5.3.0.0",
	"name":"Opioid rotation [N/V]"
},
{
	"jumpto":"ENAS5263_14.3.0.0",
	"name":"Oral and GI mucositis in HSCT, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_4.0.0.0",
	"name":"Oral and GI mucositis in HSCT [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Oral cavity mucositis guideline [Mucosa]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Oral chemotherapy [N/V]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Oral cryotherapy [Mucosa]"
},
{
	"jumpto":"ENAS5263_3.0.0.0",
	"name":"Oral mucositis, head and neck radiation [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.8.2.0",
	"name":"Oral mucositis grading, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.2.0.0",
	"name":"Oral mucositis grading [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.2.0.0",
	"name":"Oral mucositis in head and neck radiation, summary [Mucosa]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Oral quinolone therapy [FN]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Oral therapy, low-risk patients [FN]"
},
{
	"jumpto":"ENAS5269_6.4.4.1",
	"name":"Oral therapy, summary [FN]"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Organising fibrinous exudates"
},
{
	"jumpto":"ENAS5094_6.0.0.0",
	"name":"Organ preservation therapy, interactive tool [BC]"
},
{
	"jumpto":"ENAS5094_9.3.4.0",
	"name":"Organ preservation therapy in BC, summary"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"Osteoma"
},
{
	"jumpto":"ENAS5268_6.1.2.4",
	"name":"Other highly emetogenic ChT, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.2.5.0",
	"name":"Other highly emetogenic ChT [N/V]"
},
{
	"jumpto":"ENAS5270_5.2.0.0",
	"name":"Other stages of NLPHL, HL"
},
{
	"jumpto":"ENAS5270_9.4.2.0",
	"name":"Other stages of NLPHL, summary"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Ototoxicity [TS/T-NS]"
},
{
	"jumpto":"ENAS5269_6.4.3.0",
	"name":"Outcome risk assessment, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.3.0.0",
	"name":"Outcome risk assessment [FN]"
},
{
	"jumpto":"ENAS5269_6.4.4.2",
	"name":"Outpatient and early discharge policies, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.6.2.0",
	"name":"Outpatient and early discharge policies [FN]"
},
{
	"jumpto":"ENAS5285_5.2.2.1",
	"name":"Overview, advanced disease [RCC]"
},
{
	"jumpto":"ENAS5266_3.2.1.0",
	"name":"Overview, anthracyclines and cytotoxics [CV Tox]"
},
{
	"jumpto":"ENAS5268_5.1.0.0",
	"name":"Overview, antiemetics in advanced cancer [N/V]"
},
{
	"jumpto":"ENAS5266_9.1.0.0",
	"name":"Overview, cardiac toxicity induced by RT [CV Tox]"
},
{
	"jumpto":"ENAS5262_5.1.0.0",
	"name":"Overview, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5267_9.1.0.0",
	"name":"Overview, central venous access device extravasation"
},
{
	"jumpto":"ENAS5266_3.2.1.0",
	"name":"Overview, cumulative dose-related cardiotoxicity [CV Tox]"
},
{
	"jumpto":"ENAS5262_4.1.0.0",
	"name":"Overview, CVC-related infection"
},
{
	"jumpto":"ENAS5269_5.7.1.0",
	"name":"Overview, high-risk patients [FN]"
},
{
	"jumpto":"ENAS5269_4.1.0.0",
	"name":"Overview, indications for primary prophylaxis with G-CSF [FN]"
},
{
	"jumpto":"ENAS5266_3.1.0.0",
	"name":"Overview, left ventricular dysfunction [CV Tox]"
},
{
	"jumpto":"ENAS5285_5.2.1.1",
	"name":"Overview, localised disease [RCC]"
},
{
	"jumpto":"ENAS5267_7.1.0.0",
	"name":"Overview, management of extravasation"
},
{
	"jumpto":"ENAS5263_11.1.0.0",
	"name":"Overview, management [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.1.0",
	"name":"Overview, MASCC/ISOO guidelines [Mucosa]"
},
{
	"jumpto":"ENAS5284_4.3.1.0",
	"name":"Overview, mgmt. of local/ locoregional disease [Bil]"
},
{
	"jumpto":"ENAS5268_2.2.1.0",
	"name":"Overview, prevention by emetogenic ChT [N/V]"
},
{
	"jumpto":"ENAS5268_2.4.1.0",
	"name":"Overview, prevention by MEC [N/V]"
},
{
	"jumpto":"ENAS5268_3.1.0.0",
	"name":"Overview, prevention of RINV [N/V]"
},
{
	"jumpto":"ENAS5263_10.1.0.0",
	"name":"Overview, preventive measures [Mucosa]"
},
{
	"jumpto":"ENAS5285_6.2.2.1",
	"name":"Overview, systemic treatment [RCC]"
},
{
	"jumpto":"ENAS5266_3.4.1.0",
	"name":"Overview, trastuzumab cardiotoxicity"
},
{
	"jumpto":"ENAS5266_10.8.1.0",
	"name":"Overview of cardiac toxicity induced by RT, summary [CV Tox]"
},
{
	"jumpto":"ENAS5262_6.4.1.0",
	"name":"Overview of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS5262_6.3.1.0",
	"name":"Overview of CVC-related infection, summary"
},
{
	"jumpto":"ENAS5266_10.2.1.0",
	"name":"Overview of left ventricular dysfunction, summary [CV Tox]"
},
{
	"jumpto":"ENAS5263_14.10.1.0",
	"name":"Overview of management, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.9.1.0",
	"name":"Overview of preventive measures, summary [Mucosa]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Oxaliplatin, metastatic pancreatic cancer"
},
{
	"jumpto":"ENAS5268_6.1.4.3",
	"name":"Oxaliplatin, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.4.3.0",
	"name":"Oxaliplatin [N/V]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Oxaliplatin [Pancr]"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Paclitaxel (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Paclitaxel, metastatic pancreatic cancer"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Paclitaxel/carboplatin [PenCa]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Paclitaxel/cisplatin/5-fluorouracil [PenCa]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Paclitaxel/cisplatin/ifosfamide [PenCa]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Paclitaxel plus [BC]"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Paclitaxel [PenCa]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Paclitaxel [TETs]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pain management [Pancr]"
},
{
	"jumpto":"ENAS5062_8.3.11.0",
	"name":"Palliative care in anal cancer, summary"
},
{
	"jumpto":"ENAS5092_7.3.3.0",
	"name":"Palliative care in metastatic PC, summary"
},
{
	"jumpto":"ENAS5281_4.13.0.0",
	"name":"Palliative care in stage IV NSCLC"
},
{
	"jumpto":"ENAS5281_7.3.12.0",
	"name":"Palliative care in stage IV NSCLC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_4.2.0.0",
	"name":"Palliative chemotherapy (Oes CA)"
},
{
	"jumpto":"ENAS5304_7.0.0.0",
	"name":"Palliative chemotherapy [mCRC]"
},
{
	"jumpto":"ENAS5281_4.11.0.0",
	"name":"Palliative surgery in stage IV NSCLC"
},
{
	"jumpto":"ENAS5281_7.3.10.0",
	"name":"Palliative surgery in stage IV NSCLC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_4.2.0.0",
	"name":"Palliative treatment (Oes CA)"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Palonosetron [N/V]"
},
{
	"jumpto":"ENAS5068_5.5.0.0",
	"name":"Pancreatic cancer, adjuvant treatment"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pancreatic cancer, advanced"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancer, biology"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Pancreatic cancer, Borderline resectable"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancer, diagnosis"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Pancreatic cancer, diagnostic work-up"
},
{
	"jumpto":"ENAS5068_7.0.0.0",
	"name":"Pancreatic cancer, follow-up"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Pancreatic cancer, locally advanced"
},
{
	"jumpto":"ENAS5068_7.0.0.0",
	"name":"Pancreatic cancer, long-term implications"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Pancreatic cancer, lymphadenectomy"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Pancreatic cancer, metastatic"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pancreatic cancer, metastatic disease"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Pancreatic cancer, oncological treatment"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pancreatic cancer, palliative care"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancer, pathology"
},
{
	"jumpto":"ENAS5068_6.0.0.0",
	"name":"Pancreatic cancer, personalised medicine"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Pancreatic cancer, resectable"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"Pancreatic cancer, staging and assessment"
},
{
	"jumpto":"ENAS5068_8.1.0.0",
	"name":"Pancreatic cancer, summary of recommendations"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pancreatic cancer, supportive care"
},
{
	"jumpto":"ENAS5068_4.2.0.0",
	"name":"Pancreatic cancer, TNM classification"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Pancreatic cancer, treatment strategy"
},
{
	"jumpto":"ENAS5068_5.2.0.0",
	"name":"Pancreatic cancer, treatment summary"
},
{
	"jumpto":"ENAS5068_8.3.1.0",
	"name":"Pancreatic cancer, treatment summary recommendations"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancers, adenocarcinoma"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancers, ductal adenocarcinoma"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Pancreatoduodenectomy"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Pancytokeratin markers"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"Panitumumab [mCRC]"
},
{
	"jumpto":"ENAS5285_2.0.0.0",
	"name":"Paraneoplastic syndromes [RCC]"
},
{
	"jumpto":"ENAS5275_3.0.0.0",
	"name":"Paris staging system"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Partial nephrectomy [RCC]"
},
{
	"jumpto":"ENAS5407_4.7.2.5",
	"name":"Pathological assessment of response [Rectal CA]"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Pathological tumour node metastasis (pTNM) system"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Pathology (Gastric cancer)"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Pathology, rectal cancer"
},
{
	"jumpto":"ENAS5284_7.1.0.0",
	"name":"Pathology, summary [Bil]"
},
{
	"jumpto":"ENAS5282_2.0.0.0",
	"name":"Pathology/molecular biology (Oes CA)"
},
{
	"jumpto":"ENAS5406_3.0.0.0",
	"name":"Pathology/molecular biology, early NSCLC"
},
{
	"jumpto":"ENAS5273_2.0.0.0",
	"name":"Pathology/molecular biology, FL"
},
{
	"jumpto":"ENAS5280_2.1.0.0",
	"name":"Pathology/molecular biology, HCL"
},
{
	"jumpto":"ENAS5282_7.1.0.0",
	"name":"Pathology/molecular biology, summary (Oes CA)"
},
{
	"jumpto":"ENAS5263_14.7.0.0",
	"name":"Pathology/ molecular biology, summary [Mucosa]"
},
{
	"jumpto":"ENAS5273_8.1.0.0",
	"name":"Pathology/molecular biology of FL, summary"
},
{
	"jumpto":"ENAS5280_7.1.0.0",
	"name":"Pathology/molecular biology of HCL, summary"
},
{
	"jumpto":"ENAS5408_7.1.0.0",
	"name":"Pathology/molecular biology of MCL, summary"
},
{
	"jumpto":"ENAS5408_2.0.0.0",
	"name":"Pathology/molecular biology [MCL]"
},
{
	"jumpto":"ENAS5263_8.0.0.0",
	"name":"Pathology/ molecular biology [Mucosa]"
},
{
	"jumpto":"ENAS5285_9.2.0.0",
	"name":"Pathology assessment, summary [RCC]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Pathology assessment [RCC]"
},
{
	"jumpto":"ENAS5086_7.2.0.0",
	"name":"Pathology of MPM, summary"
},
{
	"jumpto":"ENAS5092_7.1.0.0",
	"name":"Pathology of PC, summary"
},
{
	"jumpto":"ENAS5284_2.0.0.0",
	"name":"Pathology [Bil]"
},
{
	"jumpto":"ENAS5267_12.3.0.0",
	"name":"Patient-related risk factors, summary [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Patient-related risk factors [Extra]"
},
{
	"jumpto":"ENAS5269_6.4.1.0",
	"name":"Patient education, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.1.0.0",
	"name":"Patient education [FN]"
},
{
	"jumpto":"ENAS5410_4.1.2.0",
	"name":"Patient selection and baseline assessment, summary [irAEs]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Patients with sensitive disease [SCLC]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Pazopanib [RCC]"
},
{
	"jumpto":"ENAS5092_4.2.1.0",
	"name":"PC, advantages and disadvantages of treatment"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"PC, androgen-deprivation therapy (ADT)"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PC, classification"
},
{
	"jumpto":"ENAS5092_4.2.4.0",
	"name":"PC, continuous ADT"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"PC, diagnosis"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"PC, follow-up and long term implications"
},
{
	"jumpto":"ENAS5092_4.2.2.0",
	"name":"PC, hormone treatment in local disease"
},
{
	"jumpto":"ENAS5092_4.2.4.0",
	"name":"PC, intermittent ADT"
},
{
	"jumpto":"ENAS5092_4.2.1.0",
	"name":"PC, management of local disease"
},
{
	"jumpto":"ENAS5092_4.3.1.0",
	"name":"PC, management of metastatic disease"
},
{
	"jumpto":"ENAS5092_5.0.0.0",
	"name":"PC, personalised medicine"
},
{
	"jumpto":"ENAS5092_4.2.3.0",
	"name":"PC, post-operative RT in local disease"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PC, risk assessment"
},
{
	"jumpto":"ENAS5092_3.3.0.0",
	"name":"PC, risk groups"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PC, staging"
},
{
	"jumpto":"ENAS5092_7.1.0.0",
	"name":"PC, summary recommendations"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"PC, therapeutic strategies"
},
{
	"jumpto":"ENAS5092_3.2.0.0",
	"name":"PC, TNM staging"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"PC, treatment of CRPC"
},
{
	"jumpto":"ENAS5092_4.2.4.0",
	"name":"PC, treatment of relapse"
},
{
	"jumpto":"ENAS5284_7.3.1.3",
	"name":"pCCA, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.3.0",
	"name":"pCCA [Bil]"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"PC metastatic, palliative care"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"PCR, diagnosis (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_2.2.0.0",
	"name":"PCR, polymerase chain reaction (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5061_5.1.0.0",
	"name":"Pedunculated polypoid carcinoma"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"Pegfilgrastim, dose [FN]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"Pegfilgrastim, route of application [FN]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"Pegfilgrastim, schedule [FN]"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Pelvic MRI [Anal cancer]"
},
{
	"jumpto":"ENAS5281_4.7.1.0",
	"name":"Pembrolizumab, second-line treatment for EGFR- and ALK-negative disease (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.7.3.0",
	"name":"Pembrolizumab, Second-line treatment in NSCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.7.2.0",
	"name":"Pembrolizumab, Second-line treatment in SCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.6.3",
	"name":"Pembrolizumab second-line treatment in NSCC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Pemetrexed, MPM therapy"
},
{
	"jumpto":"ENAS5281_4.7.3.0",
	"name":"Pemetrexed, Second-line treatment in NSCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.3.3.0",
	"name":"Pemetrexed-based combination chemotherapy (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.6.3",
	"name":"Pemetrexed second-line treatment in NSCC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.6.0.0",
	"name":"Pemetrexed switch maintenance (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"PenCa, brachytherapy"
},
{
	"jumpto":"ENAS5096_4.3.0.0",
	"name":"PenCa, chemoradiotherapy"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"PenCa, chemotherapy"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"PenCa, chemotherapy for advanced disease"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"PenCa, combination chemotherapy"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"PenCa, diagnosis"
},
{
	"jumpto":"ENAS5096_2.2.0.0",
	"name":"PenCa, diagnosis guidelines"
},
{
	"jumpto":"ENAS5096_6.1.0.0",
	"name":"PenCa, follow-up"
},
{
	"jumpto":"ENAS5096_6.2.0.0",
	"name":"PenCa, follow-up of local recurrence"
},
{
	"jumpto":"ENAS5096_6.3.0.0",
	"name":"PenCa, follow-up of regional recurrence"
},
{
	"jumpto":"ENAS5096_5.0.0.0",
	"name":"PenCa, personalised medicine"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"PenCa, radiotherapy"
},
{
	"jumpto":"ENAS5096_4.6.1.0",
	"name":"PenCa, recommendations for treatment"
},
{
	"jumpto":"ENAS5096_3.1.0.0",
	"name":"PenCa, risk factors"
},
{
	"jumpto":"ENAS5096_3.1.0.0",
	"name":"PenCa, risk groups"
},
{
	"jumpto":"ENAS5096_3.1.0.0",
	"name":"PenCa, staging and risk assessment"
},
{
	"jumpto":"ENAS5096_4.1.0.0",
	"name":"PenCa, surgical treatment"
},
{
	"jumpto":"ENAS5096_3.2.0.0",
	"name":"PenCa, TNM staging"
},
{
	"jumpto":"ENAS5096_4.6.5.0",
	"name":"PenCa, treat. algo. for regional lymph node [Interactive tool]"
},
{
	"jumpto":"ENAS5096_4.6.3.0",
	"name":"PenCa, treat. algorithm of primary tumour"
},
{
	"jumpto":"ENAS5096_4.6.4.0",
	"name":"PenCa, treatment for regional lymph nodes"
},
{
	"jumpto":"ENAS5096_4.6.7.0",
	"name":"PenCa, treatment of metastatic disease"
},
{
	"jumpto":"ENAS5096_4.6.2.0",
	"name":"PenCa, treatment of primary tumour"
},
{
	"jumpto":"ENAS5096_4.6.6.0",
	"name":"PenCa, treatment strategies for recurrence"
},
{
	"jumpto":"ENAS5096_4.1.0.0",
	"name":"Penectomy, effects on QoL [PenCa]"
},
{
	"jumpto":"ENAS5096_6.2.0.0",
	"name":"Penectomy, in local recurrence [PenCa]"
},
{
	"jumpto":"ENAS5096_6.2.0.0",
	"name":"Penile-preserving treatment [PenCa]"
},
{
	"jumpto":"ENAS5280_4.2.3.0",
	"name":"Pentostatin"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Pentoxifylline [Mucosa]"
},
{
	"jumpto":"ENAS5284_3.2.1.2",
	"name":"Peri-hilar, cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5284_3.1.0.0",
	"name":"Peri-hilar cholangiocarcinoma, Bismuth-Corlette classification [Bil]"
},
{
	"jumpto":"ENAS5266_9.4.0.0",
	"name":"Pericarditis [CV Tox]"
},
{
	"jumpto":"ENAS5284_7.3.1.3",
	"name":"Perihilar cholangiocarcinoma, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.3.0",
	"name":"Perihilar cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5062_4.9.0.0",
	"name":"Perineal reconstruction"
},
{
	"jumpto":"ENAS5283_4.3.2.0",
	"name":"Perioperative chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.2",
	"name":"Perioperative chemotherapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Perioperative chemotherapy [mCRC]"
},
{
	"jumpto":"ENAS5283_4.3.2.0",
	"name":"Perioperative trastuzumab therapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5267_7.4.0.0",
	"name":"Peripheral line extravasation, steps"
},
{
	"jumpto":"ENAS5262_6.2.1.0",
	"name":"Peripherally inserted central catheters, summary[CVC]"
},
{
	"jumpto":"ENAS5262_3.1.0.0",
	"name":"Peripherally inserted central catheters [CVC]"
},
{
	"jumpto":"ENAS5410_3.6.1.2",
	"name":"Peripheral neurological symptoms, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.1.3",
	"name":"Peripheral neurological syndromes, interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001769",
	"name":"Peripheral neurological toxicity mgmt-2., interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001766",
	"name":"Peripheral neurological toxicity mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5283_8.5.0.0",
	"name":"Peritoneal metastases, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_8.6.6.0",
	"name":"Peritoneal metastases, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.13.0.0",
	"name":"Peritoneal metastases [mCRC]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Peritonectomy [mCRC]"
},
{
	"jumpto":"ENAS5282_5.0.0.0",
	"name":"Personalised medicine (Oes CA)"
},
{
	"jumpto":"ENAS5062_4.10.0.0",
	"name":"Personalised medicine, anal cancer"
},
{
	"jumpto":"ENAS5279_5.0.0.0",
	"name":"Personalised medicine, CLL"
},
{
	"jumpto":"ENAS5271_6.0.0.0",
	"name":"Personalised medicine, DLBCL"
},
{
	"jumpto":"ENAS5278_5.0.0.0",
	"name":"Personalised medicine, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5061_6.0.0.0",
	"name":"Personalised medicine, early colon cancer"
},
{
	"jumpto":"ENAS5273_6.0.0.0",
	"name":"Personalised medicine, FL"
},
{
	"jumpto":"ENAS5280_5.0.0.0",
	"name":"Personalised medicine, HCL"
},
{
	"jumpto":"ENAS5270_7.0.0.0",
	"name":"Personalised medicine, HL"
},
{
	"jumpto":"ENAS5275_5.0.0.0",
	"name":"Personalised medicine, MALT"
},
{
	"jumpto":"ENAS5276_5.0.0.0",
	"name":"Personalised medicine, PCLs"
},
{
	"jumpto":"ENAS5277_5.0.0.0",
	"name":"Personalised medicine, PTCL"
},
{
	"jumpto":"ENAS5071_4.4.0.0",
	"name":"Personalised medicine, SCLC"
},
{
	"jumpto":"ENAS5281_7.1.0.0",
	"name":"Personalised medicine, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_7.5.0.0",
	"name":"Personalised medicine, summary (Oes CA)"
},
{
	"jumpto":"ENAS5284_7.4.0.0",
	"name":"Personalised medicine, summary [Bil]"
},
{
	"jumpto":"ENAS5304_8.7.0.0",
	"name":"Personalised medicine, summary [mCRC]"
},
{
	"jumpto":"ENAS5263_14.11.0.0",
	"name":"Personalised medicine, summary [Mucosa]"
},
{
	"jumpto":"ENAS5285_9.5.0.0",
	"name":"Personalised medicine, summary [RCC]"
},
{
	"jumpto":"ENAS5407_9.6.0.0",
	"name":"Personalised medicine, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5098_6.0.0.0",
	"name":"Personalised medicine, TETs"
},
{
	"jumpto":"ENAS5274_5.0.0.0",
	"name":"Personalised medicine, WM"
},
{
	"jumpto":"ENAS5283_5.0.0.0",
	"name":"Personalised medicine and targeted therapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.4.0.0",
	"name":"Personalised medicine and targeted therapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5062_8.3.9.0",
	"name":"Personalised medicine in anal cancer, summary"
},
{
	"jumpto":"ENAS5094_9.5.0.0",
	"name":"Personalised medicine in BC, summary"
},
{
	"jumpto":"ENAS5279_7.4.0.0",
	"name":"Personalised medicine in CLL, summary"
},
{
	"jumpto":"ENAS5271_7.5.0.0",
	"name":"Personalised medicine in DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.4.0.0",
	"name":"Personalised medicine in DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5061_8.4.4.0",
	"name":"Personalised medicine in early colon cancer, summary"
},
{
	"jumpto":"ENAS5273_8.4.0.0",
	"name":"Personalised medicine in FL, summary"
},
{
	"jumpto":"ENAS5280_7.4.0.0",
	"name":"Personalised medicine in HCL, summary"
},
{
	"jumpto":"ENAS5270_9.6.0.0",
	"name":"Personalised medicine in HL, summary"
},
{
	"jumpto":"ENAS5275_7.4.0.0",
	"name":"Personalised medicine in MALT, summary"
},
{
	"jumpto":"ENAS5408_7.4.0.0",
	"name":"Personalised medicine in MCL, summary"
},
{
	"jumpto":"ENAS5068_8.4.0.0",
	"name":"Personalised medicine in pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5092_7.4.0.0",
	"name":"Personalised medicine in PC, summary"
},
{
	"jumpto":"ENAS5096_7.4.0.0",
	"name":"Personalised medicine in PenCa, summary"
},
{
	"jumpto":"ENAS5277_7.4.0.0",
	"name":"Personalised medicine in PTCL, summary"
},
{
	"jumpto":"ENAS5098_8.4.0.0",
	"name":"Personalised medicine in TETs, summary"
},
{
	"jumpto":"ENAS5274_7.4.0.0",
	"name":"Personalised medicine in WM, summary"
},
{
	"jumpto":"ENAS5281_2.2.0.0",
	"name":"Personalised medicine synopsis (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5283_5.0.0.0",
	"name":"Personalised medicine synopsis table (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_5.0.0.0",
	"name":"Personalised medicine synopsis table (Oes CA)"
},
{
	"jumpto":"ENAS5094_7.0.0.0",
	"name":"Personalised medicine [BC]"
},
{
	"jumpto":"ENAS5284_5.0.0.0",
	"name":"Personalised medicine [Bil]"
},
{
	"jumpto":"ENAS5408_5.0.0.0",
	"name":"Personalised medicine [MCL]"
},
{
	"jumpto":"ENAS5304_6.0.0.0",
	"name":"Personalised medicine [mCRC]"
},
{
	"jumpto":"ENAS5263_12.0.0.0",
	"name":"Personalised medicine [Mucosa]"
},
{
	"jumpto":"ENAS5285_7.0.0.0",
	"name":"Personalised medicine [RCC]"
},
{
	"jumpto":"ENAS5407_7.0.0.0",
	"name":"Personalised medicine [Rectal CA]"
},
{
	"jumpto":"ENAS5071_6.4.0.0",
	"name":"Personlised medicine in SCLC, summary"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"PET-CT imaging (Gastric cancer)"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PET/CT [PC]"
},
{
	"jumpto":"ENAS5278_3.3.0.0",
	"name":"PET 5-point scale, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Peutz-Jeghers syndrome"
},
{
	"jumpto":"ENAS5096_4.1.0.0",
	"name":"Phalloplasty [PenCa]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Phosphatase and tensin homologue (PTEN) [mCRC]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Phrenic nerve preservation [TETs]"
},
{
	"jumpto":"ENAS5062_4.3.0.0",
	"name":"Piecemeal resection"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"PIK3CA exon [mCRC]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Pilocarpine [Mucosa]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Platin salts [Extra]"
},
{
	"jumpto":"ENAS5282_4.1.6.0",
	"name":"Platinum, treatment (Oes CA)"
},
{
	"jumpto":"ENAS5281_4.5.0.0",
	"name":"Platinum-based chemotherapy (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5094_4.3.0.0",
	"name":"Platinum-based combination chemotherapy [BC]"
},
{
	"jumpto":"ENAS5283_4.3.2.0",
	"name":"Platinum/fluoropyrimidine combination chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.2",
	"name":"Platinum/fluoropyrimidine combination chemotherapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5409_11.1.3.0",
	"name":"Platinum derivatives [IRs]"
},
{
	"jumpto":"ENAS5086_5.3.0.0",
	"name":"Platinum doublet, unresectable mesothelioma"
},
{
	"jumpto":"ENAS5269_5.9.3.0",
	"name":"Pneumocystis jirovecii [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.3",
	"name":"Pneumonia, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.3.0",
	"name":"Pneumonia [FN]"
},
{
	"jumpto":"ENAS5410_3.5.1.0",
	"name":"Pneumonitis, immune related [irAEs]"
},
{
	"jumpto":"ENAS5410_3.5.2.2",
	"name":"Pneumonitis mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001768",
	"name":"Pneumonitis mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5262_6.2.2.0",
	"name":"Pneumothorax, summary [CVC]"
},
{
	"jumpto":"ENAS5262_3.2.0.0",
	"name":"Pneumothorax [CVC]"
},
{
	"jumpto":"ENAS5063_4.2.2.0",
	"name":"Polyposis syndromes, genetic diagnosis"
},
{
	"jumpto":"ENAS5285_6.2.2.4",
	"name":"Poor prognosis, first-line treat. [RCC]"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Portal hypertension, HCC staging"
},
{
	"jumpto":"ENAS5406_5.1.5.0",
	"name":"PORT [Early NSCLC]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Positron-emission tomography (PET)/CT"
},
{
	"jumpto":"ENAS5098_8.3.4.0",
	"name":"Post-op chemotherapy in TETs, summary"
},
{
	"jumpto":"ENAS5062_8.3.6.0",
	"name":"Post-operative chemoradiotherapy in anal cancer, summary"
},
{
	"jumpto":"ENAS5092_7.3.1.3",
	"name":"Post-operative radiotherapy of PC, summary"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Post-op radiotherapy, TETs"
},
{
	"jumpto":"ENAS5098_8.3.3.0",
	"name":"Post-op radiotherapy in TETs, summary"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Post-orchiectomy staging [TS/T-NS]"
},
{
	"jumpto":"ENAS5271_4.6.1.0",
	"name":"Post-treatment evaluation, DLBCL"
},
{
	"jumpto":"ENAS5407_4.8.1.0",
	"name":"Postoperative chemoradiotherapy [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.8.2.0",
	"name":"Postoperative chemotherapy [Rectal CA]"
},
{
	"jumpto":"ENAS5407_9.3.6.0",
	"name":"Postoperative therapy, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5267_12.2.0.0",
	"name":"Potential for anticancer agents, summary [Extra]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Potential for anticancer agents [Extra]"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Potentially curative surgery [mCRC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Prednisolone [PC]"
},
{
	"jumpto":"interactive_0001745",
	"name":"Preoperative cardiac evaluation, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.9.0.0",
	"name":"Preoperative cardiac evaluation, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5407_9.3.5.1",
	"name":"Preoperative chemotherapy, summary [Rectal CA]"
},
{
	"jumpto":"interactive_0001744",
	"name":"Preoperative respiratory evaluation, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.7.0.0",
	"name":"Preoperative respiratory evaluation, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.6.0.0",
	"name":"Pretreatment risk assessment [Early NSCLC]"
},
{
	"jumpto":"ENAS5268_2.8.0.0",
	"name":"Prev., anticipatory nausea and vomiting"
},
{
	"jumpto":"ENAS5268_2.6.0.0",
	"name":"Prev., ChT with low & minimal emetogenic potential [N/V]"
},
{
	"jumpto":"ENAS5268_2.5.0.0",
	"name":"Prev., multiple-day cisplatin ChT [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.6.0",
	"name":"Prev. by ChT with low & min. emetogenic pot., summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.5.0",
	"name":"Prev. by multiple-day cisplatin ChT, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.8.0",
	"name":"Prev. of anticipatory nausea and vomiting, summary [N/V]"
},
{
	"jumpto":"ENAS5268_4.0.0.0",
	"name":"Prevention, acute CINV in children [N/V]"
},
{
	"jumpto":"ENAS5262_5.6.0.0",
	"name":"Prevention, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5262_5.5.2.0",
	"name":"Prevention, catheter-related thrombosis [CVC]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Prevention, CINV"
},
{
	"jumpto":"ENAS5262_4.4.0.0",
	"name":"Prevention, CVC-related infections"
},
{
	"jumpto":"ENAS5267_5.0.0.0",
	"name":"Prevention, extravasation [Extra]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"Prevention, high-dose chemotherapy [N/V]"
},
{
	"jumpto":"ENAS5267_12.4.0.0",
	"name":"Prevention, summary [Extra]"
},
{
	"jumpto":"ENAS5268_2.2.1.0",
	"name":"Prevention by emetogenic ChT, overview [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.9.0",
	"name":"Prevention by high-dose chemotherapy, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.2.1",
	"name":"Prevention by highly emetogenic ChT, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.4.1.0",
	"name":"Prevention by MEC, overview [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.4.1",
	"name":"Prevention by MEC, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.3.0.0",
	"name":"Prevention of acute CINV in children, summary [N/V]"
},
{
	"jumpto":"ENAS5262_6.4.5.0",
	"name":"Prevention of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS5262_6.3.4.0",
	"name":"Prevention of CVC-related infections, summary [CVC]"
},
{
	"jumpto":"ENAS5268_3.1.0.0",
	"name":"Prevention of RINV, overview [N/V]"
},
{
	"jumpto":"ENAS5268_6.2.1.0",
	"name":"Prevention of RINV, summary [N/V]"
},
{
	"jumpto":"ENAS5265_4.2.0.0",
	"name":"Prevention of VTE, medical patients"
},
{
	"jumpto":"ENAS5265_4.1.0.0",
	"name":"Prevention of VTE, surgical patients"
},
{
	"jumpto":"ENAS5265_8.3.2.0",
	"name":"Prevention of VTE in medical patients, summary"
},
{
	"jumpto":"ENAS5265_8.3.1.0",
	"name":"Prevention of VTE in surgical patients, summary"
},
{
	"jumpto":"ENAS5263_10.1.0.0",
	"name":"Preventive measures, overview [Mucosa]"
},
{
	"jumpto":"ENAS5098_8.3.6.0",
	"name":"Primary/induction chemotherapy, summary [TETs]"
},
{
	"jumpto":"ENAS5062_4.3.0.0",
	"name":"Primary abdomino-perineal excision (APE)"
},
{
	"jumpto":"ENAS5278_2.4.0.0",
	"name":"Primary central nervous system lymphoma (PCNSL)"
},
{
	"jumpto":"ENAS5063_4.4.0.0",
	"name":"Primary chemoprevention [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5276_4.4.0.0",
	"name":"Primary cutaneous CD30-positive LPDs"
},
{
	"jumpto":"ENAS5276_7.3.5.0",
	"name":"Primary cutaneous CD30-positive LPDs, summary"
},
{
	"jumpto":"ENAS5276_4.7.0.0",
	"name":"Primary cutaneous PTCL-NOS"
},
{
	"jumpto":"ENAS5276_7.3.8.0",
	"name":"Primary cutaneous PTCL-NOS, summary"
},
{
	"jumpto":"ENAS5278_2.6.0.0",
	"name":"Primary diffuse large B-cell lymphoma of the bone (PBoL)"
},
{
	"jumpto":"ENAS5278_2.5.0.0",
	"name":"Primary diffuse large B-cell lymphoma of the breast (PBL)"
},
{
	"jumpto":"ENAS5269_4.2.0.0",
	"name":"Primary G-CSF prophylaxis, algo. [FN]"
},
{
	"jumpto":"ENAS5278_2.2.0.0",
	"name":"Primary mediastinal large B-cell lymphoma (PMBCL)"
},
{
	"jumpto":"ENAS5096_4.6.3.0",
	"name":"Primary penile tumour, treatment algorithm [Interactive tool]"
},
{
	"jumpto":"ENAS5269_6.3.1.0",
	"name":"Primary prophylaxis, summary [FN]"
},
{
	"jumpto":"ENAS5269_4.1.0.0",
	"name":"Primary prophylaxis [FN]"
},
{
	"jumpto":"ENAS5278_2.3.0.0",
	"name":"Primary testicular lymphoma (PTL)"
},
{
	"jumpto":"ENAS5281_3.2.0.0",
	"name":"Primary tumour (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Probiotics [Mucosa]"
},
{
	"jumpto":"ENAS5267_12.3.0.0",
	"name":"Procedure-related risk factors, summary [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Procedure-related risk factors [Extra]"
},
{
	"jumpto":"ENAS5063_4.4.0.0",
	"name":"Proctocolectomy"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Proctoscopy"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Proctoscopy, risk assessment"
},
{
	"jumpto":"ENAS5270_6.0.0.0",
	"name":"Prognosis, HL"
},
{
	"jumpto":"ENAS5270_9.5.0.0",
	"name":"Prognosis of HL, summary"
},
{
	"jumpto":"ENAS5281_3.3.0.0",
	"name":"Prognostic groups (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5061_4.3.0.0",
	"name":"Prognostic groups, early colon cancer"
},
{
	"jumpto":"ENAS5097_4.5.2.0",
	"name":"Prognostic score, relapsing TS/ T-NS"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Prophylactic cranial irradiation (PCI)[SCLC]"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Prophylactic irradiation [TETs]"
},
{
	"jumpto":"ENAS5263_11.3.0.0",
	"name":"Prophylactic systematic gastrostomy [Mucosa]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Prostate specific antigen"
},
{
	"jumpto":"ENAS5281_4.4.0.0",
	"name":"PS 2 and beyond (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.3.0",
	"name":"PS 2 and beyond, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"PSA, PC follow-up [PC]"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PSA in risk assessment of PC"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"PSA [PC]"
},
{
	"jumpto":"ENAS5283_7.0.0.0",
	"name":"Psychological support, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.6.0.0",
	"name":"Psychological support, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"PTA and BCoG [Mucosa]"
},
{
	"jumpto":"ENAS5277_4.2.0.0",
	"name":"PTCL Mgmt.: Front-line & relapsed, interactive tool"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Pulmonary [TS/T-NS]"
},
{
	"jumpto":"ENAS5266_10.5.0.0",
	"name":"QT prolongation, summary [CV Tox]"
},
{
	"jumpto":"ENAS5266_6.0.0.0",
	"name":"QT prolongation [CV Tox]"
},
{
	"jumpto":"ENAS5062_8.4.0.0",
	"name":"Quality of life in anal cancer, summary"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Radiation techniques [mCRC]"
},
{
	"jumpto":"ENAS5281_4.14.1.0",
	"name":"Radiation therapy oncology group (RTOG)"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Radiation Therapy Oncology Group (RTOG)"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"Radical cystectomy [BC]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Radical gastrectomy, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Radical gastrectomy in stage IB–III gastric cancer, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Radical oesophagectomy, surgical technique (Oes CA)"
},
{
	"jumpto":"ENAS5064_6.0.0.0",
	"name":"Radical treatment for HCC, follow-up"
},
{
	"jumpto":"ENAS5064_4.3.0.0",
	"name":"Radioembolisation, with glass"
},
{
	"jumpto":"ENAS5064_4.3.0.0",
	"name":"Radioembolisation, with resin yttrium-90"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Radioembolisation [mCRC]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Radiofrequency ablation (RFA) [mCRC]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Radiofrequency ablation [RCC]"
},
{
	"jumpto":"ENAS5304_2.0.0.0",
	"name":"Radiological imaging [mCRC]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Radiotherapy, advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5098_5.9.0.0",
	"name":"Radiotherapy, definitive [TETs]"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Radiotherapy, locally advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Radiotherapy, post-op [TETs]"
},
{
	"jumpto":"ENAS5277_4.7.0.0",
	"name":"Radiotherapy, PTCL"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Radiotherapy, role [RCC]"
},
{
	"jumpto":"ENAS5284_7.3.2.1",
	"name":"Radiotherapy, summary [Bil]"
},
{
	"jumpto":"ENAS5285_9.4.2.3",
	"name":"Radiotherapy, summary [RCC]"
},
{
	"jumpto":"ENAS5062_4.8.0.0",
	"name":"Radiotherapy, supportive care"
},
{
	"jumpto":"ENAS5062_4.8.0.0",
	"name":"Radiotherapy, toxicity"
},
{
	"jumpto":"ENAS5266_9.3.0.0",
	"name":"Radiotherapy-related cardiac complications, Tx [CV Tox]"
},
{
	"jumpto":"ENAS5268_3.2.0.0",
	"name":"Radiotherapy emetic risk levels [N/V]"
},
{
	"jumpto":"ENAS5407_9.3.4.0",
	"name":"Radiotherapy field sizes, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.6.0.0",
	"name":"Radiotherapy field sizes [Rectal CA]"
},
{
	"jumpto":"ENAS5086_7.4.3.1",
	"name":"Radiotherapy in MPM, summary"
},
{
	"jumpto":"ENAS5096_7.3.2.0",
	"name":"Radiotherapy in PenCa, summary"
},
{
	"jumpto":"ENAS5277_7.3.5.0",
	"name":"Radiotherapy in PTCL, summary"
},
{
	"jumpto":"ENAS5284_4.4.1.0",
	"name":"Radiotherapy [Bil]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Radiotherapy [mCRC]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Radiotherapy [Pancr]"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"Radiotherapy [PenCa]"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Radiotherapy [TETs]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Radiotherapy [TS/T-NS]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Radium-223 [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Radium-223, side effects [PC]"
},
{
	"jumpto":"ENAS5279_3.2.0.0",
	"name":"RAI system [CLL]"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Raltitrexed, MPM therapy, Combination doublet chemotherapy"
},
{
	"jumpto":"ENAS5281_4.7.1.0",
	"name":"Ramucirumab, second-line treatment for EGFR- and ALK-negative disease (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5410_4.2.6.1",
	"name":"Rare immune-related toxicities, summary [irAEs]"
},
{
	"jumpto":"ENAS5304_8.5.1.0",
	"name":"RAS, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"RAS analysis [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.9.0",
	"name":"RAS mutant disease [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"RAS mutation status [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"RAS mutation [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.9.0",
	"name":"RAS wild-type disease [mCRC]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Raynaud syndrome [Extra]"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"RC [BC]"
},
{
	"jumpto":"ENAS5407_9.3.5.2",
	"name":"Reassessment after preop chemoradiotherapy, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.7.2.1",
	"name":"Reassessment after preoperative (chemo) radiotherapy [Rectal CA]"
},
{
	"jumpto":"ENAS5409_13.7.0.0",
	"name":"Rechallenge, summary [IRs]"
},
{
	"jumpto":"ENAS5409_10.0.0.0",
	"name":"Rechallenge [IRs]"
},
{
	"jumpto":"ENAS5281_5.0.0.0",
	"name":"RECIST criteria (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"RECIST [TETs]"
},
{
	"jumpto":"ENAS5266_10.8.2.0",
	"name":"Recomm. to reduce cardiac toxicity in RT, summary [CV Tox]"
},
{
	"jumpto":"ENAS5266_9.2.0.0",
	"name":"Recommendations, reduce cardiac toxicity"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Recommendations, targeted therapy-associated stomatitis [Mucosa]"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Rectal cancer, diagnosis"
},
{
	"jumpto":"ENAS5407_3.6.3.0",
	"name":"Rectal cancer, histopathology"
},
{
	"jumpto":"ENAS5407_4.1.0.0",
	"name":"Rectal cancer, management of local/locoregional disease"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Rectal cancer, molecular biology"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Rectal cancer, pathology"
},
{
	"jumpto":"ENAS5407_3.6.2.0",
	"name":"Rectal cancer, stage grouping"
},
{
	"jumpto":"ENAS5407_3.5.0.0",
	"name":"Rectal cancer, subclassification of T3 stage"
},
{
	"jumpto":"ENAS5407_3.4.0.0",
	"name":"Rectal cancer, TNM staging"
},
{
	"jumpto":"ENAS5407_2.2.0.0",
	"name":"Rectal cancer diagnosis interactive tool"
},
{
	"jumpto":"ENAS5407_3.1.0.0",
	"name":"Rectal cancer staging"
},
{
	"jumpto":"ENAS5407_3.2.0.0",
	"name":"Rectal cancer staging, interactive tool"
},
{
	"jumpto":"interactive_0001756",
	"name":"Rectal cancer surveillance and follow-up [tool]"
},
{
	"jumpto":"ENAS5407_4.1.0.0",
	"name":"Rectal cancer treatment, interactive tool"
},
{
	"jumpto":"interactive_0001749",
	"name":"Rectal cancer treatment of local recurrence [tool]"
},
{
	"jumpto":"interactive_0001747",
	"name":"Rectal cancer treatment recommendations [tool]"
},
{
	"jumpto":"interactive_0001751",
	"name":"Rectal cancer Tx of metastatic disease [tool]"
},
{
	"jumpto":"ENAS5071_5.0.0.0",
	"name":"Recurrence, SCLC"
},
{
	"jumpto":"ENAS5407_4.4.0.0",
	"name":"Recurrence risk according to postop histology [Rectal CA]"
},
{
	"jumpto":"ENAS5265_5.4.0.0",
	"name":"Recurrent VTE, treatment"
},
{
	"jumpto":"ENAS5265_8.4.4.0",
	"name":"Recurrent VTE treatment, summary"
},
{
	"jumpto":"ENAS5281_4.14.1.0",
	"name":"Recursive partitioning analysis (RPA)"
},
{
	"jumpto":"ENAS5266_9.2.0.0",
	"name":"Reduce cardiac toxicity, recommendations"
},
{
	"jumpto":"ENAS5266_9.2.0.0",
	"name":"Reduce cardiac toxicity by RT"
},
{
	"jumpto":"ENAS5064_4.3.0.0",
	"name":"Reduced portal vein flow"
},
{
	"jumpto":"ENAS5268_2.7.0.0",
	"name":"Refractory emesis [N/V]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Refractory patients"
},
{
	"jumpto":"ENAS5281_3.2.0.0",
	"name":"Regional lymph nodes (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5304_5.14.5.0",
	"name":"Regorafenib [mCRC]"
},
{
	"jumpto":"ENAS5271_7.4.2.1",
	"name":"Relapsed and refractory DLBCL, summary"
},
{
	"jumpto":"ENAS5270_4.6.0.0",
	"name":"Relapsed cHL"
},
{
	"jumpto":"ENAS5270_9.3.4.0",
	"name":"Relapsed cHL, summary"
},
{
	"jumpto":"ENAS5273_5.6.0.0",
	"name":"Relapsed disease, FL"
},
{
	"jumpto":"ENAS5274_4.5.0.0",
	"name":"Relapsed disease, WM"
},
{
	"jumpto":"ENAS5273_8.3.3.0",
	"name":"Relapsed disease in FL, summary"
},
{
	"jumpto":"ENAS5408_7.3.5.0",
	"name":"Relapsed disease in MCL, summary"
},
{
	"jumpto":"ENAS5274_7.3.3.0",
	"name":"Relapsed disease in WM, summary"
},
{
	"jumpto":"ENAS5408_4.6.0.0",
	"name":"Relapsed disease [MCL]"
},
{
	"jumpto":"ENAS5270_5.3.0.0",
	"name":"Relapsed NLPHL, HL"
},
{
	"jumpto":"ENAS5270_9.4.3.0",
	"name":"Relapsed NLPHL, summary"
},
{
	"jumpto":"ENAS5279_4.2.3.2",
	"name":"Relapse treatment, interactive tool"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Remission induction chemotherapy [FN]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Renal cell tumors, WHO classification"
},
{
	"jumpto":"ENAS5410_4.2.6.4",
	"name":"Renal toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.4.1",
	"name":"Renal toxicity [irAEs]"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Renal toxicity [TS/T-NS]"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Resectable TETs, treatment algorithm [TETs]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Resistant patients with early relapse"
},
{
	"jumpto":"ENAS5269_5.10.2.0",
	"name":"Response assessment, algo. [FN]"
},
{
	"jumpto":"ENAS5064_5.0.0.0",
	"name":"Response assessment, HCC"
},
{
	"jumpto":"ENAS5407_4.7.2.1",
	"name":"Response assessment after preoperative (chemo) radiotherapy [Rectal CA]"
},
{
	"jumpto":"ENAS5281_5.0.0.0",
	"name":"Response evaluation (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5279_4.3.0.0",
	"name":"Response evaluation, CLL"
},
{
	"jumpto":"ENAS5271_4.6.1.0",
	"name":"Response evaluation, DLBCL"
},
{
	"jumpto":"ENAS5278_4.7.0.0",
	"name":"Response evaluation, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5273_5.8.0.0",
	"name":"Response evaluation, FL"
},
{
	"jumpto":"ENAS5280_4.3.0.0",
	"name":"Response evaluation, HCL"
},
{
	"jumpto":"ENAS5270_5.4.0.0",
	"name":"Response evaluation, HL"
},
{
	"jumpto":"ENAS5275_4.6.0.0",
	"name":"Response evaluation, MALT"
},
{
	"jumpto":"ENAS5281_7.4.0.0",
	"name":"Response evaluation, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5285_9.6.0.0",
	"name":"Response evaluation, summary [RCC]"
},
{
	"jumpto":"ENAS5274_4.6.0.0",
	"name":"Response evaluation, WM"
},
{
	"jumpto":"ENAS5304_8.8.0.0",
	"name":"Response evaluation and follow-up, summary [mCRC]"
},
{
	"jumpto":"ENAS5277_7.5.0.0",
	"name":"Response evaluation and follow-up in PTCL, summary"
},
{
	"jumpto":"ENAS5304_7.0.0.0",
	"name":"Response evaluation and follow-up [mCRC]"
},
{
	"jumpto":"ENAS5277_6.0.0.0",
	"name":"Response evaluation and follow up, PTCL"
},
{
	"jumpto":"ENAS5281_3.1.0.0",
	"name":"Response evaluation criteria in solid tumours (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Response evaluation criteria [TETs]"
},
{
	"jumpto":"ENAS5271_7.3.4.0",
	"name":"Response evaluation in DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.3.7.0",
	"name":"Response evaluation in DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5273_8.3.5.0",
	"name":"Response evaluation in FL, summary"
},
{
	"jumpto":"ENAS5280_7.3.3.0",
	"name":"Response evaluation in HCL, summary"
},
{
	"jumpto":"ENAS5270_9.4.4.0",
	"name":"Response evaluation in HL, summary"
},
{
	"jumpto":"ENAS5275_7.3.3.0",
	"name":"Response evaluation in MALT, summary"
},
{
	"jumpto":"ENAS5408_7.3.6.0",
	"name":"Response evaluation in MCL, summary"
},
{
	"jumpto":"ENAS5274_7.3.4.0",
	"name":"Response evaluation in WM, summary"
},
{
	"jumpto":"ENAS5408_4.7.0.0",
	"name":"Response evaluation [MCL]"
},
{
	"jumpto":"ENAS5285_8.0.0.0",
	"name":"Response evaluation [RCC]"
},
{
	"jumpto":"ENAS5279_7.3.3.0",
	"name":"Response revaluation in CLL, summary"
},
{
	"jumpto":"ENAS5062_8.5.0.0",
	"name":"Response to treatment evaluation in anal cancer, summary"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"Reverse transcription-polymerase chain reaction (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5276_3.3.0.0",
	"name":"Revised clinical staging system, PCLs"
},
{
	"jumpto":"ENAS5410_4.2.6.3",
	"name":"Rheumatological toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.3.1",
	"name":"Rheumatological toxicity [irAEs]"
},
{
	"jumpto":"ENAS5407_9.3.1.1",
	"name":"Risk adapted treatment of rectal cancer, summary"
},
{
	"jumpto":"ENAS5407_4.3.1.0",
	"name":"Risk adapted treatment [Rectal CA]"
},
{
	"jumpto":"ENAS5407_9.3.1.1",
	"name":"Risk adapted Tx, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Risk assessment (Gastric cancer)"
},
{
	"jumpto":"ENAS5281_2.2.0.0",
	"name":"Risk assessment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_3.1.0.0",
	"name":"Risk assessment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_3.1.0.0",
	"name":"Risk assessment (Oes CA)"
},
{
	"jumpto":"ENAS5279_3.1.0.0",
	"name":"Risk assessment, CLL"
},
{
	"jumpto":"ENAS5271_3.1.0.0",
	"name":"Risk assessment, DLBCL"
},
{
	"jumpto":"ENAS5278_3.1.0.0",
	"name":"Risk assessment, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5278_3.1.0.0",
	"name":"Risk assessment, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"Risk assessment, early colon cancer"
},
{
	"jumpto":"ENAS5273_4.1.0.0",
	"name":"Risk assessment, FL"
},
{
	"jumpto":"ENAS5270_3.0.0.0",
	"name":"Risk assessment, hodgkin's lymphoma"
},
{
	"jumpto":"ENAS5275_3.0.0.0",
	"name":"Risk assessment, MALT"
},
{
	"jumpto":"ENAS5406_4.6.0.0",
	"name":"Risk assessment, pretreatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5277_3.0.0.0",
	"name":"Risk assessment, PTCL"
},
{
	"jumpto":"ENAS5407_3.1.0.0",
	"name":"Risk assessment, rectal CA"
},
{
	"jumpto":"ENAS5284_7.2.0.0",
	"name":"Risk assessment, summary [Bil]"
},
{
	"jumpto":"ENAS5263_14.8.6.0",
	"name":"Risk assessment, summary [Mucosa]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Risk assessment, summary [RCC]"
},
{
	"jumpto":"ENAS5274_3.1.0.0",
	"name":"Risk assessment, WM"
},
{
	"jumpto":"ENAS5064_7.2.0.0",
	"name":"Risk assessment in HCC, summary"
},
{
	"jumpto":"ENAS5284_3.1.0.0",
	"name":"Risk assessment [Bil]"
},
{
	"jumpto":"ENAS5408_3.1.0.0",
	"name":"Risk assessment [MCL]"
},
{
	"jumpto":"ENAS5263_9.6.0.0",
	"name":"Risk assessment [Mucosa]"
},
{
	"jumpto":"ENAS5285_5.2.1.1",
	"name":"Risk assessment [RCC]"
},
{
	"jumpto":"ENAS5268_6.2.2.0",
	"name":"Risk classification, summary [N/V]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Risk classification [N/V]"
},
{
	"jumpto":"ENAS5262_5.2.0.0",
	"name":"Risk factors, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Risk factors, early colon cancer"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Risk factors, extravasation [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Risk factors, patient-related [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Risk factors, procedure-related [Extra]"
},
{
	"jumpto":"ENAS5267_12.3.0.0",
	"name":"Risk factors, summary [Extra]"
},
{
	"jumpto":"ENAS5265_2.1.0.0",
	"name":"Risk factors, VTE [VTE]"
},
{
	"jumpto":"ENAS5265_8.1.0.0",
	"name":"Risk factors for VTE, summary"
},
{
	"jumpto":"ENAS5262_6.4.2.0",
	"name":"Risk factors of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS5061_8.1.0.0",
	"name":"Risk factors of early colon cancer, summary"
},
{
	"jumpto":"ENAS5407_9.3.2.0",
	"name":"Risk of recurrence of rectal cancer, summary"
},
{
	"jumpto":"ENAS5280_3.0.0.0",
	"name":"Risk stratification, HCL"
},
{
	"jumpto":"ENAS5409_11.2.3.0",
	"name":"Rituximab [IRs]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Rolapitant [N/V]"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Role, bisphosphonates [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Role, radiotherapy [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Role, surgery and local therapy"
},
{
	"jumpto":"ENAS5279_4.2.4.0",
	"name":"Role of HSCT"
},
{
	"jumpto":"ENAS5279_7.3.2.4",
	"name":"Role of HSCT, summary"
},
{
	"jumpto":"ENAS5285_9.4.2.3",
	"name":"Role of radiotherapy and bisphosphonates, summary [RCC]"
},
{
	"jumpto":"ENAS5285_9.4.2.1",
	"name":"Role of surgery and local therapy, summary [RCC]"
},
{
	"jumpto":"ENAS5268_6.1.3.1",
	"name":"Route of administration of antiemetics, summary [N/V]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Route of application of G-CSF, summary [FN]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Route of application of pegfilgrastim, summary [FN]"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"RT-PCR, diagnosis (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_2.2.0.0",
	"name":"RT-PCR, reverse transcription polymerase chain reaction (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.10.0.0",
	"name":"RT in stage IV NSCLC"
},
{
	"jumpto":"ENAS5281_7.3.9.0",
	"name":"RT in stage IV NSCLC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"RT [PC]"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"RT [TETs]"
},
{
	"jumpto":"ENAS5262_4.3.7.0",
	"name":"S. lugdunensis [CVC]"
},
{
	"jumpto":"ENAS5268_6.1.3.1",
	"name":"Safety of antiemetics, summary [N/V]"
},
{
	"jumpto":"ENAS5282_6.0.0.0",
	"name":"Salvage surgery (Oes CA)"
},
{
	"jumpto":"ENAS5062_4.9.0.0",
	"name":"Salvage surgical treatment, anal cancer"
},
{
	"jumpto":"ENAS5062_8.3.8.0",
	"name":"Salvage surgical treatment in anal cancer, summary"
},
{
	"jumpto":"ENAS5097_7.3.4.0",
	"name":"Salvage treatment, summary [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_4.5.1.0",
	"name":"Salvage treatment, TS/ T-NS"
},
{
	"jumpto":"ENAS5281_7.3.2.2",
	"name":"SCC first-line treatment, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.6.2",
	"name":"SCC second-line treatment, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5268_6.1.3.1",
	"name":"Schedule of antiemetics, summary [N/V]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Schedule of G-CSF, summary [FN]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Schedule of pegfilgrastim, summary [FN]"
},
{
	"jumpto":"ENAS5410_3.1.3.2",
	"name":"Schematic of body surface area [irAEs]"
},
{
	"jumpto":"ENAS5071_6.5.0.0",
	"name":"SCLC follow-up, summary"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Screening, early colon cancer"
},
{
	"jumpto":"ENAS5061_8.1.0.0",
	"name":"Screening for early colon cancer, summary"
},
{
	"jumpto":"ENAS5406_2.0.0.0",
	"name":"Screening [Early NSCLC]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"SCT [N/V]"
},
{
	"jumpto":"ENAS5283_4.6.0.0",
	"name":"Second- and further-line treatment (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.4.0",
	"name":"Second- and further-line treatment, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_8.6.10.0",
	"name":"Second-line therapy, summary [mCRC]"
},
{
	"jumpto":"ENAS5281_4.7.1.0",
	"name":"Second-line treatment (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_7.3.6.1",
	"name":"Second-line treatment, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"Second-line treatment, summary [RCC]"
},
{
	"jumpto":"ENAS5281_4.7.3.0",
	"name":"Second-line treatment of NSCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.7.2.0",
	"name":"Second-line treatment of SCC (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5285_6.2.2.5",
	"name":"Second-line treatment [RCC]"
},
{
	"jumpto":"ENAS5063_4.4.0.0",
	"name":"Secondary chemoprevention [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5269_6.3.1.0",
	"name":"Secondary prophylaxis, summary [FN]"
},
{
	"jumpto":"ENAS5269_4.1.0.0",
	"name":"Secondary prophylaxis [FN]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Selective internal radiotherapy (SIRT) [mCRC]"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Sentinel lymph node biopsy"
},
{
	"jumpto":"ENAS5267_12.7.0.0",
	"name":"Severe tissue damage, summary [Extra]"
},
{
	"jumpto":"ENAS5267_8.0.0.0",
	"name":"Severe tissue damage, surgical mgmt. [Extra]"
},
{
	"jumpto":"ENAS5086_5.4.1.0",
	"name":"Short course radiotherapy, MPM"
},
{
	"jumpto":"ENAS5283_8.5.0.0",
	"name":"Signet cell tumours, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Single IV antineoplastics [N/V]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Sipleucel-T [PC]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Sipuleucel-T [PC]"
},
{
	"jumpto":"ENAS5410_4.2.1.2",
	"name":"Skin toxicities diagnosis & pathology, summary [irAEs]"
},
{
	"jumpto":"ENAS5281_4.1.0.0",
	"name":"Smoking cessation, management (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5071_5.0.0.0",
	"name":"Smoking cessation counselling, SCLC"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Sodium thiosulfate [Extra]"
},
{
	"jumpto":"ENAS5281_3.1.0.0",
	"name":"Solitary metastatic lesion (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5268_5.2.0.0",
	"name":"Somatostatin analogues [N/V]"
},
{
	"jumpto":"ENAS5064_4.4.0.0",
	"name":"Sorafenib, in HCC"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Sorafenib [RCC]"
},
{
	"jumpto":"ENAS5271_7.3.3.0",
	"name":"Special considerations for some DLBCLs"
},
{
	"jumpto":"ENAS5269_5.9.1.0",
	"name":"Specific indications, overview [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.1",
	"name":"Specific indications, summary [FN]"
},
{
	"jumpto":"ENAS5267_12.6.3.0",
	"name":"Specific measures, summary [Extra]"
},
{
	"jumpto":"ENAS5267_7.3.0.0",
	"name":"Specific measures [Extra]"
},
{
	"jumpto":"ENAS5283_8.5.0.0",
	"name":"Specific situations, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5407_3.6.4.0",
	"name":"Specimen grading in mesorectal excision [Rectal CA]"
},
{
	"jumpto":"ENAS5062_4.8.0.0",
	"name":"Sperm banking"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Spinal cord compression, metastatic PC"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Spinal cord compression [PC]"
},
{
	"jumpto":"ENAS5280_4.5.0.0",
	"name":"Splenectomy, HCL"
},
{
	"jumpto":"ENAS5280_7.3.5.0",
	"name":"Splenectomy in HCL, summary"
},
{
	"jumpto":"ENAS5282_2.0.0.0",
	"name":"Squamous cell carcinomas (Oes CA)"
},
{
	"jumpto":"ENAS5282_4.1.5.0",
	"name":"Squamous cell carcinomas, management (Oes CA)"
},
{
	"jumpto":"ENAS5285_5.2.1.2",
	"name":"SSIGN score [RCC]"
},
{
	"jumpto":"ENAS5061_5.3.0.0",
	"name":"Stage 0 treatment, early colon cancer"
},
{
	"jumpto":"ENAS5407_3.6.2.0",
	"name":"Stage grouping, rectal cancer"
},
{
	"jumpto":"ENAS5270_5.1.0.0",
	"name":"Stage IA treatment of NLPHL, HL"
},
{
	"jumpto":"ENAS5270_9.4.1.0",
	"name":"Stage IA treatment of NLPHL, summary"
},
{
	"jumpto":"ENAS5061_5.3.0.0",
	"name":"Stage IIA treatment, early colon cancer"
},
{
	"jumpto":"ENAS5061_5.3.0.0",
	"name":"Stage III treatment, early colon cancer"
},
{
	"jumpto":"ENAS5406_4.8.0.0",
	"name":"Stage I lung CA with emphysema, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5061_5.3.0.0",
	"name":"Stage I treatment, early colon cancer"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Staging (Gastric cancer)"
},
{
	"jumpto":"ENAS5281_3.1.0.0",
	"name":"Staging (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_3.1.0.0",
	"name":"Staging (Oes CA)"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"Staging (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5279_3.1.0.0",
	"name":"Staging, CLL"
},
{
	"jumpto":"ENAS5271_3.1.0.0",
	"name":"Staging, DLBCL"
},
{
	"jumpto":"ENAS5278_3.1.0.0",
	"name":"Staging, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5278_3.1.0.0",
	"name":"Staging, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"Staging, early colon cancer"
},
{
	"jumpto":"ENAS5273_4.1.0.0",
	"name":"Staging, FL"
},
{
	"jumpto":"ENAS5280_3.0.0.0",
	"name":"Staging, HCL"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Staging, hepatocellular cancer"
},
{
	"jumpto":"ENAS5270_3.0.0.0",
	"name":"Staging, hodgkin's lymphoma"
},
{
	"jumpto":"ENAS5275_3.0.0.0",
	"name":"Staging, MALT"
},
{
	"jumpto":"ENAS5276_3.1.0.0",
	"name":"Staging, PCLs"
},
{
	"jumpto":"ENAS5277_3.0.0.0",
	"name":"Staging, PTCL"
},
{
	"jumpto":"ENAS5407_3.1.0.0",
	"name":"Staging, rectal CA"
},
{
	"jumpto":"ENAS5071_3.1.0.0",
	"name":"Staging, SCLC"
},
{
	"jumpto":"ENAS5284_7.2.0.0",
	"name":"Staging, summary [Bil]"
},
{
	"jumpto":"ENAS5263_14.8.1.0",
	"name":"Staging, summary [Mucosa]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Staging, summary [RCC]"
},
{
	"jumpto":"ENAS5274_3.1.0.0",
	"name":"Staging, WM"
},
{
	"jumpto":"ENAS5406_4.1.0.0",
	"name":"Staging and risk assessment, NSCLC [Early NSCLC]"
},
{
	"jumpto":"ENAS5278_3.9.0.0",
	"name":"Staging and risk assessment, PBL"
},
{
	"jumpto":"ENAS5278_3.8.1.0",
	"name":"Staging and risk assessment, PCNSL"
},
{
	"jumpto":"ENAS5278_3.6.0.0",
	"name":"Staging and risk assessment, PMBCL"
},
{
	"jumpto":"ENAS5278_3.7.0.0",
	"name":"Staging and risk assessment, PTL"
},
{
	"jumpto":"ENAS5283_8.2.0.0",
	"name":"Staging and risk assessment, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5281_7.2.0.0",
	"name":"Staging and risk assessment, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_7.2.0.0",
	"name":"Staging and risk assessment, summary (Oes CA)"
},
{
	"jumpto":"ENAS5098_8.2.0.0",
	"name":"Staging and risk assessment, summary [TETs]"
},
{
	"jumpto":"ENAS5279_7.2.0.0",
	"name":"Staging and risk assessment of CLL, summary"
},
{
	"jumpto":"ENAS5271_7.2.0.0",
	"name":"Staging and risk assessment of DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.2.1.0",
	"name":"Staging and risk assessment of DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5273_8.2.0.0",
	"name":"Staging and risk assessment of FL, summary"
},
{
	"jumpto":"ENAS5270_9.2.0.0",
	"name":"Staging and risk assessment of HL, summary"
},
{
	"jumpto":"ENAS5275_7.2.0.0",
	"name":"Staging and risk assessment of MALT, summary"
},
{
	"jumpto":"ENAS5408_7.2.1.0",
	"name":"Staging and risk assessment of MCL, summary"
},
{
	"jumpto":"ENAS5278_7.2.5.0",
	"name":"Staging and risk assessment of PBL, summary"
},
{
	"jumpto":"ENAS5278_7.2.6.0",
	"name":"Staging and risk assessment of PBoL, summary"
},
{
	"jumpto":"ENAS5092_7.2.0.0",
	"name":"Staging and risk assessment of PC, summary"
},
{
	"jumpto":"ENAS5278_7.2.4.0",
	"name":"Staging and risk assessment of PCNSL, summary"
},
{
	"jumpto":"ENAS5278_7.2.2.0",
	"name":"Staging and risk assessment of PMBCL, summary"
},
{
	"jumpto":"ENAS5277_7.2.0.0",
	"name":"Staging and risk assessment of PTCL, summary"
},
{
	"jumpto":"ENAS5278_7.2.3.0",
	"name":"Staging and risk assessment of PTL, summary"
},
{
	"jumpto":"ENAS5407_9.2.1.0",
	"name":"Staging and risk assessment of rectal cancer, summary"
},
{
	"jumpto":"ENAS5274_7.2.0.0",
	"name":"Staging and risk assessment of WM, summary"
},
{
	"jumpto":"ENAS5280_7.2.0.0",
	"name":"Staging and risk stratification of HCL, summary"
},
{
	"jumpto":"ENAS5061_8.3.0.0",
	"name":"Staging of early colon cancer, summary"
},
{
	"jumpto":"ENAS5064_3.1.0.0",
	"name":"Staging of HCC"
},
{
	"jumpto":"ENAS5086_7.3.0.0",
	"name":"Staging of MPM, summary"
},
{
	"jumpto":"ENAS5068_8.2.0.0",
	"name":"Staging of pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5276_7.2.0.0",
	"name":"Staging of PCLs, summary"
},
{
	"jumpto":"ENAS5096_7.2.0.0",
	"name":"Staging of PenCa, summary"
},
{
	"jumpto":"ENAS5071_6.2.0.0",
	"name":"Staging of SCLC, summary"
},
{
	"jumpto":"ENAS5279_3.2.0.0",
	"name":"Staging systems for CLL"
},
{
	"jumpto":"ENAS5098_4.1.0.0",
	"name":"Staging TETs"
},
{
	"jumpto":"ENAS5284_3.1.0.0",
	"name":"Staging [Bil]"
},
{
	"jumpto":"ENAS5408_3.1.0.0",
	"name":"Staging [MCL]"
},
{
	"jumpto":"ENAS5263_9.1.0.0",
	"name":"Staging [Mucosa]"
},
{
	"jumpto":"ENAS5061_3.0.0.0",
	"name":"Standard pathological assessment"
},
{
	"jumpto":"ENAS5304_5.11.0.0",
	"name":"Standard treatment algorithm, oligometastatic disease [mCRC]"
},
{
	"jumpto":"ENAS5262_6.3.3.6",
	"name":"Staphylococcus aureus, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.8.0",
	"name":"Staphylococcus aureus [CVC]"
},
{
	"jumpto":"ENAS5262_6.3.3.5",
	"name":"Staphylococcus coagulase-negative, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.7.0",
	"name":"Staphylococcus coagulase-negative [CVC]"
},
{
	"jumpto":"ENAS5285_2.0.0.0",
	"name":"Stauf­fer’s syn­drome [RCC]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Steatorrhoea (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5277_4.8.0.0",
	"name":"Stem cell transplantation, PTCL"
},
{
	"jumpto":"ENAS5277_7.3.6.0",
	"name":"Stem cell transplantation in PTCL, summary"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"Stem cell transplantation [N/V]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Stent, advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5267_9.2.0.0",
	"name":"Steps, CVAD extravasation"
},
{
	"jumpto":"ENAS5267_7.4.0.0",
	"name":"Steps, peripheral line extravasation"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Stereotactic ablative body radiotherapy (SBRT) [mCRC]"
},
{
	"jumpto":"ENAS5406_5.1.3.0",
	"name":"Stereotactic body radiotherapy [Early NSCLC]"
},
{
	"jumpto":"ENAS5281_4.14.1.0",
	"name":"Stereotactic radiosurgery (SRS)"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Steroids [Mucosa]"
},
{
	"jumpto":"ENAS5410_3.1.2.0",
	"name":"Stevens John­son syndrome [irAEs]"
},
{
	"jumpto":"ENAS5263_14.1.0.0",
	"name":"Stomatitis, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.5.0.0",
	"name":"Stomatitis in targeted therapy, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_6.0.0.0",
	"name":"Stomatitis in targeted therapy [Mucosa]"
},
{
	"jumpto":"ENAS5263_2.0.0.0",
	"name":"Stomatitis [Mucosa]"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Stool DNA testing"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Sub-total gastrectomy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5276_4.5.0.0",
	"name":"Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)"
},
{
	"jumpto":"ENAS5276_7.3.6.0",
	"name":"Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), summary"
},
{
	"jumpto":"ENAS5061_5.2.0.0",
	"name":"Subtotal colectomy"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Succinate dehydrogenase-deficient RCCs"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Sucralfate enemas [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Sucralfate mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Sulfasalazine [Mucosa]"
},
{
	"jumpto":"ENAS5283_8.1.0.0",
	"name":"Summary of recommendations (Gastric cancer)"
},
{
	"jumpto":"ENAS5281_7.1.0.0",
	"name":"Summary of recommendations (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_7.1.0.0",
	"name":"Summary of recommendations (Oes CA)"
},
{
	"jumpto":"ENAS5062_8.1.0.0",
	"name":"Summary of recommendations, anal cancer"
},
{
	"jumpto":"ENAS5284_7.1.0.0",
	"name":"Summary of recommendations, biliary cancer"
},
{
	"jumpto":"ENAS5279_7.1.0.0",
	"name":"Summary of recommendations, CLL"
},
{
	"jumpto":"ENAS5262_6.1.0.0",
	"name":"Summary of recommendations, CVC"
},
{
	"jumpto":"ENAS5266_10.1.0.0",
	"name":"Summary of recommendations, CV Tox"
},
{
	"jumpto":"ENAS5271_7.1.0.0",
	"name":"Summary of recommendations, DLBCL"
},
{
	"jumpto":"ENAS5278_7.1.1.0",
	"name":"Summary of recommendations, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5061_8.1.0.0",
	"name":"Summary of recommendations, early colon cancer"
},
{
	"jumpto":"ENAS5267_12.1.0.0",
	"name":"Summary of recommendations, Extra"
},
{
	"jumpto":"ENAS5273_8.1.0.0",
	"name":"Summary of recommendations, FL"
},
{
	"jumpto":"ENAS5269_6.1.0.0",
	"name":"Summary of recommendations, FN"
},
{
	"jumpto":"ENAS5064_7.1.0.0",
	"name":"Summary of recommendations, HCC"
},
{
	"jumpto":"ENAS5280_7.1.0.0",
	"name":"Summary of recommendations, HCL"
},
{
	"jumpto":"ENAS5270_9.1.0.0",
	"name":"Summary of recommendations, HL"
},
{
	"jumpto":"ENAS5275_7.1.0.0",
	"name":"Summary of recommendations, MALT"
},
{
	"jumpto":"ENAS5263_14.1.0.0",
	"name":"Summary of recommendations, Mucosa"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Summary of recommendations, N/V"
},
{
	"jumpto":"ENAS5276_7.1.0.0",
	"name":"Summary of recommendations, PCLs"
},
{
	"jumpto":"ENAS5277_7.1.0.0",
	"name":"Summary of recommendations, PTCL"
},
{
	"jumpto":"ENAS5285_9.1.0.0",
	"name":"Summary of recommendations, RCC"
},
{
	"jumpto":"ENAS5071_6.1.0.0",
	"name":"Summary of recommendations, SCLC"
},
{
	"jumpto":"ENAS5098_8.1.0.0",
	"name":"Summary of recommendations, TETs"
},
{
	"jumpto":"ENAS5265_8.1.0.0",
	"name":"Summary of recommendations, VTE"
},
{
	"jumpto":"ENAS5274_7.1.0.0",
	"name":"Summary of recommendations, WM"
},
{
	"jumpto":"ENAS5408_7.1.0.0",
	"name":"Summary of recommendations [MCL]"
},
{
	"jumpto":"ENAS5304_8.1.0.0",
	"name":"Summary of recommendations [mCRC]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Sunitinib [RCC]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Superior mesenteric artery (SMA)"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"Supernumerary teeth"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Supportive care (Pancreatic Cancer)"
},
{
	"jumpto":"ENAS5062_8.3.7.0",
	"name":"Supportive care in anal cancer, summary"
},
{
	"jumpto":"ENAS5280_4.8.0.0",
	"name":"Supportive treatment, HCL"
},
{
	"jumpto":"ENAS5280_7.3.8.0",
	"name":"Supportive treatment of HCL, summary"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Surgery, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Surgery, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Surgery and local therapy, role"
},
{
	"jumpto":"ENAS5062_8.3.2.0",
	"name":"Surgery in anal cancer, summary"
},
{
	"jumpto":"ENAS5086_7.4.4.0",
	"name":"Surgery in MPM, summary"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Surgery [mCRC]"
},
{
	"jumpto":"ENAS5304_5.4.0.0",
	"name":"Surgical criteria [mCRC]"
},
{
	"jumpto":"ENAS5267_12.7.0.0",
	"name":"Surgical debridement, summary [Extra]"
},
{
	"jumpto":"ENAS5267_8.0.0.0",
	"name":"Surgical debridement [Extra]"
},
{
	"jumpto":"ENAS5267_8.0.0.0",
	"name":"Surgical mgmt., severe tissue damage [Extra]"
},
{
	"jumpto":"ENAS5267_12.7.0.0",
	"name":"Surgical mgmt., summary [Extra]"
},
{
	"jumpto":"ENAS5265_4.1.0.0",
	"name":"Surgical patients, prevention of VTE"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Surgical resection, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_8.6.2.2",
	"name":"Surgical resection, summary [mCRC]"
},
{
	"jumpto":"ENAS5063_4.4.0.0",
	"name":"Surgical resection [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5304_5.2.2.0",
	"name":"Surgical resection [mCRC]"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"Surgical staging, early colon cancer"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"Surgical treatment, stage I and II [Early NSCLC]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Surgical treatment, TETs"
},
{
	"jumpto":"ENAS5096_7.3.1.0",
	"name":"Surgical treatment of PenCa, summary"
},
{
	"jumpto":"ENAS5098_8.3.2.0",
	"name":"Surgical treatment of TETs, summary"
},
{
	"jumpto":"ENAS5407_8.2.0.0",
	"name":"Surveillance and follow-up, tool [Rectal CA]"
},
{
	"jumpto":"ENAS5096_6.3.0.0",
	"name":"Surveillance [PenCa]"
},
{
	"jumpto":"ENAS5098_4.2.0.0",
	"name":"Survival rates, TETs"
},
{
	"jumpto":"ENAS5285_9.6.0.0",
	"name":"Survivorship, summary [RCC]"
},
{
	"jumpto":"ENAS5061_7.0.0.0",
	"name":"Survivorship care"
},
{
	"jumpto":"ENAS5285_8.0.0.0",
	"name":"Survivorship [RCC]"
},
{
	"jumpto":"ENAS5269_6.4.6.6",
	"name":"Suspected meningitis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Suspected meningitis [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.5",
	"name":"Suspected viral infection, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.5.0",
	"name":"Suspected viral infection [FN]"
},
{
	"jumpto":"ENAS5410_3.1.2.0",
	"name":"Sweet syndrome [irAEs]"
},
{
	"jumpto":"ENAS5266_3.4.2.0",
	"name":"Symptomatic LVD [CV Tox]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Symptoms (Pancreatic Cancer)"
},
{
	"jumpto":"ENAS5263_11.1.0.0",
	"name":"Systematic enteral nutrition, emergent data [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.3.0.0",
	"name":"Systematic enteral nutrition, emergent data [Mucosa]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Systematic lymphadenectomy [TETs]"
},
{
	"jumpto":"ENAS5284_7.3.2.2",
	"name":"Systemic chemotherapy, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.4.2.0",
	"name":"Systemic chemotherapy [Bil]"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"Systemic perioperative therapy [mCRC]"
},
{
	"jumpto":"ENAS5281_4.1.0.0",
	"name":"Systemic therapy, management (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5304_5.14.8.0",
	"name":"Systemic therapy choices [mCRC]"
},
{
	"jumpto":"ENAS5285_6.2.2.2",
	"name":"Systemic treatment, algorithm [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.2.1",
	"name":"Systemic treatment, overview [RCC]"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"Systemic treatment, summary [RCC]"
},
{
	"jumpto":"ENAS5276_4.3.0.0",
	"name":"Sézary syndrome (SS)"
},
{
	"jumpto":"ENAS5276_7.3.4.0",
	"name":"Sézary syndrome (SS), summary"
},
{
	"jumpto":"ENAS5097_4.4.2.0",
	"name":"T-NS, standard treatment strategies"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for high-risk stage I"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for low-risk stage I"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for stage IIA/IIB marker-negative disease"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for stage IIA/IIB marker-positive disease"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for stage IS/ II/III"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, overview"
},
{
	"jumpto":"ENAS5097_7.3.2.0",
	"name":"T-NS treatment, summary"
},
{
	"jumpto":"ENAS5285_9.4.1.1",
	"name":"T1 tumours (&lt;7 cm), summary [RCC]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"T1 tumours (&lt;7 cm) [RCC]"
},
{
	"jumpto":"ENAS5285_9.4.1.2",
	"name":"T2 tumours (&gt;7 cm), summary [RCC]"
},
{
	"jumpto":"ENAS5285_6.1.2.0",
	"name":"T2 tumours (&gt;7 cm) [RCC]"
},
{
	"jumpto":"ENAS5064_4.3.0.0",
	"name":"TACE"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Targeted therapy-associated stomatitis, recommendations [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.8.5.0",
	"name":"Targeted therapy-associated stomatitis grading, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.5.0.0",
	"name":"Targeted therapy-associated stomatitis grading [Mucosa]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Taurolidine [CVC]"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Taxanes [Anal cancr]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Taxanes [Extra]"
},
{
	"jumpto":"ENAS5409_11.1.4.0",
	"name":"Taxanes [IRs]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"TBI [N/V]"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Tegafur [Mucosa]"
},
{
	"jumpto":"ENAS5285_6.2.2.4",
	"name":"Temsirolimus [RCC]"
},
{
	"jumpto":"ENAS5263_14.1.0.0",
	"name":"Terminology, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_2.0.0.0",
	"name":"Terminology [Mucosa]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"Testicular germ cell tumour (TGCT) [TS/T-NS]"
},
{
	"jumpto":"ENAS5098_5.12.0.0",
	"name":"TET chemotherapy agents"
},
{
	"jumpto":"ENAS5098_8.5.0.0",
	"name":"TETs follow-up, summary"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"TGF-α [mCRC]"
},
{
	"jumpto":"ENAS5280_4.10.0.0",
	"name":"Therapeutic algo. for HCL-V, interactive tool"
},
{
	"jumpto":"ENAS5273_5.3.2.0",
	"name":"Therapeutic algorithm, interactive tool"
},
{
	"jumpto":"ENAS5098_5.2.0.0",
	"name":"Therapeutic strategies, thymic carcinoma [TETs]"
},
{
	"jumpto":"ENAS5098_5.2.0.0",
	"name":"Therapeutic strategies, thymoma [TETs]"
},
{
	"jumpto":"ENAS5304_8.6.8.0",
	"name":"Therapeutic strategy, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Therapeutic strategy [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.11.0",
	"name":"Third-line therapy, summary [mCRC]"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"Third-line treatment, summary [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.2.6",
	"name":"Third-line treatment [RCC]"
},
{
	"jumpto":"ENAS5265_5.1.2.0",
	"name":"Thrombolytic therapy, acute treatment [VTE]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Thymectomy [TETs]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Thymic carcinomas [TETs]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Thymic epithelial tumours (TETs)"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Thymidylate synthase (TS) activity [mCRC]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Thymomas [TETs]"
},
{
	"jumpto":"interactive_0001763",
	"name":"Thyroid function, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.1.2",
	"name":"Thyroid function monitoring, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.1.3",
	"name":"Thyroid function – TSH, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.2.1",
	"name":"Thyroid gland disorders, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.1.1",
	"name":"Thyroid gland disorders [irAEs]"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Tinzaparin [CVC]"
},
{
	"jumpto":"ENAS5304_8.3.0.0",
	"name":"Tissue handling, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_8.4.0.0",
	"name":"Tissue selection for biomarker testing, summary [mCRC]"
},
{
	"jumpto":"ENAS5276_3.2.0.0",
	"name":"TNMB classification, PCLs"
},
{
	"jumpto":"ENAS5407_3.6.2.0",
	"name":"TNM pathological classification [Rectal CA]"
},
{
	"jumpto":"ENAS5283_3.2.0.0",
	"name":"TNM staging (Gastric cancer)"
},
{
	"jumpto":"ENAS5281_3.2.0.0",
	"name":"TNM staging (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5282_3.2.0.0",
	"name":"TNM staging (Oes CA)"
},
{
	"jumpto":"ENAS5061_4.2.0.0",
	"name":"TNM staging, early colon cancer"
},
{
	"jumpto":"ENAS5407_3.4.0.0",
	"name":"TNM staging, rectal cancer"
},
{
	"jumpto":"ENAS5071_3.2.0.0",
	"name":"TNM staging, SCLC"
},
{
	"jumpto":"ENAS5098_4.3.0.0",
	"name":"TNM staging, TETs"
},
{
	"jumpto":"ENAS5406_4.4.0.0",
	"name":"TNM staging [Early NSCLC]"
},
{
	"jumpto":"ENAS5285_5.1.0.0",
	"name":"TNM staging [RCC]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Toolbox of ablative treatments [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.5.0",
	"name":"Toolbox of LATs, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Toolbox of LATs [mCRC]"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Topical DMSO [Extra]"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Topical [Mucosa]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Topoisomerase II inhibitors [Extra]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Topoisomerase I inhibitors [Extra]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Topotecan, second-line treatment [SCLC]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"Total body irradiation [N/V]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Total nodal irradiation [N/V]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Total testosterone [TS/T-NS]"
},
{
	"jumpto":"ENAS5304_8.5.4.0",
	"name":"Toxicity biomarkers, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Toxicity biomarkers [mCRC]"
},
{
	"jumpto":"ENAS5282_7.2.0.0",
	"name":"Tracheo-bronchoscopy, summary (Oes CA)"
},
{
	"jumpto":"ENAS5262_4.3.8.0",
	"name":"Trans-oesophageal echocardiogram [CVC]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Transarterial chemoembolisation (TACE) [mCRC]"
},
{
	"jumpto":"ENAS5064_4.3.0.0",
	"name":"Transcatheter devices, HCC"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Transdermal fentanyl [Mucosa]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Transforming growth factor-α [mCRC]"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Transthoracic oesophagectomy, surgical technique (Oes CA)"
},
{
	"jumpto":"ENAS5094_2.0.0.0",
	"name":"Transurethral resection of the bladder tumour (TURBT)"
},
{
	"jumpto":"ENAS5266_3.4.2.0",
	"name":"Trastuzumab cardiotoxicity, mgmt."
},
{
	"jumpto":"ENAS5266_3.4.1.0",
	"name":"Trastuzumab cardiotoxicity, overview"
},
{
	"jumpto":"ENAS5409_11.2.4.0",
	"name":"Trastuzumab [IRs]"
},
{
	"jumpto":"ENAS5282_4.1.2.0",
	"name":"Treat. of local/ locoregional Oes CA, interactive tool"
},
{
	"jumpto":"ENAS5283_4.1.0.0",
	"name":"Treatment (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_4.1.1.0",
	"name":"Treatment (Oes CA)"
},
{
	"jumpto":"ENAS5262_5.4.0.0",
	"name":"Treatment, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Treatment, catheter-related thrombosis [CVC]"
},
{
	"jumpto":"ENAS5279_4.1.0.0",
	"name":"Treatment, CLL"
},
{
	"jumpto":"ENAS5271_4.4.0.0",
	"name":"Treatment, CNS prophylaxis (DLBCL)"
},
{
	"jumpto":"ENAS5262_4.3.1.0",
	"name":"Treatment, CVC infections"
},
{
	"jumpto":"ENAS5271_4.1.0.0",
	"name":"Treatment, DLBCL"
},
{
	"jumpto":"ENAS5278_4.1.0.0",
	"name":"Treatment, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5407_4.3.2.0",
	"name":"Treatment, early rectal cancer not suitable for local excision"
},
{
	"jumpto":"ENAS5304_5.14.10.4",
	"name":"Treatment, elderly patients [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.10.2",
	"name":"Treatment, fit patients with symptomatic disease [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Treatment, fit patients [mCRC]"
},
{
	"jumpto":"ENAS5273_5.1.1.0",
	"name":"Treatment, FL"
},
{
	"jumpto":"ENAS5280_4.1.0.0",
	"name":"Treatment, HCL"
},
{
	"jumpto":"ENAS5407_4.3.3.0",
	"name":"Treatment, intermediate/more locally advanced rectal cancer"
},
{
	"jumpto":"ENAS5284_4.1.0.0",
	"name":"Treatment, introduction [Bil]"
},
{
	"jumpto":"ENAS5061_5.2.0.0",
	"name":"Treatment, localised disease [Early colon cancer]"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Treatment, localised disease [SCLC]"
},
{
	"jumpto":"ENAS5406_5.2.1.0",
	"name":"Treatment, locally advanced (stage III) NSCLC [Early NSCLC]"
},
{
	"jumpto":"ENAS5407_4.3.4.0",
	"name":"Treatment, locally advanced rectal cancer"
},
{
	"jumpto":"ENAS5061_5.1.0.0",
	"name":"Treatment, malignant polyps"
},
{
	"jumpto":"ENAS5275_4.1.0.0",
	"name":"Treatment, MALT"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Treatment, management of metastatic disease [RCC]"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"Treatment, metastatic disease [mCRC]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Treatment, mgmt. of local/ locoregional disease [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.2.7",
	"name":"Treatment, non-clear cell histology [RCC]"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"Treatment, NSCLC stages I and II [Early NSCLC]"
},
{
	"jumpto":"ENAS5278_4.5.0.0",
	"name":"Treatment, PBL"
},
{
	"jumpto":"ENAS5278_4.6.0.0",
	"name":"Treatment, PBoL"
},
{
	"jumpto":"ENAS5276_4.1.0.0",
	"name":"Treatment, PCLs"
},
{
	"jumpto":"ENAS5278_4.4.0.0",
	"name":"Treatment, PCNSL"
},
{
	"jumpto":"ENAS5278_4.2.0.0",
	"name":"Treatment, PMBCL"
},
{
	"jumpto":"ENAS5277_4.1.0.0",
	"name":"Treatment, PTCL"
},
{
	"jumpto":"ENAS5278_4.3.0.0",
	"name":"Treatment, PTL"
},
{
	"jumpto":"ENAS5407_4.2.0.0",
	"name":"Treatment, rectal cancer without distant mets. [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.3.5.0",
	"name":"Treatment, rectal tumours with threatened resection margin [Rectal CA]"
},
{
	"jumpto":"ENAS5265_5.4.0.0",
	"name":"Treatment, recurrent VTE"
},
{
	"jumpto":"ENAS5271_5.2.2.0",
	"name":"Treatment, response evaluation and FU (DLBCL)"
},
{
	"jumpto":"ENAS5271_7.4.2.2",
	"name":"Treatment, response evaluation and FU in DLBCL, summary"
},
{
	"jumpto":"ENAS5271_4.5.0.0",
	"name":"Treatment, special considerations for some DLBCLs"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"Treatment, stage II [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"Treatment, stage I [Early NSCLC]"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Treatment, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_7.3.1.1",
	"name":"Treatment, summary (Oes CA)"
},
{
	"jumpto":"ENAS5304_8.6.1.0",
	"name":"Treatment, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.10.3",
	"name":"Treatment, unfit patients [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Treatment, unfit patients [mCRC]"
},
{
	"jumpto":"ENAS5407_4.3.1.0",
	"name":"Treatment, very early rectal cancer"
},
{
	"jumpto":"ENAS5274_4.1.0.0",
	"name":"Treatment, WM"
},
{
	"jumpto":"ENAS5274_4.3.0.0",
	"name":"Treatment algo. for WM: Newly diagnose, interactive tool"
},
{
	"jumpto":"ENAS5274_4.4.0.0",
	"name":"Treatment algo. for WM: Relapse, interactive tool"
},
{
	"jumpto":"ENAS5071_4.1.0.0",
	"name":"Treatment algorithm, SCLC"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Treatment algorithms [TETs]"
},
{
	"jumpto":"ENAS5262_6.3.3.4",
	"name":"Treatment duration, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.6.0",
	"name":"Treatment duration [CVC]"
},
{
	"jumpto":"ENAS5280_4.7.0.0",
	"name":"Treatment during pregnancy, HCL"
},
{
	"jumpto":"ENAS5063_4.5.0.0",
	"name":"Treatment follow-up [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5281_4.9.2.0",
	"name":"Treatment for stage IIIB-IV with ALK translocation, interactive tool"
},
{
	"jumpto":"ENAS5281_4.8.2.0",
	"name":"Treatment for stage IIIB–IV with EGFR mutation, interactive tool"
},
{
	"jumpto":"ENAS5281_4.2.2.0",
	"name":"Treatment for stage IV NSCC, interactive tool"
},
{
	"jumpto":"ENAS5281_4.2.1.0",
	"name":"Treatment for stage IV SCC, interactive tool"
},
{
	"jumpto":"ENAS5062_8.3.5.0",
	"name":"Treatment in elderly with anal cancer, summary"
},
{
	"jumpto":"ENAS5279_4.2.1.0",
	"name":"Treatment of advanced-stage disease, CLL"
},
{
	"jumpto":"ENAS5279_7.3.2.1",
	"name":"Treatment of advanced-stage disease in CLL, summary"
},
{
	"jumpto":"ENAS5098_5.7.0.0",
	"name":"Treatment of advanced TETs"
},
{
	"jumpto":"ENAS5274_4.1.0.0",
	"name":"Treatment of asymptomatic patients, WM"
},
{
	"jumpto":"ENAS5274_7.3.1.0",
	"name":"Treatment of asymptomatic patients in WM, summary"
},
{
	"jumpto":"ENAS5262_6.4.4.0",
	"name":"Treatment of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS5270_4.1.0.0",
	"name":"Treatment of cHL"
},
{
	"jumpto":"ENAS5270_4.5.0.0",
	"name":"Treatment of cHL, advanced-stage"
},
{
	"jumpto":"ENAS5270_4.4.0.0",
	"name":"Treatment of cHL, intermediate-stage"
},
{
	"jumpto":"ENAS5270_4.3.0.0",
	"name":"Treatment of cHL, limited-stage"
},
{
	"jumpto":"ENAS5270_9.3.1.0",
	"name":"Treatment of cHL, summary"
},
{
	"jumpto":"ENAS5279_4.2.5.0",
	"name":"Treatment of CLL, complications"
},
{
	"jumpto":"ENAS5279_4.2.2.1",
	"name":"Treatment of CLL, front-line"
},
{
	"jumpto":"ENAS5279_7.3.1.0",
	"name":"Treatment of CLL, summary"
},
{
	"jumpto":"ENAS5279_7.3.2.5",
	"name":"Treatment of CLL complications, summary"
},
{
	"jumpto":"ENAS5092_7.3.2.2",
	"name":"Treatment of CRPC, summary [PC]"
},
{
	"jumpto":"ENAS5262_6.3.3.1",
	"name":"Treatment of CVC infections, summary"
},
{
	"jumpto":"ENAS5271_7.3.1.0",
	"name":"Treatment of DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.3.1.0",
	"name":"Treatment of DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5279_7.3.1.0",
	"name":"Treatment of early-stage disease in CLL, summary"
},
{
	"jumpto":"ENAS5407_9.3.1.2",
	"name":"Treatment of early rectal cancer not suitable for local excision, summary"
},
{
	"jumpto":"ENAS5279_4.1.0.0",
	"name":"Treatment of early stage disease, CLL"
},
{
	"jumpto":"ENAS5408_7.3.3.0",
	"name":"Treatment of elderly patients of MCL, summary"
},
{
	"jumpto":"ENAS5408_4.4.0.0",
	"name":"Treatment of elderly patients [MCL]"
},
{
	"jumpto":"ENAS5273_8.3.1.0",
	"name":"Treatment of FL, Summary"
},
{
	"jumpto":"ENAS5280_7.3.1.0",
	"name":"Treatment of HCL, summary"
},
{
	"jumpto":"ENAS5280_4.9.0.0",
	"name":"Treatment of HCL-V"
},
{
	"jumpto":"ENAS5280_7.3.9.0",
	"name":"Treatment of HCL-V, summary"
},
{
	"jumpto":"ENAS5407_9.3.1.3",
	"name":"Treatment of intermediate rectal cancer, summary"
},
{
	"jumpto":"ENAS5061_8.4.2.0",
	"name":"Treatment of localised early colon cancer, summary"
},
{
	"jumpto":"ENAS5071_6.3.1.0",
	"name":"Treatment of localised SCLC, summary"
},
{
	"jumpto":"ENAS5407_9.3.1.4",
	"name":"Treatment of locally advanced rectal cancer, summary"
},
{
	"jumpto":"ENAS5407_5.2.0.0",
	"name":"Treatment of local recurrence of rectal cancer, tool [Rectal CA]"
},
{
	"jumpto":"ENAS5061_8.4.1.0",
	"name":"Treatment of malignant polyps, summary"
},
{
	"jumpto":"ENAS5275_7.3.1.0",
	"name":"Treatment of MALT, summary"
},
{
	"jumpto":"ENAS5408_7.3.1.0",
	"name":"Treatment of MCL, summary"
},
{
	"jumpto":"ENAS5304_8.6.7.0",
	"name":"Treatment of metastatic disease, summary [mCRC]"
},
{
	"jumpto":"ENAS5407_6.2.0.0",
	"name":"Treatment of metastatic disease, tool [Rectal CA]"
},
{
	"jumpto":"ENAS5068_8.3.6.0",
	"name":"Treatment of metastatic pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5071_6.3.2.0",
	"name":"Treatment of metastatic SCLC, summary"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Treatment of metastatic TETs, interactive tool"
},
{
	"jumpto":"ENAS5094_9.3.2.0",
	"name":"Treatment of MIBC, summary"
},
{
	"jumpto":"ENAS5086_7.4.1.0",
	"name":"Treatment of MPM, summary"
},
{
	"jumpto":"ENAS5270_5.1.0.0",
	"name":"Treatment of NLPHL, HL"
},
{
	"jumpto":"ENAS5270_9.4.1.0",
	"name":"Treatment of NLPHL, summary"
},
{
	"jumpto":"ENAS5094_9.3.1.0",
	"name":"Treatment of NMIBC, summary"
},
{
	"jumpto":"ENAS5068_8.3.5.0",
	"name":"Treatment of non-resectable pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5281_4.15.0.0",
	"name":"Treatment of oligometastatic NSCLC"
},
{
	"jumpto":"ENAS5281_7.3.14.0",
	"name":"Treatment of oligometastatic NSCLC, summary (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5278_7.3.5.0",
	"name":"Treatment of PBL, summary"
},
{
	"jumpto":"ENAS5278_7.3.6.0",
	"name":"Treatment of PBoL, summary"
},
{
	"jumpto":"ENAS5276_7.3.1.0",
	"name":"Treatment of PCLs, summary"
},
{
	"jumpto":"ENAS5278_7.3.4.0",
	"name":"Treatment of PCNSL, summary"
},
{
	"jumpto":"ENAS5096_7.3.1.0",
	"name":"Treatment of PenCa, summary"
},
{
	"jumpto":"ENAS5278_7.3.2.0",
	"name":"Treatment of PMBCL, summary"
},
{
	"jumpto":"ENAS5277_7.3.1.0",
	"name":"Treatment of PTCL, summary"
},
{
	"jumpto":"ENAS5278_7.3.3.0",
	"name":"Treatment of PTL, summary"
},
{
	"jumpto":"ENAS5098_5.11.0.0",
	"name":"Treatment of recurrences in TETs"
},
{
	"jumpto":"ENAS5098_8.3.9.0",
	"name":"Treatment of recurrences in TETs, summary"
},
{
	"jumpto":"ENAS5265_8.4.4.0",
	"name":"Treatment of recurrent VTE, summary"
},
{
	"jumpto":"ENAS5092_7.3.1.4",
	"name":"Treatment of relapse of PC, summary"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Treatment of resectable TETs, interactive tool"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Treatment of unresectable TETs. Interactive tool"
},
{
	"jumpto":"ENAS5274_7.3.1.0",
	"name":"Treatment of WM, summary"
},
{
	"jumpto":"ENAS5408_7.3.4.0",
	"name":"Treatment of younger patients of MCL, summary"
},
{
	"jumpto":"ENAS5408_4.5.0.0",
	"name":"Treatment of younger patients [MCL]"
},
{
	"jumpto":"ENAS5271_4.2.5.0",
	"name":"Treatment strategies, >2 relapses/ progressions (DLBCL)"
},
{
	"jumpto":"ENAS5271_4.2.1.0",
	"name":"Treatment strategies, DLBCL"
},
{
	"jumpto":"ENAS5271_4.2.3.0",
	"name":"Treatment strategies, elderly >60 years (DLBCL)"
},
{
	"jumpto":"ENAS5271_4.2.4.0",
	"name":"Treatment strategies, first relapse/ progression (DLBCL)"
},
{
	"jumpto":"ENAS5271_4.2.2.0",
	"name":"Treatment strategies, patients ≤60 years (DLBCL)"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Treatment stratification [mCRC]"
},
{
	"jumpto":"ENAS5271_4.3.0.0",
	"name":"Treatment stratified according to age, DLBCL"
},
{
	"jumpto":"ENAS5063_4.4.0.0",
	"name":"Treatment [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5408_4.1.0.0",
	"name":"Treatment [MCL]"
},
{
	"jumpto":"ENAS5304_5.1.0.0",
	"name":"Treatment [mCRC]"
},
{
	"jumpto":"ENAS5304_5.1.0.0",
	"name":"Treatment [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.5.0",
	"name":"Trifluridine/tipiracil [mCRC]"
},
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"Tropisetron [N/V]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"TRUS guided prostate biopsy [PC]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"TS/T-NS, diagnosis"
},
{
	"jumpto":"ENAS5097_6.0.0.0",
	"name":"TS/T-NS, follow-up and surveillance"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"TS/T-NS, iso-chromosome 12p"
},
{
	"jumpto":"ENAS5097_5.0.0.0",
	"name":"TS/T-NS, personalised medicine"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS, post-orchiectomy staging"
},
{
	"jumpto":"ENAS5097_4.3.2.0",
	"name":"TS/T-NS, standard treatment strategies"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"TS/T-NS, syncytiotrophoblasts"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS, TNM staging"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"TS/T-NS, WHO classification"
},
{
	"jumpto":"ENAS5097_7.1.0.0",
	"name":"TS/T-NS diagnosis, summary"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS staging"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"TS/T-NS staging, for metastatic disease"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"TS/T-NS staging, for stage I disease"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS staging, IGCCCG prognostic groups"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS staging, serum tumour markers"
},
{
	"jumpto":"ENAS5097_7.2.0.0",
	"name":"TS/T-NS staging, summary"
},
{
	"jumpto":"ENAS5097_4.1.0.0",
	"name":"TS/T-NS treatment"
},
{
	"jumpto":"ENAS5097_4.1.0.0",
	"name":"TS/T-NS treatment, chemotherapy regimens"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, for stage I"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, for stage IIA"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, for stage IIB/ IIC"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, for stage III"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, overview"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"TS/T-NS treatment chemotherapy regimens, summary"
},
{
	"jumpto":"ENAS5097_4.6.0.0",
	"name":"TS/T-NS treatment in late relapse"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"TS/T-NS treatment in late toxicity"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"TS enhancer region (TSER) genotyping [mCRC]"
},
{
	"jumpto":"ENAS5097_7.3.1.0",
	"name":"TS treatment, summary"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"Tumor marker (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5064_4.1.0.0",
	"name":"Tumor recurrence, HCC"
},
{
	"jumpto":"ENAS5071_3.3.0.0",
	"name":"Tumor stage grouping, SCLC"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"Tumour biology [mCRC]"
},
{
	"jumpto":"ENAS5273_7.3.0.0",
	"name":"Tumour burden: Low/high, interactive tool"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"Tumour burden [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Tumour marker measurements [mCRC]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Tumour markers in staging [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"Tumour markers [TS/T-NS]"
},
{
	"jumpto":"ENAS5281_2.1.0.0",
	"name":"Tumour rebiopsy at disease progression (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Tumour shrinkage"
},
{
	"jumpto":"ENAS5407_9.3.1.5",
	"name":"Tumours with threatened resection margin, summary"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"TURBT [BC]"
},
{
	"jumpto":"ENAS5063_4.1.0.0",
	"name":"Turcot's syndrome [Fam. colorectal cancer]"
},
{
	"jumpto":"ENAS5061_2.0.0.0",
	"name":"Turcot syndrome"
},
{
	"jumpto":"ENAS5063_2.1.0.0",
	"name":"Turcot syndrome [Fam. Colorectal cancer]"
},
{
	"jumpto":"ENAS5266_9.3.0.0",
	"name":"Tx, radiotherapy-related cardiac complications [CV Tox]"
},
{
	"jumpto":"ENAS5270_4.2.0.0",
	"name":"Tx algo. for cHL, interactive tool"
},
{
	"jumpto":"ENAS5280_7.3.7.0",
	"name":"Tx during pregnancy in HCL, summary"
},
{
	"jumpto":"ENAS5266_8.0.0.0",
	"name":"Tx of LVD, anticancer treatment [CV Tox]"
},
{
	"jumpto":"ENAS5266_10.7.0.0",
	"name":"Tx of LVD induced by anticancer treatment, summary [CV Tox]"
},
{
	"jumpto":"ENAS5279_4.2.3.1",
	"name":"Tx of relapsed and refractory disease, CLL"
},
{
	"jumpto":"ENAS5279_7.3.2.3",
	"name":"Tx of relapsed and refractory disease in CLL, summary"
},
{
	"jumpto":"ENAS5280_4.4.1.0",
	"name":"Tx of replapse & refra. pts., HCL"
},
{
	"jumpto":"ENAS5280_7.3.4.0",
	"name":"Tx of replapse & refra. pts., summary"
},
{
	"jumpto":"ENAS5410_4.2.2.3",
	"name":"Type 1 diabetes mellitus, summary [irAEs]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Tyrosine kinase inhibitor (TKI)"
},
{
	"jumpto":"ENAS5285_5.2.1.3",
	"name":"UISS risk groups [RCC]"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Ultrasonography [BC]"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"Ultrasonography [Early colon cancer]"
},
{
	"jumpto":"ENAS5096_6.3.0.0",
	"name":"Ultrasound-guided FNAC biopsy [PenCa]"
},
{
	"jumpto":"ENAS5266_2.0.0.0",
	"name":"Ultrasound assessment [CV Tox]"
},
{
	"jumpto":"ENAS5304_8.6.12.2",
	"name":"Unfit patients, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.2.5",
	"name":"Unresectable colorectal liver metastases, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.8.0.0",
	"name":"Unresectable colorectal liver metastase [mCRC]"
},
{
	"jumpto":"ENAS5086_5.3.0.0",
	"name":"Unresectable mesothelioma, treatment recommendations"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Unresectable TETs, treatment algorithm [TETs]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Upper body irradiation [N/V]"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"Urethral wash cytology [BC]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.12.1",
	"name":"Use of biologicals, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Use of biologicals [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.12.1",
	"name":"Use of cytotoxics, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Use of cytotoxics [mCRC]"
},
{
	"jumpto":"ENAS5266_9.4.0.0",
	"name":"Valvular disease [CV Tox]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Vancomycin [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.7.0",
	"name":"Vancomycin [FN]"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Vascular endothelial growth factor"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Vascular endothelial growth factor (VEGF) [mCRC]"
},
{
	"jumpto":"ENAS5265_8.4.5.0",
	"name":"Vena cava filter, summary [VTE]"
},
{
	"jumpto":"ENAS5265_5.5.0.0",
	"name":"Vena cava filter [VTE]"
},
{
	"jumpto":"ENAS5096_3.1.0.0",
	"name":"Verrucous carcinoma [PenCa]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Vesicant [Extra]"
},
{
	"jumpto":"ENAS5269_6.4.6.5",
	"name":"Vesicular lesions, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.5.0",
	"name":"Vesicular lesions [FN]"
},
{
	"jumpto":"ENAS5064_5.0.0.0",
	"name":"Viable tumor assessment, HCC"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Vinca alkaloids [Extra]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Vincristine, second-line treatment [SCLC]"
},
{
	"jumpto":"ENAS5094_5.2.0.0",
	"name":"Vinflunine, second line treatment [BC]"
},
{
	"jumpto":"ENAS5061_3.0.0.0",
	"name":"Virtual colonoscopy"
},
{
	"jumpto":"ENAS5061_4.1.0.0",
	"name":"Visceromegaly"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Vogt-Koyanagi-Harada syndrome [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Vogt-‍Koyanagi-‍Harada syn­drome [irAEs]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Von Hippel-Lindau gene alterations [RCC]"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Voriconazole [FN]"
},
{
	"jumpto":"ENAS5265_2.1.0.0",
	"name":"VTE, risk factors [VTE]"
},
{
	"jumpto":"ENAS5265_8.1.0.0",
	"name":"VTE risk factors, summary"
},
{
	"jumpto":"ENAS5265_5.1.1.0",
	"name":"VTE treatment, acute"
},
{
	"jumpto":"ENAS5265_5.2.0.0",
	"name":"VTE treatment, long-term"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Vulval intra-epithelial neoplasis (VIN)"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Weight loss (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"WHO classification, renal cell tumors"
},
{
	"jumpto":"ENAS5276_2.0.0.0",
	"name":"WHO EORTC classification of PCLs"
},
{
	"jumpto":"ENAS5281_4.14.1.0",
	"name":"Whole brain radiotherapy (WBRT)"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Whole exome analyses [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Whole genome analyses [mCRC]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Whole genome sequencing (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Whole transcriptome analyses [mCRC]"
},
{
	"jumpto":"ENAS5263_9.2.0.0",
	"name":"WHO scale, oral mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.8.2.0",
	"name":"WHO scale, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Zinc supplements [Mucosa]"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Zoledronate [PC]"
},
{
	"jumpto":"ENAS5281_4.14.2.0",
	"name":"Zoledronic acid (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5281_4.14.2.0",
	"name":"Zoledronic acid reduces skeletal-related events (Metastatic NSCLC)"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Zoledronic acid [RCC]"
},
{
	"jumpto":"ENAS5304_5.14.7.0",
	"name":"Zurich treatment algorithm [mCRC]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"α-fetoprotein [TS/T-NS]"
},
{
	"jumpto":"ENAS5283_4.3.3.1",
	"name":"≥ stage IB gastric cancer"
}
]